2024-03-28T17:27:42Zhttp://uvadoc.uva.es/oai/requestoai:uvadoc.uva.es:10324/58102021-06-23T11:41:35Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Effect of Quinapril, Quinapril-Hydrochlorothiazide, and Enalapril on the Bone Mass of Hypertensive Subjects: Relationship With Angiotensin Converting Enzyme Polymorphisms
Pérez Castrillon, José Luis
Silva, Jesús
Justo, Isabel
Sanz Cantalapiedra, Alberto
Martín-Luquero Ibáñez, Miguel
Igea, Rosa
Escudero, Pilar
Pueyo, Carol
Díaz, Cristina
Hernández, Gonzalo
Dueñas Laita, Antonio
Hipertension arterial - Tratamiento
Producción Científica
Background: Many alterations in extracellular metabolism
of calcium have been associated to hypertension, but
the number of studies relating this disease with osteoporosis
is extremely low. This study clarifies the therapeutic
effect of three treatments— quinapril, quinapril hydrochlorothiazide
(HCTZ), enalapril—on bone remodeling
markers, bone mineral density (BMD) in hypertensive
patients, and relationship with angiotensin converting enzyme
(ACE) polymorphism.
2014-09-03
2015-09-03
2003
info:eu-repo/semantics/article
American Journal of Hypertension, 2003, vol. 16, p. 453-459
0895-7061
http://uvadoc.uva.es/handle/10324/5810
10.1016/S0895-7061(03)00845-8
453
459
American Journal of Hypertension
16
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Elsevier
oai:uvadoc.uva.es:10324/58132021-11-16T09:06:16Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Hypertension as a Risk Factor for Hip Fracture
Pérez Castrillon, José Luis
Martín Escudero, Juan Carlos
Álvarez Manzanares, P.
Cortés Sancho, R.
Iglesias Zamora, S.
García Alonso, Manuel Francisco
Hipertension Arterial - Tratamiento
Producción Científica
Arterial hypertension is a chronic disease in which prevalence
increases with age, as occurs in osteoporosis. It is
clinically silent and is only revealed in the form of complications,
an aspect that it also shares with osteoporosis.
Various alterations of calcium metabolism have been described
in association with hypertension; such alterations
can cause decreased bone mass, the principal determining
factor of fracture.1,2 Another important factor is the occurrence
of falls. Hypertensive patients may experience a
greater number of falls resulting from fainting associated
with diminished baroreflex sensitivity or hypotension secondary
to therapy.3,4 The purpose of this study was to
assess the effect of hypertension and its various therapeutic
alternatives on the risk of hip fracture.
2014-09-03
2015-09-03
2005
info:eu-repo/semantics/article
American Journal of Hypertension, Enero 2005, vol. 18, n. 1, p. 146-147
0895-7061
http://uvadoc.uva.es/handle/10324/5813
10.1016/j.amjhyper.2004.08.016
146
1
147
American Journal of Hypertension
18
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Universidad de Valladolid. Facultad de Medicina
oai:uvadoc.uva.es:10324/58282021-06-23T11:41:36Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Relationship Between Bone Mineral Density and Angiotensin Converting Enzyme Polymorphism in Hypertensive Postmenopausal Women
Pérez Castrillon, José Luis
Justo, Isabel
Silva, Jesús
Sanz Cantalapiedra, Alberto
Martín Escudero, Juan Carlos
Igea, Rosa
Escudero, Pilar
Pueyo, Carol
Díaz, Cristina
Hernández, Gonzalo
Dueñas Laita, Antonio
Osteopatía - Tratamiento
Menopausia
Hipertension - Tratamiento
Producción Científica
The purpose of this study was to assess
the relationship between bone mineral density and insertion/
deletion (I/D) angiotensin converting enzyme polymorphism
(ACE) in hypertensive postmenopausal women.
2014-09-04
2015-09-04
2003
info:eu-repo/semantics/article
American Journal of Hypertension, Marzo 2003, vol. 16, n. 3, p. 233-235
0895-7061
http://uvadoc.uva.es/handle/10324/5828
233
3
235
American Journal of Hypertension
16
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Elsevier Science Inc.
oai:uvadoc.uva.es:10324/58322021-11-03T12:22:56Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Association of aromatase and estrogen receptor gene polymorphisms with hip fractures
Valero, C.
Pérez Castrillon, José Luis
Zarrabeitia Cimiano, María Teresa
Hernández, J. L.
Alonso, María A.
Pino Montes, Javier del
Olmos, José M.
González Macías, Jesús
Riancho Moral, José Antonio
Osteoporosis - Tratamiento
Cadera - Fracturas
Producción Científica
Summary Two polymorphisms of the aromatase and estrogen
receptor genes appeared to interact to influence the risk of
hip fractures in women.
Introduction Allelic variants of the aromatase gene have
been associated with bone mineral density and vertebral
fractures. Our objective was to analyze the relationship
between two polymorphisms of the aromatase and estrogen
receptor genes and hip fractures
2014-09-04
2014-09-04
2008
info:eu-repo/semantics/article
Osteoporosis International, 2008, vol. 19, p. 787-792
0937-941X
http://uvadoc.uva.es/handle/10324/5832
10.1007/s00198-007-0491-0
787
792
Osteoporosis International
19
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
International Osteoporosis Foundation and National Osteoporosis Foundation
oai:uvadoc.uva.es:10324/58332021-06-23T11:41:20Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Effects of Atorvastatin on Vitamin D Levels in Patients With Acute Ischemic Heart Disease
Pérez Castrillon, José Luis
Vega, Gemma
Abad Manteca, Laura
Sanz Cantalapiedra, Alberto
Chaves, Jose
Hernández, Gonzalo
Dueñas Laita, Antonio
Cardiologia - Tratamiento
Vitamina D
Producción Científica
Vitamin D deficiency is a risk factor for osteoporosis and other chronic diseases, including
type 1 diabetes, hypertension, metabolic syndrome, and ischemic heart disease. Cholesterol
and vitamin D share the 7-dehydrocolesterol metabolic pathway. This study evaluated the
possible effect of atorvastatin on vitamin D levels in patients with acute ischemic heart
disease. Eighty-three patients (52 men and 31 women) with an acute coronary syndrome
(75 with acute myocardial infarction and 8 with unstable angina) were included. After
diagnosis, patients received atorvastatin as secondary prevention. Serum vitamin D was
measured by high-performance liquid chromatography at baseline and at 12 months.
Atorvastatin treatment produced a statistically significant decrease in cholesterol and
triglyceride levels and an increase in vitamin D levels (41 19 vs 47 19 nmol/L, p
0.003). Vitamin D deficiency was decreased by 75% to 57% at 12 months. In conclusion,
atorvastatin increases vitamin D levels. This increase could explain some of the beneficial
effects of atorvastatin at the cardiovascular level that are unrelated to cholesterol
levels.
2014-09-05
2014-09-05
2007
info:eu-repo/semantics/article
American Journal of Cardiology, 2007, vol. 99, p. 903-905
0002-9149
http://uvadoc.uva.es/handle/10324/5833
10.1016/j.amjcard.2006.11.036
903
905
American Journal of Cardiology
99
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Elsevier Inc.
oai:uvadoc.uva.es:10324/58342021-06-23T11:41:37Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Genetic polymorphisms of the wint receptor LRP5 are differentially associated with trochanteric and cervical hip fractures
Riancho, Javier
García Ibarbia, Carmen
Pérez Núñez, María A.
Alonso, María A.
Díaz, Teresa
Pérez Castrillon, José Luis
Riancho Moral, José Antonio
Cadera - Fracturas - Aspecto Genetico
Producción Científica
Purpose. Epidemiological studies suggest that cervical and trochanteric hip fractures have
different pathogenesis. We planned to test the hypothesis that genetic factors have different
influences on both types of fractures.
Methods. Ten polymorphisms of genes known to play an important role in skeletal homeostasis
(estrogen receptor alpha [ESR1], aromatase [CYP19A1], type I collagen [COL1A1], and
lipoprotein receptor-related protein 5 [LRP5]) were analyzed in 471 Spanish patients with
fragility hip fractures.
Results. Two polymorphisms of the LRP5 gene (rs7116604 and rs3781600) were associated
with the type of fracture (p-value 0.0085 and 0.0047, respectively). The presence of rare alleles
at each locus was associated with trochanteric fractures over cervical fractures (OR 1.7 in
individuals with at least one rare allele at rs7116604 or rs3781600 loci, in comparison with the
common homozygotes). Considering individuals bearing the four common alleles as reference,
the OR for trochanteric fractures was 1.6 in those with 1 or 2 rare alleles, and 7.5 in those with 3
or 4 rare alleles (p-value for trend 0.0074), which is consistent with an allele-dosage effect.
There were no significant differences in the frequency distributions of the ESR1, CYP19A1 and
COL1A1 genotypes between trochanteric and cervical fractures in either the original group or in
an extended group of 818 patients.
Conclusions. These results suggest LRP5 alleles influence the type of hip fractures. They
support the view that different genetic factors are involved in cervical and trochanteric fractures,
which should be taken into consideration in future genetic association studies.
2014-09-05
2014-09-05
2011
info:eu-repo/semantics/article
Calcified Tissue International, 2011, p. 1-25
0171-967X
http://uvadoc.uva.es/handle/10324/5834
1
25
Calcified Tissue International
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Springer
oai:uvadoc.uva.es:10324/58362021-06-23T11:41:38Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Antibodies against Chlamydia pneumoniae and their relation to lymphocyte population levels
González Castañeda, Candelas
Pérez Castrillon, José Luis
Romero Gómez, Mercedes
Herreros Fernández, Vicente
Cardiovascular, Aparato, Efectos de los medicamentos sobre el
Atherosclerosis
Neumonia
Producción Científica
Chlamydia pneumoniae infection has long been suspected as a possible cause of atherosclerosis and has been frequently detected in
atheromatous plaques of the coronary arteries. Nevertheless, its distribution is not correlated to the severity or extent of the disease, but it
would support the hypothesis that the organism may be an active factor in the pathogenesis of atherosclerosis. A group of patients with
stable angina were examined as to whether or not the positivity of antibodies against Chlamydia pneumoniae modified cellular
populations as mechanisms responsible for the alterations of inflammatory response. We concluded that the presence of IgG anti-C.
pneumoniae antibodies do not participate in the activation of inflammatory mechanisms that may intervene in the genesis of
atherosclerosis in patients with stable angina.
2014-09-05
2014-09-05
2002
info:eu-repo/semantics/article
International Journal of Cardiology, 2002, vol. 82, p. 293-295
0167-5273
http://uvadoc.uva.es/handle/10324/5836
293
295
International Journal of Cardiology
82
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Elsevier Science Ireland Ltd.
oai:uvadoc.uva.es:10324/58372021-11-04T09:21:16Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Antibodies against Chlamydia pneumoniae in stable angina and interleukin-6 levels
González Castañeda, Candelas
Pérez Castrillon, José Luis
Arranz Peña, Maria Luisa
González, Victor
Herreros Fernández, Vicente
Neumonia
Cardiovascular, Aparato - Enfermedades
Producción Científica
Inflammation is a key mechanism in atherogenesis and the rapid progression of coronary artery disease. Tissue lesion occasions the release of chemical mediators, cytokines, accompanied by an increase in the blood concentrations of acute phase reactants, such as fibrinogen, C-reactive protein, serum amyloid A protein, sialic acid and ceruloplasmin and a reduction
of those of albumin. It has been observed that these proteins are higher in patients with is-chemic heart disease and, furthermore, who have a higher tendency to present adverse cardiovascular incidents [1]. On the other hand, the inflammation appears
to be directly linked to the ‘vulnerability’ or ‘instability’ of the atheromatous plaques that pre-dispose to disruption and acute coronary incidents. The inflammatory mechanism, therefore, can repre-sent the final common connection channel of chronic infection between atherogenesis and the clinical manifestations of coronary artery disease [2].
2014-09-05
2014-09-05
2003
info:eu-repo/semantics/article
International Journal of Cardiology, 2003, vol. 88, p. 99-100
0167-5273
http://uvadoc.uva.es/handle/10324/5837
10.1016/S0167-5273(02)00383-2
99
100
International Journal of Cardiology
88
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Elsevier Science Ireland Ltd.
oai:uvadoc.uva.es:10324/58382021-06-23T11:41:22Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Valor pronóstico de los anticuerpos anti-Chlamydia pneumoniae en la cardiopatía isquémica
González Castañeda, Candelas
Pérez Castrillon, José Luis
Casero Lambas, Antonio
Mazón Ramos, María de los Ángeles
Cañibano González, M. Á.
López Bello, M.
Herreros Fernández, Vicente
Neumonía
Cardiovascular, Aparato - Enfermedades
Producción Científica
Se ha relacionado la
enfermedad arterial coronaria con infección por
Chlamydia pneumoniae, pero existen pocos estudios
que valoren la presencia de anticuerpos frente a este
microorganismo y el pronóstico de los pacientes con
cardiopatía isquémica. El objetivo de nuestro estudio
fue valorar el impacto de la positividad de
anticuerpos anti-Chlamydia pneumoniae en la
morbimortalidad asociada a la cardiopatía isquémica.
2014-09-05
2014-09-05
2004
info:eu-repo/semantics/article
Revista Clínica Española, 2004, vol. 11, n. 204, p. 583-587
0014-2565
http://uvadoc.uva.es/handle/10324/5838
583
204
587
Revista Clínica Española
11
spa
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Elsevier Inc.
oai:uvadoc.uva.es:10324/58622021-06-23T11:41:24Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Levels of DKK1 in patients with acute myocardial infarction and response to atorvastatin
Pérez Castrillon, José Luis
San Miguel, Ángel
Vega, Gemma
Abad Manteca, Laura
Andrés Domingo, María
González Sagrado, Manuel
Luis Román, Daniel Antonio de
Dueñas Laita, Antonio
Arteriosclerosis - Tratamiento
Cardiovascular, Aparato - Enfermedades
Producción Científica
The atherosclerosis that appears in coronary, cerebrovascular and
peripheral arterial disease is responsible for most cardiovascular
diseases. It is characterized by chronic arterial inflammation caused
and exacerbated by disorders of the lipidic metabolism and other
clearly identified risk factors [1]. Calcification, which is initiated by an
active process in which inflammatory cytokines and other mediators
that regulate the phospho-calcium metabolism intervene, is characteristic
of atherosclerosis [2]. These mechanisms can intervene in an
opposite phenomenon that takes place at the level of the bone
characterized by a reduction in bone mineral content and alterations
in the microarchitecture that define osteoporosis. The association
between the two diseases, which share mechanisms but have a
different expression, is noteworthy.
2014-09-09
2014-09-09
2009
info:eu-repo/semantics/article
International Journal of Cardiology, 2009, p. 164-165
0167-5273
http://uvadoc.uva.es/handle/10324/5862
10.1016/j.ijcard.2009.07.025
164
165
International Journal of Cardiology
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Elsevier Ireland Ltd.
oai:uvadoc.uva.es:10324/58652021-06-23T11:41:26Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Contribution of genetic and epigenetic mechanisms to Wnt pathway activity in prevalent skeletal disorders
García Ibarbia, Carmen
Delgado Calle, Jesús
Casafont, Íñigo
Velasco Bernal, Javier
Arozamena, Jana
Pérez Núñez, María I.
Alonso, María A.
Berciano, María T.
Ortiz, Fernando
Pérez Castrillon, José Luis
Fernández, Agustín F.
Fraga, Mario F.
Zarrabeitia Cimiano, María Teresa
Riancho Moral, José Antonio
Osteoporosis
Cadera - Fracturas
Producción Científica
We reported previously that the expression of Wnt-related genes is lower in osteoporotic hip fractures than in 26
osteoarthritis. We aimed to confirm those results by analyzing β-catenin levels and explored potential genetic 27
and epigenetic mechanisms involved. 28
β-Catenin gene expression and nuclear levelswere analyzed by real time PCR and confocal immunofluorescence. 29
Increased nuclear β-catenin was found in osteoblasts isolated from patients with osteoarthritis (99 ± 4 30
units vs. 76 ± 12, p = 0.01, n = 10), without differences in gene transcription, which is consistent with 31
a post-translational down-regulation of β-catenin and decreased Wnt pathway activity. 32
Twenty four single nucleotide polymorphisms (SNPs) of genes showing differential expression between fractures 33
and osteoarthritis (WNT4, WNT10A, WNT16 and SFRP1) were analyzed in DNA isolated from blood of 853 pa- 34
tients. The genotypic frequencies were similar in both groups of patients, with no significant differences. 35
Methylation ofWnt pathway genes was analyzed in bone tissue samples (15 with fractures and 15 with osteo- 36
arthritis) by interrogating a CpG-based methylation array. Six genes showed significant methylation differences 37
between both groups of patients: FZD10, TBL1X, CSNK1E, WNT8A, CSNK1A1L and SFRP4. The DNA demethylating 38
agent 5-deoxycytidine up-regulated 8 genes, including FZD10, in an osteoblast-like cell line, whereas it down- 39
regulated other 16 genes. 40
In conclusion,Wnt activity is reduced in patientswith hip fractures, in comparisonwith thosewith osteoarthritis. 41
It does not appear to be related to differences in the allele frequencies of the Wnt genes studied. On the other 42
hand, methylation differences between both groups could contribute to explain the differences inWnt activity
2014-09-09
2014-09-09
2013
info:eu-repo/semantics/article
Gene, 2013, p. 1-8
0378-1119
http://uvadoc.uva.es/handle/10324/5865
10.1016/j.gene.2013.09.080
1
8
Gene
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Elsevier B.V.
oai:uvadoc.uva.es:10324/58682021-06-23T11:41:39Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Haplotypes of intron 4 of the estrogen receptor alpha gene and hip fractures: a replication study in Caucasians
Velasco Bernal, Javier
Hernández, Jose L.
Pérez Castrillon, José Luis
Zarrabeitia Cimiano, María Teresa
Alonso, María A.
González Macías, Jesús
Riancho Moral, José Antonio
Cadera - Fracturas
Producción Científica
Background: Despite their great impact, few genetic association studies have used hip fractures as an endpoint.
However, the association of two polymorphisms on intron 4 of estrogen receptor alpha (ESR1) with hip fractures
was recently reported in a Chinese population. The aim of this study was to investigate whether such association is
also present in Caucasians.
Methods: We analyzed those two SNPs and another neighbour SNP located on the exon 4 of ESR1 in 787 patients
with hip fractures and 953 controls from Spain.
Results: The allelic frequencies differed markedly from those reported in Asian populations. Nevertheless,
haplotypes including the rs3020314 and rs1884051 loci in intron 4 showed a significant association with hip
fractures (omnibus test p = 0.006 in the whole group and 0.00005 in women). In the sex-stratified analysis, the
association was significant in females, but not in males. In women, the CA haplotype appeared to have a
protective influence, being present in 6.5% of the controls, but only in 3% of patients with fractures (odds ratio
0.39; 95% confidence interval 0.26-0.59; estimated population preventive fraction 3.5%). The inclusion of the
rs1801132 SNP of exon 4 further increased the statistical significance of the association (odds ratio 0.17; 95% CI
0.08-0.37; p = 0.00001). Each SNP appeared to contribute independently to the association. No genotype-related
differences in gene expression were found in 42 femoral bone samples.
Conclusions: This study confirms the association of some polymorphisms in the region of exon 4/intron 4 of ESR1
and hip fractures in women. However, there are marked differences in allele frequencies between Asian and
Caucasian populations.
2014-09-09
2014-09-09
2010
info:eu-repo/semantics/article
BMC Medical Genetics, 2010, vol. 11, n. 16, p. 1-7
1471-2350
http://uvadoc.uva.es/handle/10324/5868
10.1186/1471-2350-11-16
1
16
7
BMC Medical Genetics
11
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
BioMed Central Ltd.
oai:uvadoc.uva.es:10324/58732021-06-23T11:41:40Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Lichen planus and hepatitis C virus infection
Giménez García, Rosa María
Pérez Castrillon, José Luis
Hepatitis C-Tratamiento
Producción Científica
The association of lichen planus (LP) with liver diseases is well established. The reported
prevalence rates of hepatitis C virus (HCV) antibodies in patients with LP tend to appear quite variable.
The aim of this study was to assess the prevalence of HCV antibodies in a group of patients with
LP and evaluate the clinical characteristics of the subgroup with LP associated with HCV.
2014-09-09
2015-09-09
2003
info:eu-repo/semantics/article
Journal of the European Academy of Dermatology and Venereology, 2003, vol. 17, p. 291-295
0926-9959
http://uvadoc.uva.es/handle/10324/5873
291
295
Journal of the European Academy of Dermatology and Venereology
17
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
European Academy of Dermatology and Venereology
oai:uvadoc.uva.es:10324/58792021-06-23T11:41:43Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Odanacatib: a possible new therapeutic option for the treatment of osteoporosis
Pérez Castrillon, José Luis
Pinacho Peláez, Florentino
Ruiz Mambrilla, Marta María
Dueñas Laita, Antonio
Osteoporosis
Producción Científica
Cathepsin K is a protease released by osteoclasts, which is involved in the destruction of collagen fibers that form the organic phase of the bone matrix, and plays a key role in bone resorption. Odanacatib is a selective inhibitor of cathepsin K, which blocks bone remodeling by inhibiting resorption. Phase II trials have shown that odanacatib is a potent antiresorptive agent and does not significantly reduce biochemical markers of bone formation during long-term treatment of postmenopausal women. This increases the bone mineral density that is comparable with the most powerful antiresorptive agents. Odanacatib has a generally favorable tolerability and safety profile. Currently, only Phase II studies have been reported and its efficacy in reducing fractures has not been demonstrated. The adverse effects are reversible and disappear after discontinuation. If this antifracture efficacy can be shown, odanacatib could be a a safe, efficacious option for the treatment of osteoporosis.
2014-09-09
2015-09-09
2012
info:eu-repo/semantics/article
International Journal of Clinical Rheumatology, vol. 7, n. 4, p. 1-8
1758-4272
http://uvadoc.uva.es/handle/10324/5879
1
4
8
International Journal of Clinical Rheumatology
7
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Future Medicine
oai:uvadoc.uva.es:10324/58812021-06-23T11:41:28Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Bone mineral density, bone remodeling and osteoprotegerin in patients with acute coronary syndrome
Pérez Castrillon, José Luis
Abad Manteca, Laura
Vega, Gemma
Sanz Cantalapiedra, Alberto
San Miguel, Ángel
Mazón Ramos, María de los Ángeles
Luis Román, Daniel Antonio de
Dueñas Laita, Antonio
Osteoporosis
Producción Científica
The objective of this study was to evaluate the relationship between coronary disease and osteoporosis and determine the effect of
osteoprotegerin (OPG) on bone remodeling and bone mineral density (BMD) in a group of patients with acute coronary syndrome. Eightythree
patients (52 males and 31 women) with acute coronary syndrome (75 patients with acute myocardial infarction and 8 with unstable
angina) with an average age of 61±10 years were studied. Levels of osteocalcin, urinarydeoxypyridinoline, OPG and the receptor activator of
nuclear factor-κB ligand (RANKL) were determined during the hospital stay. Femoral neck, trochanter and lumbar spine densitometry was
carried out using a DXA densitometer. Thirty percent of patients presented osteoporosis (39% of females and 26% of males). Osteoporotic
patients were older and had a lower weight and height and elevated serum levels of osteocalcin (3.6±2.25 2.63 versus ±1.55, p=0.05).
Levels of OPG and RANKL were similar in both groups and showed no relationship with BMD. In conclusion, no relationship was observed
between the OPG/RANKL system and BMD in these patients.
2014-09-09
2014-09-09
2008
info:eu-repo/semantics/article
International Journal of Cardiology, 2008, vol. 129, p. 144-145
0167-5273
http://uvadoc.uva.es/handle/10324/5881
10.1016/j.ijcard.2007.06.035
144
145
International Journal of Cardiology
129
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Elsevier Ireland Ltd.
oai:uvadoc.uva.es:10324/58822022-02-01T10:38:01Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Relation of resistin levels with cardiovascular risk factors, insulin resistance and inflammation in naı¨ve diabetes obese patients
Luis Román, Daniel Antonio de
González Sagrado, Manuel
Conde, R.
Aller de la Fuente, Rocío
Izaola Jauregui, Olatz
Fuente, Beatriz de la
Pérez Castrillon, José Luis
Romero, E.
Cardiovascular, Aparato - Enfermedades
Diabetes
Producción Científica
Background: The aim of the present study was to explore the relationship of resistin levels
with cardiovascular risk factors, insulin resistance and inflammation in naı¨ve diabetic
patients.
Subjects: A population of 66 naı¨ve diabetic patients with obesity was analyzed. A complete
nutritional and biochemical evaluation was performed.
Results: The mean age 56.9 11.6 years and the mean BMI was 37.8 6.3. Patients were
divided in two groups by median resistin value (3.3 ng/ml), group I (patients with the low
values, average value 2.5 0.5) and group II (patients with the high values, average value
4.8 1.8). Patients in the group I had lower waist circumference, total cholesterol, LDLcholesterol
and C-reactive protein than patients in group II. Correlation analysis showed a
significant correlation among resistin levels and the independent variables; BMI (r = 0.26;
p < 0.05), waist circumference (r = 0.38; p < 0.05), fat mass (r = 0.28; p < 0.05), LDL-cholesterol
(r = 0.3; p < 0.05), C-reactive protein (r = 0.28; p < 0.05). In the multivariate analysis, resistin
concentration increase 0.024 ng/ml (CI 95%: 0.006–0.42) for each mg/dl of C-reactive protein.
Conclusion: Circulating resistins are associated with C-reactive protein in an independent
way in naı¨ve diabetic patients.
2014-09-09
2014-09-09
2010
info:eu-repo/semantics/article
Diabetes Research and Clinical Practice, 2010, vol. 89, p. 110-114
0168-8227
http://uvadoc.uva.es/handle/10324/5882
10.1016/j.diabres.2010.03.031
110
114
Diabetes Research and Clinical Practice
89
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Elsevier
oai:uvadoc.uva.es:10324/59402021-06-23T11:41:30Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin
Pérez Castrillon, José Luis
Zarrabeitia Cimiano, María Teresa
Abad Manteca, Laura
Vega, Gemma
Ruiz Mambrilla, Marta María
González Sagrado, Manuel
Dueñas Laita, Antonio
Riancho Moral, José Antonio
Osteoporosis
Producción Científica
Although their primary therapeutic indications
are different, aminobisphosphonates and statins target
enzymes in the mevalonate pathway, which is critical for
bone homeostasis. Previous studies have shown that some
polymorphisms of the gene encoding farnesyl diphosphate
synthase (FDPS), the main target of aminobisphosphonates,
modulate the response to these drugs. In this study,
we explored whether those single nucleotide polymorphisms
(SNPs) also influence the changes in bone mineral
density (BMD) following therapy with statins. Sixty-six
patients with coronary heart disease were studied at baseline
and after 1-year therapy with atorvastatin. BMD
was measured by DXA. Three SNPs of the FDPS gene
(rs2297480, rs11264359 and rs17367421) were analyzed by using Taqman assays. The results showed that there was
no association between the SNPs and basal BMD. However,
rs2297480 and rs11264359 alleles, which are in linkage
disequilibrium, were associated with changes in hip
BMD following atorvastatin therapy. Thus, patients with
AA genotype at the rs2297480 locus had a 0.8 ± 0.8 %
increase in BMD at the femoral neck, whereas in patients
with AC/CC genotypes, BMD showed a 2.3 ± 0.8 %
decrease (p = 0.02). Similar results were obtained regarding
changes of BMD at the femoral trochanter and when
alleles at the rs11264359 locus were analyzed. However,
there was no association between BMD and rs17367421
alleles. In conclusion, these results suggest that polymorphisms
of the FDPS gene may influence the bone response
to various drugs targeting the mevalonate pathway, including
not only aminobisphosphonates but also statins.
2014-09-15
2014-09-15
2013
info:eu-repo/semantics/article
Rheumatology International, 2013, p. 1-5
0172-8172
http://uvadoc.uva.es/handle/10324/5940
10.1007/s00296-013-2914-x
1
5
Rheumatology International
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Springer-Verlag Berlin Heidelberg
oai:uvadoc.uva.es:10324/59412021-06-23T11:41:31Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Sarcoidosis and sacroiliitis, a case report
Briongos Figuero, Laisa Socorro
Ruiz de Temiño de la Peña, Ángela
Pérez Castrillon, José Luis
Huesos - Enfermedades
Producción Científica
Sarcoidosis is amultisystem disorder of unknown
etiology characterized by the presence of non-caseating
granulomas in the organs affected. Sarcoid arthropathy is a
rare manifestation, and sacroiliitis is an unusual first manifestation
of the disorder
2014-09-15
2014-09-15
2011
info:eu-repo/semantics/article
Rheumatology International, 2011, p. 1-2
0172-8172
http://uvadoc.uva.es/handle/10324/5941
10.1007/s00296-011-2100-y
1
2
Rheumatology International
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Springer-Verlag
oai:uvadoc.uva.es:10324/59432021-06-23T11:41:44Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Effect of the TNF -308 G/A Polymorphism on the Changes Produced by Atorvastatin in Bone Mineral Density in Patients with Acute Coronary Syndrome
Pérez Castrillon, José Luis
Vega, Gemma
Abad Manteca, Laura
Sanz Cantalapiedra, Alberto
González Sagrado, Manuel
Luis Román, Daniel Antonio de
Dueñas Laita, Antonio
Huesos - Enfermedades
Cardiovascular, Aparato - Enfermedades
Producción Científica
Aims: To evaluate the effect of atorvastatin on bone mass
and markers of bone remodeling in patients with acute coronary
syndrome depending on the tumor necrosis factor-
(TNF )-308 G/A polymorphism. Methods: Sixty-two patients
with acute coronary syndrome (35 males and 27 females),
average age 60 8 10 years, were included. Patients
were given low (10–20 mg) and high doses (40–80 mg) atorvastatin
according to their baseline levels of cholesterol and
triglycerides and their index of vascular risk. Patients were
studied during hospital admission (baseline) and at 12
months of follow-up. Cholesterol, triglycerides, total calcium,
phosphorus, magnesium, osteocalcin and urinary deoxypyridinoline
were determined in all patients at baseline
and at 12 months of follow-up. Densitometric studies were
conducted in the lumbar spine (L 2 –L 4 ), femoral neck and
trochanter using an X-ray densitometer. The TNF -308 G/A
polymorphism was determined by the polymerase chain reaction.
Results: Forty-five patients were homozygous for
G/G (72.5%) and 17 were heterozygous for G/A (27.5%). The
prevalence of osteoporosis (T score ^ 2.5 in the lumbar spineand/or hip) was 33% for the G/G genotype and 35% for the
G/A genotype, with no statistically significant differences
between groups. There was a statistically significant increase
in bone mineral density (BMD) in the lumbar spine (1.107 8
0.32 vs. 1.129 8 0.23; p = 0.0001) in patients with the G/G
genotype. No changes were observed in patients with the
G/A genotype. Conclusion: In patients with acute coronary
syndrome, atorvastatin increases lumbar spine BMD solely
in patients with the G/G genotype of the TNF -308 G/A polymorphism.
2014-09-15
2014-09-15
2008
info:eu-repo/semantics/article
Annals of Nutrition and Metabolism, 2008, vol. 53, p. 117-121
0250-6807
http://uvadoc.uva.es/handle/10324/5943
10.1159/000170886
117
121
Annals of Nutrition and Metabolism
53
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Karger
oai:uvadoc.uva.es:10324/59452021-06-23T11:41:33Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Association between vitamin D deficiency and heart failure in the elderly
Ruiz de Temiño de la Peña, Ángela
Gil, Judith
Maceda Pérez Grueso, María Teresa
González, Marta
Pineda, Mónica
Dueñas Laita, Antonio
Pérez Castrillon, José Luis
Osteoporosis
Producción Científica
Vitamin D (25-OH-vitamin D) is a hormone which acts on the
calcium-phosphorus metabolism and also has extraskeletal effects.
In the cardiovascular system, it regulates the renin-angiotensinaldosterone
system (RAAS), inhibits vascular smooth muscle proliferation,
and suppresses cardiac hypertrophy and hypercontractility [1].
We assessed the relationship between vitamin D deficiency
and heart failure (HF) in an elderly population. We carried out a
prospective case-control study in the Internal Medicine Department,
Rio Hortega Hospital, Valladolid in 2010. Twenty-five patients were
diagnosed with HF and 19 were institutionalized controls with no
history of cardiovascular disease (CVD). The age of patients and control
group was similar (83±7 years vs. 85±8 years, pN0.05). The sex
distribution don't show differences. HF was diagnosed according to
clinical and laboratory criteria (B-type natriuretic peptideN400 pg/mL).
Vitamin D insufficiency was defined as levelsb20 ng/ml and deficiency
asb10 ng/ml. Two-dimensional echocardiography evaluated systolic
and diastolic function, pulmonary artery systolic pressure (PASP), atrial
fibrillation and valvular disease in the HF group.
2014-09-15
2014-09-15
2011
info:eu-repo/semantics/article
International Journal of Cardiology, 2011, p. 407-408
0167-5273
http://uvadoc.uva.es/handle/10324/5945
10.1016/j.ijcard.2011.08.042
407
408
International Journal of Cardiology
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Elsevier Ireland Ltd.
oai:uvadoc.uva.es:10324/59472021-06-23T11:41:45Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study
Velasco Bernal, Javier
Zarrabeitia Cimiano, María Teresa
Prieto de Paula, José María
Pérez Castrillon, José Luis
Pérez Aguilar, M.
Sañudo, C.
Pérez Núñez, María I.
Hernández Elena, J.
Calvo, I.
Ortiz de Solorzano Aurusa, Francisco Javier
González Macías, Jesús
Riancho Moral, José Antonio
Osteoporosis
Producción Científica
In comparison with hip fractures, increased
expression of genes in the Wnt pathway and increased
Wnt activity were found in bone samples and osteoblast
cultures from patients with osteoarthritis, suggesting the
involvement of this pathway in subchondral bone changes.
No consistent differences were found in the genetic
association study.
2014-09-15
2014-09-15
2010
info:eu-repo/semantics/article
Osteoporosis International, 2010, vol. 21, p. 109-118
0937-941X
http://uvadoc.uva.es/handle/10324/5947
10.1007/s00198-009-0931-0
109
118
Osteoporosis International
21
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
International Osteoporosis Foundation and National Osteoporosis Foundation
oai:uvadoc.uva.es:10324/59482021-06-23T11:41:34Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Polymorphisms of the WNT10B Gene, Bone Mineral Density, and Fractures in Postmenopausal Women
Pérez Castrillon, José Luis
Olmos, José M.
Nan, Daniel N.
Castillo Vegas, Jesús Luis
Arozamena, Jana
Montero, Antonio
Pérez Núñez, María I.
Riancho Moral, José Antonio
Osteoporosis
Huesos-Fracturas
Producción Científica
Wnt ligands are important regulators of skeletal
homeostasis. Wnt10B tends to stimulate the differentiation
of common mesenchymal precursors toward the osteoblastic
lineage, while inhibiting adipocytic differentiation.
Hence, we decided to explore the association of WNT10B
allelic variants with bone mineral density and osteoporotic
fractures. A set of tag SNPs capturing most common
variations of the WNT10B gene was genotyped in 1438
Caucasian postmenopausal women, including 146 with
vertebral fractures and 432 with hip fractures. We found no
association between single SNPs and spine or hip bone
mineral density (BMD). In the multilocus analysis, some
haplotypes showed a slight association with spine BMD
(P = 0.03), but it was not significant after multiple-test
correction. There was no association between genotype and
vertebral or hip fractures. Transcripts of WNT10B and
other Wnt ligands were detected in human bone samples by
real-time PCR. However, there was no relationship
between genotype and RNA abundance. Thus, WNT10B is
expressed in the bone microenvironment and may be an
important regulator of osteoblastogenesis, but we have not found evidence for a robust association of common
WNT10B gene allelic variants with either BMD or fractures
in postmenopausal women.
2014-09-15
2014-09-15
2009
info:eu-repo/semantics/article
Calcified Tissue International, 2009, vol. 85, p. 113-118
0171-967X
http://uvadoc.uva.es/handle/10324/5948
10.1007/s00223-009-9256-4
113
118
Calcified Tissue International
85
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Springer Science+Business Media
oai:uvadoc.uva.es:10324/72162021-06-23T11:41:46Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Anaphylaxis caused by hidden soybean allergens in pillows
Armentia Medina, Alicia
Pineda, Fernando
Martín, Blanca
San Miguel, Ángel
Martín Gil, Francisco Javier
Puente, Yolanda
Licea, Carlos de
Palacios Peláez, Ricardo
Anafilaxis
Producción Científica
Pillow stuffing can contain polyester, feathers, down, or, more recently, soy-based materials. Component-resolved diagnosis and microarray technology might be useful in patients with foodsensitized allergies or anaphylaxis caused by hidden allergens.
We report 4 patients with repeated anaphylaxis, which was defined as a decrease in blood pressure and possibly lifethreatening adverse reactions1 during sleep at home but not in other places. Patient 1 was a 64-year-old woman with previous nocturnal rhinitis who began to experience anaphylaxis during sleep. Patient 2 was a 58-year-old man with progressive rhinitis, asthma, and anaphylaxis after changing his bedroom furniture and bed linen. Patient 3 was a 64-year-old woman with previous sensitization to Anisakis simplex and nocturnal pharyngeal angioedema unrelated to eating fish or other sources of A simplex who experienced severe anaphylaxis during sleep. Patient 4 was a 69-year-old woman with nocturnal anaphylaxis for 1 year before diagnosis
2014-11-21
2014-11-21
2013
info:eu-repo/semantics/article
Journal Allergy Clinical Inmunology, 2013, vol.131, n.1
0091-6749
http://uvadoc.uva.es/handle/10324/7216
10.1016/j.jaci2012.09.012
1
Journal Allergy Clinical Inmunology
131
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Universidad de Valladolid. Facultad de Medicina
oai:uvadoc.uva.es:10324/72172021-06-23T11:41:47Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Allergic hypersensitivity to cannabis in patients with allergy and illicit drug users
Armentia Medina, Alicia
Castrodeza Sanz, José Javier
Ruiz Muñoz, Pedro
Martínez Quesada, Jorge
Postigo Resa, Idoia
Herrero, Manuel
González Sagrado, Manuel
Martín Armentia, Blanca
Guisantes, Jorge A.
Luis Román, Daniel Antonio de
Cannabis - Alergia
Producción Científica
: Cannabis is the illicit drug most widely used by young people in high-income countries. Allergy symptoms have only occasionally been reported as one of the adverse health effects of cannabis use.
Objectives: To study IgE-mediated response to cannabis in drug users, atopic patients, and healthy controls.
Methods: Asthmatic patients sensitised to pollen, and all patients sensitised to tobacco, tomato and latex, considered as cross-reacting allergens, were selected from a data base of 21,582 patients. Drug users attending a drug-rehabilitation clinic were also included. Controls were 200 non-atopic blood donors. Specific IgE determination, prick tests and specific challenge with cannabis extracts were performed in patients and controls.
2014-11-21
2014-11-21
2011
info:eu-repo/semantics/article
Allergologia et Immunopathologia, vol.39, n.5. p.271-279.
0301-0546
http://uvadoc.uva.es/handle/10324/7217
10.1016/j.jaci2012.09.012
271
5
279
Allergologia et immunopathologia
39
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Elsevier-Doyma
Attribution-NonCommercial-NoDerivatives 4.0 International
Elsevier-Doyma
oai:uvadoc.uva.es:10324/80642021-06-23T11:41:52Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Prevalence of dementia and subtypes in Valladolid, northwestern Spain: The deminvall study
Tola Arribas, Miguel Ángel
Yugueros Fernández, María Isabel
Garea García-Malvar, María José
Ortega Valín, Fernando
Cerón Fernández, Ana Isabel
Fernández Malvido, Beatriz
San José Gallegos, Antonio
González Touya, Marta
Botrán Velicia, Ana
Iglesias Rodríguez, Vanessa
Díaz Gómez, Bárbara
Personas de edad - Enfermedades mentales
Producción Científica
To describe the prevalence of dementia and subtypes in a general elderly population in northwestern
Spain and to analyze the influence of socio-demographic factors.
Methods: Cross-sectional, two-phase, door-to-door, population-based study. A total of 870 individuals from a rural
region and 2,119 individuals from an urban region of Valladolid, Spain, were involved. The seven-minute screen
neurocognitive battery was used in the screening phase. A control group was included.
Results: A total of 2,170 individuals aged 65 to 104 years (57% women) were assessed. There were 184 subjects
diagnosed with dementia. The crude prevalence was 8.5% (95% CI: 7.3-9.7). Age- and sex-adjusted prevalence was
5.5 (95% CI: 4.5-6.5). Main subtypes of dementia were: Alzheimer’s disease (AD) 77.7%, Lewy Body disease, 7.6%
and vascular dementia (VD) 5.9%. Crude prevalences were 6.6% (AD), 0.6% (Lewy Body disease), and 0.5% (VD).
Dementia was associated with age (OR 1.14 for 1-year increase in age), female sex (OR 1.79) and the absence of
formal education (OR 2.53 compared to subjects with primary education or more).
Conclusion: The prevalence of dementia in the study population was lower than the most recent estimates for
Western Europe. There was a high proportion of AD among all dementia cases and very low prevalence of VD. Old
age, female sex, and low education level were independent risk factors for dementia and AD.
2015-02-02
2015-02-02
2013
info:eu-repo/semantics/article
Plos One, Octubre 2013, vol 8 (10)
1932-6203
http://uvadoc.uva.es/handle/10324/8064
10.1371/journal.pone.0077688
Plos One
8
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Public Library of Science
oai:uvadoc.uva.es:10324/81272021-06-23T11:41:49Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Prevalence of multiple sclerosis in Valladolid, northern Spain
Tola Arribas, Miguel Ángel
Yugueros Fernández, María Isabel
Fernández Buey, Nieves
Fernández Herranz, Rosario
Esclerósis múltiple
Producción Científica
The aim of this study was to ascertain the prevalence of multiple sclerosis (MS) in a northern Spanish region and to compare it with that from the most recent epidemiological studies in the country. MS prevalence was studied for a period of 2 years using multiple sources of information in the province of Valladolid, with a sample comprising a total population of 92,632. Patients were classified according to the Poser criteria. The crude prevalence of definite and probable MS was 58.3 per 100,000 (95% confidence interval: 43.7–75.7). The same methods have been used in ascertaining similar prevalence rates in Vélez-Málaga, Osona, and Gijón and a slightly lower rate in Teruel. Our survey confirms Spain as a high-risk area for MS, with prevalence rates over 50 per 100,000
2015-02-04
2015-02-04
1999
info:eu-repo/semantics/article
Journal of Neurology, (1999), vol.246, n. 3 p.170-174
0340-5354
http://uvadoc.uva.es/handle/10324/8127
10.1007/s004150050329
170
3
174
Journal of Neurology
246
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Steinkopff Verlag
oai:uvadoc.uva.es:10324/81372021-06-23T11:41:50Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Design, methods and demographic findings of the DEMINVALL survey: a population-based study of Dementia in Valladolid, Northwestern Spain
Tola Arribas, Miguel Ángel
Garea García-Malvar, María José
Yugueros Fernández, María Isabel
Ortega Valín, Fernando
Cerón Fernández, Ana Isabel
Fernández Malvido, Beatriz
González Touya, Marta
San José Gallegos, Antonio
Botrán Velicia, Ana
Iglesias Rodríguez, Vanessa
Díaz Gómez, Bárbara
Enfermedades mentales
Producción Científica
This article describes the rationale and design of a population-based survey of dementia in Valladolid
(northwestern Spain). The main aim of the study was to assess the epidemiology of dementia and its subtypes.
Prevalence of anosognosia in dementia patients, nutritional status, diet characteristics, and determinants of
non-diagnosed dementia in the community were studied. The main sociodemographic, educational, and general
health status characteristics of the study population are described.
Methods: Cross-over and cohort, population-based study. A two-phase door-to-door study was performed. Both
urban and rural environments were included. In phase 1 (February 2009 – February 2010) 28 trained physicians
examined a population of 2,989 subjects (age: ≥ 65 years). The seven-minute screen neurocognitive battery was
used. In phase 2 (May 2009 – May 2010) 4 neurologists, 1 geriatrician, and 3 neuropsychologists confirmed the
diagnosis of dementia and subtype in patients screened positive by a structured neurological evaluation. Specific
instruments to assess anosognosia, the nutritional status and diet characteristics were used. Of the initial sample,
2,170 subjects were evaluated (57% female, mean age 76.5 ± 7.8, 5.2% institutionalized), whose characteristics are
described. 227 persons were excluded for various reasons. Among those eligible were 592 non-responders. The
attrition bias of non-responders was lower in rural areas. 241 screened positive (11.1%).
Discussion: The survey will explore some clinical, social and health related life-style variables of dementia. The
population size and the diversification of social and educational backgrounds will contribute to a better knowledge
of dementia in our environment.
Keywords: Dementia prevalence, Epidemiology, Undiagnosed dementia, Population-based survey, Seven-minute
screen, Anosognosia, Nutritional assessment
2015-02-04
2015-02-04
2012
info:eu-repo/semantics/article
BMC Neurology 2012, vol. 12:86
1471-2377
http://uvadoc.uva.es/handle/10324/8137
10.1186/1471-2377-12-86
86
BMC Neurology
12
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
BioMed Central
oai:uvadoc.uva.es:10324/478872022-07-18T09:32:54Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Prehospital troponin as a predictor of early clinical deterioration
Martín Rodríguez, Francisco
Sanz García, Ancor
Castro Portillo, Enrique
Delgado Benito, Juan F.
Pozo Vegas, Carlos del
Ortega Rabbione, Guillermo
Martín Herrero, Francisco
Martín Conty, José Luis
López Izquierdo, Raúl
Producción Científica
Antecedentes y objetivos
Los valores elevados de la troponina T (cTnT) se asocian a comorbilidades y a mortalidad temprana, en enfermedades cardiovasculares y noncardiovascular. El objetivo de este estudio es evaluar la exactitud pronóstica de la utilización única de la troponina cardíaca T del punto de atención prehospital para identificar el riesgo de deterioro prehospital del hospital, incluyendo mortalidad en el plazo de 28 días.
Métodos
Se realizó un estudio prospectivo, multicéntrico, controlado, basado en ambulancias, observacional en adultos con enfermedades agudas transferidos con alta prioridad en ambulancia a los departamentos de emergencia, entre el 1 de enero y el 30 de septiembre de 2020. Excluyeron a los pacientes con diagnosis del hospital del síndrome coronario agudo. El poder discriminativo de la cTnT predictiva fue evaluado a través de un modelo de discriminación entrenado utilizando una cohorte de derivación y evaluado por el área bajo la curva de la característica operativa del receptor en una cohorte de validación.
Resultados
Un total de 848 pacientes fueron incluidos en nuestro estudio. La edad media era de 68 años (percentiles 25º-75º: 50-81 años), y 385 (45,4%) eran mujeres. La tasa de mortalidad en 28 días fue del 12,4% (156 casos). La capacidad predictiva de la cTnT para predecir la mortalidad presentó un área por debajo de la curva de 0,903 (IC95%: 0,85-0,954; P < .001). Se realizó estratificación del riesgo, resultando en tres categorías con los siguientes puntos de corte óptimos de cTnT: alto riesgo mayor o igual a 100, riesgo intermedio 40-100 y bajo riesgo menor a 40 ng/L. En el grupo de alto riesgo, la tasa de mortalidad fue de 61,7%, y por el contrario, el grupo de bajo riesgo presentó una mortalidad de 2,3%.
Conclusiones
La implementación de una determinación rutinaria de cTnT en la ambulancia en pacientes transferidos con alta prioridad al servicio de urgencias puede ayudar a estratificar el riesgo de estos pacientes y a detectar un deterioro clínico temprano desconocido.
Background and Objectives: Elevated troponin T (cTnT) values are associated
with comorbidities and early mortality, in both cardiovascular and noncardiovascular
diseases. The objective of this study is to evaluate the prognostic accuracy of the sole
utilization of prehospital point-of-care cardiac troponin T to identify the risk of early
in-hospital deterioration, including mortality within 28 days.
Methods: We conducted a prospective, multicentric, controlled, ambulance-based,
observational study in adults with acute diseases transferred with high priority by
ambulance to emergency departments, between 1 January and 30 September 2020.
Patients with hospital diagnosis of acute coronary syndrome were excluded. The
discriminative power of the predictive cTnT was assessed through a discrimination
model trained using a derivation cohort and evaluated by the area under the curve of
the receiver operating characteristic on a validation cohort.
Results: A total of 848 patients were included in our study. The median age was
68 years (25th-75th percentiles: 50-81 years), and 385 (45.4%) were women. The mortality rate within 28 days was 12.4% (156 cases). The predictive ability of cTnT
to predict mortality presented an area under the curve of 0.903 (95% CI: 0.85-0.954;
P < .001). Risk stratification was performed, resulting in three categories with the
following optimal cTnT cut-off points: high risk greater than or equal to 100, interme diate risk 40-100 and low risk less than 40 ng/L. In the high-risk group, the mortality
rate was 61.7%, and on the contrary, the low-risk group presented a mortality of 2.3%.
Conclusions: The implementation of a routine determination of cTnT on the am bulance in patients transferred with high priority to the emergency department
can help to stratify the risk of these patients and to detect unknown early clinical
deterioration.
2021-08-18
2021-08-18
2021
info:eu-repo/semantics/article
European Journal of Clinical Investigation, 2021, vol. 00, e13591
0014-2972
https://uvadoc.uva.es/handle/10324/47887
10.1111/eci.13591
European Journal of Clinical Investigation
1365-2362
eng
https://onlinelibrary.wiley.com/doi/full/10.1111/eci.13591
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc/4.0/
© 2021 The Authors
Atribución-NoComercial 4.0 Internacional
Wiley
oai:uvadoc.uva.es:10324/480972021-08-26T20:47:00Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Time for a prehospital-modified sequential organ failure assessment score: An ambulance–Based cohort study
Martín Rodríguez, Francisco
Sanz García, Ancor
Pozo Vegas, Carlos del
Ortega, Guillermo José
Castro Villamor, Miguel Ángel
López Izquierdo, Raúl
Producción Científica
Background: To adapt the Sequential Organ Failure Assessment (SOFA) score to fit the prehospital care needs; to do that, the SOFA was modified by replacing platelets and bilirubin, by lactate, and tested this modified SOFA (mSOFA) score in its prognostic capacity to assess the mortality-risk at 2 days since the first Emergency Medical Service (EMS) contact.
Methods: Prospective, multicentric, EMS-delivery, ambulance-based, pragmatic cohort study of adults with acute diseases, referred to two tertiary care hospitals (Spain), between January 1st and December 31st, 2020. The discriminative power of the predictive variable was assessed through a prediction model trained using the derivation cohort and evaluated by the area under the curve (AUC) of the receiver operating characteristic (ROC) on the validation cohort.
Results: A total of 1114 participants comprised two separated cohorts recruited from 15 ambulance stations. The 2-day mortality rate (from any cause) was 5.9% (66 cases). The predictive validity of the mSOFA score was assessed by the calculation of the AUC of ROC in the validation cohort, resulting in an AUC of 0.946 (95% CI, 0.913–0.978, p < .001), with a positive likelihood ratio was 23.3 (95% CI, 0.32–46.2).
Conclusions: Scoring systems are now a reality in prehospital care, and the mSOFA score assesses multiorgan dysfunction in a simple and agile manner either bedside or en route. Patients with acute disease and an mSOFA score greater than 6 points transferred with high priority by EMS represent a high early mortality group.
2021-08-26
2021-08-26
2021
info:eu-repo/semantics/article
The American Journal of Emergency Medicine, 2021, vol. 49. p. 331-337
0735-6757
https://uvadoc.uva.es/handle/10324/48097
10.1016/j.ajem.2021.06.042
eng
https://www.sciencedirect.com/science/article/pii/S073567572100526X?via%3Dihub
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2021 The Authors
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Elsevier
oai:uvadoc.uva.es:10324/507592022-07-18T09:32:55Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Validation of a survival benefit estimator tool in a cohort of European kidney transplant recipients
Coca Rojo, Armando
Arias Cabrales, Carlos Enrique
Valencia Peláez, Ana Lucía
Burballa Tarrega, Carla Cristina
Bustamante Munguira, Juan
Redondo Pachón, María Dolores
Acosta Ochoa, María Isabel
Crespo Barrio, Marta
Bustamante Bustamante, Jesús
Mendiluce Herrero, Alicia
Pascual Santos, Julio
Pérez Saéz, María José
Riñones - Enfermedades - Tratamiento
Riñones - Trasplante
Survival
Supervivencia
Producción Científica
Pre-transplant prognostic scores help to optimize donor/recipient allocation and to minimize organ
discard rates. Since most of these scores come from the US, direct application in non-US populations is
not advisable. The Survival Benefit Estimator (SBE), built upon the Estimated Post-Transplant Survival
(EPTS) and the Kidney Donor Profile Index (KDPI), has not been externally validated. We aimed to
examine SBE in a cohort of Spanish kidney transplant recipients. We designed a retrospective cohortbased study of deceased-donor kidney transplants carried out in two different Spanish hospitals.
Unadjusted and adjusted Cox models were applied for patient survival. Predictive models were
compared using Harrell’s C statistics. SBE, EPTS and KDPI were independently associated with patient
survival (p ≤ 0.01 in all models). Model discrimination measured with Harrell’s C statistics ranged from
0.57 (KDPI) to 0.69 (SBE) and 0.71 (EPTS). After adjustment, SBE presented similar calibration and
discrimination power to that of EPTS. SBE tended to underestimate actual survival, mainly among
high EPTS recipients/high KDPI donors. SBE performed acceptably well at discriminating posttransplant
survival in a cohort of Spanish deceased-donor kidney transplant recipients, although its use as the main allocation guide, especially for high KDPI donors or high EPTS recipients requires further testing.
2021-12-02
2021-12-02
2020
info:eu-repo/semantics/article
Scientific Reports, 2020, vol. 10, 17109
2045-2322
https://uvadoc.uva.es/handle/10324/50759
10.1038/s41598-020-74295-3
1
1
10
Scientific Reports
10
2045-2322
eng
https://www.nature.com/articles/s41598-020-74295-3
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2020 Springer
Atribución 4.0 Internacional
Springer
oai:uvadoc.uva.es:10324/507642022-06-28T07:28:50Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Hypoglycemia following intravenous insulin plus glucose for hyperkalemia in patients with impaired renal function
Coca Rojo, Armando
Valencia Peláez, Ana Lucía
Bustamante Bustamante, Jesús
Mendiluce Herrero, Alicia
Floege, Jürgen
Hipoglucemia
Insuficiencia renal
Insulina
Riñones - Enfermedades
Producción Científica
Background: Hypoglycemia is a serious complication following the administration of insulin for hyperkalemia. We determined the incidence of hypoglycemia and severe hypoglycemia (blood glucose <70 or ≤40 mg/dl, respectively) in a cohort of AKI and non-dialysis dependent CKD patients who received an intravenous infusion of insulin plus glucose to treat hyperkalemia.
Methods: We retrospectively reviewed charts of all AKI and non-dialysis dependent CKD patients who received 10 U of insulin plus 50 g glucose to treat hyperkalemia from December 1, 2013 to May 31, 2015 at our Department.
Results: One hundred sixty four episodes of hyperkalemia were treated with insulin plus glucose and were eligible for analysis. Serum potassium levels dropped by 1.18 ± 1.01 mmol/l. Eleven treatments (6.1%) resulted in hypoglycemia and two (1.2%) in severe hypoglycemia. A lower pretreatment blood glucose tended to associate with a higher subsequent risk of hypoglycemia. Age, sex, renal function, an established diagnosis of diabetes or previous treatment were not associated with the development of this complication. We did not register any significant adverse events.
Conclusion: Our intravenous regimen combining an infusion of insulin plus glucose effectively reduced serum potassium levels compared to previous studies and associated a low risk of symptomatic hypoglycemia and other complications.
2021-12-02
2021-12-02
2017
info:eu-repo/semantics/article
PLoS ONE, 2017, vol. 12, n. 2
1932-6203
https://uvadoc.uva.es/handle/10324/50764
10.1371/journal.pone.0172961
1
2
12
PLoS ONE
12
eng
https://pubmed.ncbi.nlm.nih.gov/28245289/
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2017 Public Library of Science
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Public Library of Science
oai:uvadoc.uva.es:10324/507652022-07-18T09:32:55Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Reversible posterior leukoencephalopathy syndrome: a recurrent and atypical case in hemodialysis
Palacios Parada, María Anthoanet
Acosta Ochoa, María Isabel
Núñez García, Jesús Matías
Aller Aparicio, Carmen
Sanz Ballesteros, María Sandra
Mendiluce Herrero, Alicia
Riñones - Enfermedades
Diálisis
Hemodiálisis
Cerebro - Enfermedades
Producción Científica
Reversible posterior leukoencephalopathy syndrome (RPLS)is a clinical and radiological syndrome described in 1996.Its pathogenesis is still unclear and there are two theories:(1) cerebral hyperperfusion and (2) severe vasospasm.1–3Itis associated with malignant hypertension, eclampsia andother coexisting conditions in patients with chronic kidneydisease (CKD) such as hypertension, vascular or autoimmunediseases, as well as immunosuppressants, erythropoietin andtransplantation. [Texto extraído del artículo de Alicia Mendiluce Herrero].
2021-12-02
2021-12-02
2016
info:eu-repo/semantics/article
Nefrología, 2016, vol. 36, n. 2, p. 192-193
0211-6995
https://uvadoc.uva.es/handle/10324/50765
10.1016/j.nefroe.2016.03.007
192
2
193
Nefrología
36
eng
https://www.revistanefrologia.com/en-reversible-posterior-leukoencephalopathy-syndrome-recurrent-articulo-S2013251416300050
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2016 Sociedad Española de Nefrología
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Sociedad Española de Nefrología
oai:uvadoc.uva.es:10324/507682023-04-21T08:45:18Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Heterogeneity of induction therapy in Spain: changing patterns according to year, centre, indications and results
Rodrigo Calabia, Emilio
Fernandez Fresnedo, Gema
Robledo Zulet, Carmen
Palomar Fontanet, Rosa
Cantarell Aixandri, María del Carmen
Mazuecos Blanca, Auxiliadora
Osuna Ortega, Antonio
Mendiluce Herrero, Alicia
Alarcón Zurita, Antonio
Arias Rodríguez, Manuel
Riñones - Trasplante
Riñones - Enfermedades - Tratamiento
Producción Científica
Background. The use of induction drugs has increased markedly over the last 15 years in the USA, but there are few data about their use in other countries. Moreover, there are not enough data about when they are indicated and their long-term effects. The aim of our study was to know the rates of use and the drugs used as induction therapy, in which patients they were prescribed and the long-term graft survival effect in Spain.
Methods. We conducted a retrospective cohort study with adult patients (4861) receiving a kidney allograft in Spain over four different years (1990, 1994, 1998 and 2002) with a functioning graft at the end of the first post-transplant year. Induction therapy was defined as when the patient received polyclonal antibodies, OKT3 monoclonal antibodies or anti-CD25 monoclonal antibodies.
Results. From 1990 to 2002, the use of induction therapy in Spain changed, with a progressive reduction in the use of OKT3 and an increasing use of anti-CD25 antibodies. There were great differences in the rate of induction use from one centre to another, although with a common trend to greater use at each centre. Induction therapy was mainly prescribed in patients with a higher rejection risk (higher panel reactive antibody (PRA) titres and mismatches and re-transplants) and in older and diabetic recipients. Lastly, patients who were treated with induction therapy had significant higher allograft survival than those who did not (P value = 0.035).
Conclusions. The use of induction therapy in Spain has changed, with an increasing use of monoclonal antibodies in recent years. Induction therapy has a protective role in long-term graft survival.
2021-12-03
2021-12-03
2010
info:eu-repo/semantics/article
NDT Plus, 2010, vol. 3, supl. 2, p. 9-14
1753-0784
https://uvadoc.uva.es/handle/10324/50768
10.1093/ndtplus/sfq066
10.1016/S0895-7061(99)00261-7
9
suppl 2
14
NDT Plus
3
2048-8513
eng
https://academic.oup.com/ckj/article/3/suppl_2/ii9/447413
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2010 Oxford University Press
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Oxford University Press
European Renal Association
oai:uvadoc.uva.es:10324/507692022-01-05T11:54:00Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Recipient age as a determinant factor of patient and graft survival
Moreso Mateos, Francesc
Ortega Suárez, Francisco
Mendiluce Herrero, Alicia
Riñones - Trasplante
Survival
Supervivencia
Producción Científica
Background. Age of renal transplants has been related to death, alloimmune response and graft outcome. We reviewed the influence of patient age on transplant outcome in three cohorts of patients transplanted in Spain during the 1990s.
Methods. Patient age was categorized into four groups (I, 18–40; II, 41–50; III, 51–60; and IV, > 60 years). Risks factors for acute rejection were evaluated by logistic regression adjusting for transplant centre and transplantation year, while a Cox proportional hazard model was employed for analysing patient and graft survival.
Results. Older patients had a higher death rate (I, 3.5%; II, 7.7%; III, 13.2%; and IV, 16.9%; P<0.001), but a lower standardized mortality index (I, 7.6; II, 7.0; III, 5.8; and IV, 4.1; P = 0.0019). Older patients had the lowest risk of acute rejection [odds ratio (OR) 0.79 and 95% confidence interval (CI) 0.66–0.97 for group II; OR 0.75 and 95% CI 0.62–0.91 for group III; OR 0.43 and 95% CI 0.33–0.56 for group IV). Death-censored graft survival was poorer in patients older than 60 years (relative risk 1.40; 95% CI 1.09–1.80), but this result was not explained by any combination of patient age with donor age, delayed graft function or immunosuppression.
Conclusions. Patient age is a main determinant of transplant outcome. Although death rate is higher for older patients, standardized mortality was not. Thus, the efforts to reduce mortality should be also implemented in younger patients. Old patients have a low risk of acute rejection but a poorer death-censored graft survival. This last result was not explained by any controlled variable in our study.
2021-12-03
2021-12-03
2004
info:eu-repo/semantics/article
Nephrology Dialysis Transplantation, 2004, vol. 19, supl. 3, p. 16–20
0931-0509
https://uvadoc.uva.es/handle/10324/50769
https://doi.org/10.1093/ndt/gfh1009
16
Supl. 3
20
0931-0509
19
eng
https://academic.oup.com/ndt/article/19/suppl_3/iii16/1826912
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2004 Oxford University Press
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Oxford University Press
European Renal Association
oai:uvadoc.uva.es:10324/507732022-01-05T10:53:01Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
The use of antihypertensive therapy in Spain (1986-1994)
Suliman Jabary, Najaty
Mendiluce Herrero, Alicia
Álvarez González, Francisco Javier
Hipertensión arterial - Tratamiento - España - 1986-1994
Drogas
Producción Científica
We aimed to analyze the trends in antihypertensive therapy in Spain during the period 1986 to 1994, as well as the change in the pattern of different drugs, in relation to different national/international recommendations for hypertension treatment. Antihypertensive consumption was studied using the defined daily dose (DDD) and the DHD (DDD/1000 inhabitants/ day) of each drug, as defined by the Drug Utilization Research Group of the European Office of the World Health Organization. The anatomical classification of hypotensive drugs has been made according to EPhMRA (European Pharmaceutical Market Association) guidelines. A significant increase of 117.4% (41.39/90 DHD)
in antihypertensive drug consumption was observed in the period 1986 to 1994. In 1986 diuretics were the most consumed (30.27 DHD), followed by calcium antagonists (5.37), b-blockers (3.93), and the angiotensin-converting enzyme (ACE) inhibitor (1.37). In 1994 ACE inhibitors, calcium antagonists, and b-blockers increased significantly (P < .0001), whereas diuretics were still the most commonly prescribed. Nifedipine and captopril were the most used among calcium antagonists and ACE inhibitors. National and international recommendations had no effect on prescription patterns. Antihypertensive therapy of all types is increasing in Spain. Diuretics remain the most popular, b-blockers stay stable, whereas the newer types are rising rapidly. National and international recommendations had no effect on prescription patterns.
2021-12-09
2021-12-09
2000
info:eu-repo/semantics/article
American Journal of Hypertension, 2000, vol. 13, n. 6, p. 607–610
0895-7061
https://uvadoc.uva.es/handle/10324/50773
10.1016/S0895-7061(99)00261-7
607
6
610
American Journal of Hypertension
13
eng
https://academic.oup.com/ajh/article/13/6/607/186399?login=true
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2000 Oxford University Press
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Oxford University Press
oai:uvadoc.uva.es:10324/507782022-07-18T09:32:56Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice
Fernandez Ruiz, Mario
Arias Rodriguez, Manuel
Campistol Plana, Josep María
Navarro Ortega, David
Gómez Huertas, Ernesto
Gómez Márquez, Gonzalo
Díaz Gómez, Juan Manuel
Hernández Marrero, Domingo
Bernal Blanco, Gabriel
Cofán Pujol, Frederic
Jimeno García, Luisa
Franco Esteve, Antonio
Gonzalez Monte, Esther
Moreso Mateos, Francesc
Gómez Alamillo, Carlos
Mendiluce Herrero, Alicia
Luna Huerta, Enrique
Aguado García, José María
Riñones - Trasplante
SIDA (Enfermedad)
Producción Científica
There is notable heterogeneity in the implementation of cytomegalovirus (CMV) prevention practices among CMV-seropositive (R+) kidney transplant (KT) recipients. In this prospective observational study, we included 387 CMV R+ KT recipients from 25 Spanish centers. Prevention strategies (antiviral
prophylaxis or preemptive therapy) were applied according to institutional protocols at each site. The impact on the 12-month incidence of CMV disease was assessed by Cox regression. Asymptomatic CMV infection, acute rejection, graft function, non-CMV infection, graft loss, and all-cause mortality were also analyzed (secondary outcomes). Models were adjusted for a propensity score (PS) analysis for receiving antiviral prophylaxis. Overall, 190 patients (49.1%) received preemptive therapy, 185 (47.8%) antiviral prophylaxis, and 12 (3.1%) no specific intervention. Twelve-month cumulative incidences of CMV disease and asymptomatic infection were 3.6% and 39.3%, respectively. Patients on prophylaxis had lower incidence of CMV disease [PS-adjusted HR (aHR): 0.10; 95% confidence interval (CI): 0.01–0.79]
and asymptomatic infection (aHR: 0.46; 95% CI: 0.29–0.72) than those managed preemptively, with no significant differences according to the duration of prophylaxis. All cases of CMV disease in the prophylaxis group occurred after prophylaxis discontinuation. There were no differences in any of the secondary outcomes. In conclusion, antiviral prophylaxis was associated with a lower occurrence of CMV disease in CMV R+ KT recipients, although such benefit should be balanced with the risk of late-onset disease.
2021-12-09
2021-12-09
2015
info:eu-repo/semantics/article
Transplant International, 2015, vol. 28, n. 9, p. 1042-1054
0934-0874
https://uvadoc.uva.es/handle/10324/50778
10.1111/tri.12586
1042
9
1054
Transplant International
28
eng
https://onlinelibrary.wiley.com/doi/10.1111/tri.12586
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2015 European Society for Organ Transplantation
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
European Society for Organ Transplantation (ESOT)
Wiley
oai:uvadoc.uva.es:10324/509192022-01-05T21:46:42Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Impact on outcomes across KDIGO-2012 AKI criteria according to baseline renal function
Acosta Ochoa, María Isabel
Bustamante Munguira, Juan
Mendiluce Herrero, Alicia
Bustamante Bustamante, Jesús
Coca Rojo, Armando
Riñones - Enfermedades
Chronic renal failure
Insuficiencia renal crónica
Producción Científica
Acute kidney injury (AKI) and Chronic Kidney Disease (CKD) are global health problems. The pathophysiology of acute-on-chronic kidney disease (AoCKD) is not well understood. We aimed to study clinical outcomes in patients with previous normal (pure acute kidney injury; P-AKI) or impaired kidney function (AoCKD) across the 2012 Kidney Disease Improving Global Outcomes (KDIGO) AKI classification. We performed a retrospective study of patients with AKI, divided into P-AKI and AoCKD groups, evaluating clinical and epidemiological features, distribution across KDIGO-2012 criteria, in-hospital mortality and need for dialysis. One thousand, two hundred and sixty-nine subjects were included. AoCKD individuals were older and had higher comorbidity. P-AKI individuals fulfilled more often the serum creatinine (SCr) > 3.0x criterion in AKI-Stage3, AoCKD subjects reached SCr > 4.0 mg/dL criterion more frequently. AKI severity was associated with in-hospital mortality independently of baseline renal function. AoCKD subjects presented higher mortality when fulfilling AKI-Stage1 criteria or SCr > 3.0x criterion within AKI-Stage3. The relationship between mortality and associated risk factors, such as the net increase of SCr or AoCKD status, fluctuated depending on AKI stage and stage criteria sub-strata. AoCKD patients that fulfil SCr increment rate criteria may be exposed to more severe insults, possibly explaining the higher mortality. AoCKD may constitute a unique clinical syndrome. Adequate staging criteria may help prompt diagnosis and administration of appropriate therapy.
2021-12-13
2021-12-13
2019
info:eu-repo/semantics/article
Journal of Clinical Medicine (JCM), 2019, vol. 8, n. 9, 1323
2077-0383
https://uvadoc.uva.es/handle/10324/50919
https://doi.org/10.3390/jcm8091323
9
Journal of Clinical Medicine (JCM)
8
eng
https://www.mdpi.com/2077-0383/8/9/1323
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2019 MDPI
Attribution 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/509332022-07-18T09:32:56Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Impact of targeting Kt instead of Kt/V
Maduell Canals, Francisco
Ramos Sánchez, Rosa
Palomares Sancho, Inés
Martín Malo, Alejandro
Molina Núñez, Manuel
Bustamante Bustamante, Jesús
Perez Garcia, Rafael
Grassmann, Aileen
Merello Godino, José Ignacio
Diálisis
Hemodiálisis
Riñones - Enfermedades
Producción Científica
Background. Patients must receive an adequate dialysis dose in each hemodialysis (HD) session. Ionic dialysance (ID) enables the dialysis dose to be monitored in each session. The aim of this study was to compare the achievement of Kt versus eKt/V values and to analyse the main impediments to reaching
the dialysis dose. Methods. Of 5316 patients from 54 Fresenius Medical Care centers in Spain undergoing their usual HD regime, 3275 received ID and were included in the study.
Results. The minimum prescribed dose of eKt/V was reached in 91.2% of the patients, while the minimum recommended dose of Kt was reached in only 66.8%. Patients not receiving the minimum Kt dose were older, had spent 7 months less on dialysis, had a dialysis duration of 6 min less, had 5.7 kg more
of body weight and Qb was 47 mL/min lower. The target Kt was not reached by 62% of patients with catheters and by 37% of women. With each quintile increase of body weight, eKt/V decreased and Kt increased. Of patients with a body weight >80 kg, 1.4%, mostly men, reached the target Kt but not prescribed eKt/V. Conclusions. The impact of monitoring the dose with Kt instead of Kt/V is that identifies 25.8% of patients who did not reach the minimum Kt while achieving Kt/V. The main impediments
to achieving an adequate dialysis dose were catheter use, female sex, advanced age, greater body weight, shorter dialysis time and lower Qb.
2021-12-13
2021-12-13
2013
info:eu-repo/semantics/article
Nephrology Dialysis Transplantation, 2013, vol. 28, n. 10, p. 2595–2603
0931-0509
https://uvadoc.uva.es/handle/10324/50933
10.1093/ndt/gft255
2595
10
2603
Nephrology Dialysis Transplantation
28
1460-2385
eng
https://academic.oup.com/ndt/article/28/10/2595/1808268
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2013 Oxford University Press
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Oxford University Press
European Renal Association
oai:uvadoc.uva.es:10324/509392022-07-18T09:32:56Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study
Morales Cerdán, Jose Maria
Marcén Letosa, Roberto
Castillo Caba, Domingo del
Andrés Belmonte, Amado
Gonzalez Molina, Miguel
Oppenheimer Salinas, Federico
Serón Micas, Daniel
Gil Vernet, Salvador
Lampreave Gaztelu, Ildefonso
Gainza Ríos, Francisco Javier
Valdés Cañedo, Francisco Antonio
Cabello Díaz, Mercedes
Anaya Fernández-Lomana, Fernando
Escuín Sancho, Fernando
Arias Rodríguez, Manuel
Pallardó Mateu, Luis
Bustamante Bustamante, Jesús
Riñones - Trasplante
Mortalidad
Survival
Supervivencia
Riñones - Enfermedades
Producción Científica
Background. To describe the causes of graft loss, patient death and survival figures in kidney transplant patients in Spain based on the recipient’s age. Methods. The results at 5 years of post-transplant cardiovascular disease (CVD) patients, taken from a database on CVD, were prospectively analysed, i.e. a total of 2600 transplanted patients during 2000–2002 in 14 Spanish renal transplant units, most of them receiving their organ from cadaver donors. Patients were grouped according to the recipient’s age: Group A: <40 years, Group B: 40–60 years and Group C: >60 years. The most frequent immunosuppressive regimen included tacrolimus, mycophenolate mofetil and steroids. Results. Patients were distributed as follows: 25.85% in Group A (>40 years), 50.9% in Group B (40–60 years) and 23.19% in Group C (>60). The 5-year survival for the different age groups was 97.4, 90.8 and 77.7%, respectively. Death-censored graft survival was 88, 84.2 and 79.1%, respectively, and non death-censored graft survival was 82.1, 80.3 and 64.7%, respectively. Across all age groups, CVD and infections were the most frequent cause of death. The main causes of graft loss were chronic allograft
dysfunction in patients <40 years old and death with functioning graft in the two remaining groups. In the multivariate analysis for graft survival, only elevated creatinine levels and proteinuria >1 g at 6 months post-transplantation were statistically significant in the three age groups. The patient survival multivariate analysis did not achieve a statistically significant common factor in the three age groups.
Conclusions. Five-year results show an excellent recipient survival and graft survival, especially in the youngest age group. Death with functioning graft is the leading cause of graft loss in patients >40 years. Early improvement of renal function and proteinuria together with strict control of cardiovascular
risk factors are mandatory.
2021-12-14
2021-12-14
2012
info:eu-repo/semantics/article
Nephrology Dialysis Transplantation, 2012, vol. 27, supl. 4, p. 39–46
0931-0509
https://uvadoc.uva.es/handle/10324/50939
10.1093/ndt/gfs544
iv39
suppl 4
iv46
Nephrology Dialysis Transplantation
27
1460-2385
eng
https://academic.oup.com/ndt/article/27/suppl_4/iv39/1882932
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2012 Oxford University Press
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Oxford University Press
European Renal Association
oai:uvadoc.uva.es:10324/509472022-07-18T09:32:57Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Effect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study
Gonzalez-Molina Alcaide, Miguel
Gentil Govantes, Miguel Angel
Burgos Rodríguez, Dolores
Cabello Díaz, Mercedes
Cobelo Casas, Carmen
Bustamante Bustamante, Jesús
Errasti Goenaga, Pedro
Franco Esteve, Antonio
Hernández Marrero, Domingo
Riñones - Trasplante
Esteroides
Producción Científica
Background. Steroids are largely effective for the immunosuppressive treatment in renal transplant patients, but cause severe side effects. Whether steroid withdrawal confers long-term beneficial effects remains unclear.
Methods. Data on 4481 cadaveric kidney transplant recipients were collected to estimate the impact of steroid withdrawal on kidney function and graft and patient survival using multivariate Cox regression models.
Results. A total of 923 patients (20.6%) had steroid treatment withdrawn. This was more common in recipients from younger donors and in older recipients, and in recipients with a first transplant, those who had pre-transplant or de novo diabetes mellitus and those with fewer episodes of acute rejection (AR) (22.4% vs. 29.2%, P < 0.001). Cox multivariate analysis stratifying by propensity scores showed that longterm steroid therapy was associated with a 70% increase in the risk of patient death. The repeated measures linear model showed that, although the abbreviated Modification of Diet in Renal Disease (aMDRD) values changed over time (P = 0.002), this was independent of steroid withdrawal (P = 0.08). In addition, of the 772 (17.2%) recipients who developed de novo diabetes mellitus, 204 (26.4%) ceased antidiabetic therapy, with more of these among those who ceased steroids (23% vs. 33.3%, P = 0.003). Blood pressure, cholesterol and triglyceride values were all significantly lower in the patients who ceased steroids.
Conclusions. Steroid withdrawal in selected patients had no negative effect over time on renal function and graft survival, and it was associated with reduced mortality.
2021-12-15
2021-12-15
2010
info:eu-repo/semantics/article
NDT Plus, 2010, vol. 3, supl. 2, p. 32–36
2048-8505
https://uvadoc.uva.es/handle/10324/50947
10.1093/ndtplus/sfq064
ii32
suppl 2
ii36
NDT Plus
3
2048-8513
eng
https://academic.oup.com/ckj/article/3/suppl_2/ii32/447259
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2010 Oxford University Press
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Oxford University Press
European Renal Association
oai:uvadoc.uva.es:10324/509572022-07-18T09:32:57Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease
Morales Cerdán, Jose Maria
Marcén Letosa, Roberto
Andrés Belmonte, Amado
Gonzalez-Molina Alcaide, Miguel
Castillo Caba, Domingo del
Cabello Díaz, Mercedes
Capdevila Plaza, Luis
Campistol Plana, Josep María
Oppenheimer Salinas, Federico
Serón Micas, Daniel
Gil Vernet, Salvador
Lampreave Gaztelu, Ildefonso
Valdés Cañedo, Francisco Antonio
Anaya Fernández-Lomana, Fernando
Escuín Sancho, Fernando
Arias Rodríguez, Manuel
Pallardó Mateu, Luis
Bustamante Bustamante, Jesús
Riñones - Trasplante
Mortalidad
Cardiovascular, Aparato - Enfermedades
Isquemia
Producción Científica
To evaluate cardiovascular disease (CVD) after renal transplantation we established a CVD database
(no-intervention) including all patients transplanted among 2000–2002 in 14 hospitals from Spain (Renal Forum Group) (n¼2600). They were prospective followed annually thereafter and we present herein the most important results concerning survival figures and CVD at four years. Mean recipient age was 49.7±13.7 years: 16% retransplanted and 12.5% hyperimmunized. Tacrolimus, mycophenolate
mofetil, and steroids was used in 63%. Acute rejection (AR) rate at 1 year was 14.8%. Graft and patient survival at 48 months were 85.6% (death censored) and 91.7% respectively. The first cause of graft loss was vascular in the first year, death with function during the 2–3 years, and chronic allograft nephropathy at the 4th year. Donor age, time on dialysis, acute tubular necrosis (ATN), AR, SCr at 6
months, the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in the first year, and systolic blood pressure at 24 months were independent risk factors for graft loss at 4th year. The first cause of death was CVD (predominantly ischemic heart disease (IHD) in the first year). Recipient age, ATN, and SCr at 6 months were independent predictors of mortality. Despite
worsening of donor age, comorbidity, and advanced age of recipients, survival figures at four years are considered good in our Spanish non-selected population. Cardiovascular mortality is the most important cause of death and graft loss particularly, IHD in the first year. Therefore, to decrease post-transplant mortality a careful cardiovascular evaluation and treatment in the waiting list and a close follow-up of patients after transplantation is mandatory.
2021-12-16
2021-12-16
2008
info:eu-repo/semantics/article
Kidney International, 2008, vol. 74, supl. 111, p. S94-S99
0085-2538
https://uvadoc.uva.es/handle/10324/50957
10.1038/ki.2008.547
S94
Supl. 111
S99
Kidney International
74
eng
https://www.kidney-international.org/article/S0085-2538(15)53246-8/fulltext
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2008 International Society of Nephrology
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
International Society of Nephrology
oai:uvadoc.uva.es:10324/509602022-07-18T09:32:57Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Course of vascular access and relationship with treatment of anemia
Portolés Pérez, Jose Maria
López Gómez, Juan Manuel
Gruss Vergara, Enrique
Aljama García, Pedro
Diálisis
Hemodiálisis
Anemia
Cateterismo
Producción Científica
Background and objectives: Maintenance of the vascular access is a crucial factor in hemodialysis, but large studies of factors that are predictive of thrombosis are lacking. Design, setting, participants, & measurements: This prospective, multicenter study investigated a cohort to describe the management of vascular access and establish the influence of anemia as a risk factor. The cohort included 1710 patients (aged 64.4 yr; 60% men) who were followed every 3 mo at 119 centers during 12 mo. On inclusion, 9.6% had a catheter, 80.3% had a native arteriovenous fistula, and 10.1% had a polytetrafluoroethylene graft. Results: Low baseline hemoglobin increased the risk for vascular access events. The risk was higher with a polytetrafluoroethylene graft and a catheter versus arteriovenous fistula. The multivariate model included type of vascular access, previous cardiovascular events, and noncorrected anemia. The likelihood of remaining free of vascular access events 12 mo later was
0.727 (baseline hemoglobin <10.0 g/dl), 0.801 (10.01 to 11.0 g/dl), 0.814 (11.01 to 12.0 g/dl), and 0.833 (>12.0 g/dl), figures similar to those obtained with hemoglobin from the trimester before the event. The Cox model included type of vascular access. Conclusions: Correcting anemia did not increase the risk for vascular access–related events, and anemia that was resistant to treatment identified a subgroup of patients with higher comorbidity and higher likelihood of a vascular access event.
2021-12-16
2021-12-16
2007
info:eu-repo/semantics/article
Clinical Journal of the American Society of Nephrology, 2007, vol. 2, n. 6, p.1163-1169
1555-9041
https://uvadoc.uva.es/handle/10324/50960
10.2215/CJN.01320307
1163
6
1169
Clinical Journal of the American Society of Nephrology
2
1555-905X
eng
https://cjasn.asnjournals.org/content/2/6/1163
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2007 American Society of Nephrology
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
American Society of Nephrology
oai:uvadoc.uva.es:10324/509692022-01-05T21:46:51Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
The impact of donor age on the results of renal transplantation
Oppenheimer Salinas, Federico
Aljama García, Pedro
Asensio Peinado, Concepción
Bustamante Bustamante, Jesús
Crespo Albiach, Jose Francisco
Guirado Perich, Luis
Riñones - Trasplante
Survival
Supervivencia
Riñones - Enfermedades
Producción Científica
Background. The use of elderly donors is becoming more frequent. An increase in the donor’s age is
associated with a greater incidence of delayed graft function (DGF), chronic allograft nephropathy (CAN)
and worse graft survival. Poor renal graft function is a risk factor for cardiovascular (CV) complications
and, finally, for mortality of the patients. Methods. A total of 3365 adult patients transplanted in 1990 (n¼824), 1994 (n¼1075) and 1998 (n¼1466) with a functioning graft after the first year were included. The impact of donor age on renal function, DGF, acute rejection and other clinical factors was
evaluated according to two donor and recipient age categories: young (<60 years old) and elderly (>60
years old). Additionally, donor age was categorized by decades for the analysis of patient and graft survival, acute rejection and CV mortality. Results. Donor mean age significantly increased during the three transplantation periods. A total of 478 out of 3365 donors were older than 60 years. Elderly donors showed an increased risk of DGF (38.9 vs 28.8%) and CAN (56.8 vs 46.2%). Mean serum creatinine at 3 and 12 months and proteinuria were significantly higher in the old donor group. Incidence and severity of acute rejection were similar in both groups. Graft and patient survival were significantly lower in the old donor group. Also, risk of mortality due to CV events was also significantly higher. A linear increase in risk of graft loss, patient death or CV mortality was observed when donor age was divided into 10 year increase subsets. Conclusions. Donor age is a strong predictor of CAN and graft loss. Patient survival is also affected by donor age, particularly by a higher risk of CV mortality.
2021-12-17
2021-12-17
2004
info:eu-repo/semantics/article
Nephrology Dialysis Transplantation, 2004, vol. 19, supl. 3, p. 11–15
0931-0509
https://uvadoc.uva.es/handle/10324/50969
10.1093/ndt/gfh1008
iii11
suppl_3
iii15
Nephrology Dialysis Transplantation
19
1460-2385
eng
https://academic.oup.com/ndt/article/19/suppl_3/iii11/1826911
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2004 Oxford University Press
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Oxford University Press
European Renal Association
oai:uvadoc.uva.es:10324/511492022-07-18T09:32:57Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Glutathione determination and a study of the activity of glutathione-peroxidase, glutathione-transferase, and glutathione-reductase in renal transplants
Vega, L. de
Pérez Fernández, Rebeca
Martin Mateo, María Concepción
Bustamante Bustamante, Jesús
Mendiluce Herrero, Alicia
Bustamante Munguira, Elena
Riñones - Trasplante
Riñones - Enfermedades
Enzimas
Producción Científica
The aim of this work is to study the temporary variation of oxidative stress in renal transplants, both in plasma andin erythrocytes (CR). In order to do so, we determined total glutathione (GST) levels, both oxidized (GSSG) and reduced (GSH), and the activity of enzymes, glutathione peroxidase (G-px), glutathione reductase (G-red) and glutathione transferase (GSt), in renal transplant patients. Determinations were made 48 h before the transplant 1 week and 2 weeks after the renal
transplant. The results obtainedconfirm a high ‘‘oxidative stress’’ rate, resulting from the equilibrium between the production of free radicals andthe activity of antioxidants, the former being higher proportionally. Immediately after the transplant there is an increase of oxidative stress, which results in an increase of G-red, a marked decrease of G-px in plasma andin erythrocytes (CR) andan abrupt drop both in GST levels in plasma andin GSG (as well as in the [GSH]/[GSSG] relationship). As times goes on, after the transplant, there is a significant improvement in the activity of antioxidant enzymes, but there is no normalization, which is easily seen in the fact that total glutathione levels andthe activity of the various enzymes approach the average values of the control group.
2022-01-03
2022-01-03
2002
info:eu-repo/semantics/article
Renal Failure, 2002, vol. 24, n. 4, p. 421–432
0886-022X
https://uvadoc.uva.es/handle/10324/51149
10.1081/JDI-120006769
421
4
432
Renal Failure
24
1525-6049
eng
https://www.tandfonline.com/doi/full/10.1081/JDI-120006769
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2002 Taylor & Francis
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Taylor & Francis
oai:uvadoc.uva.es:10324/511532022-02-07T10:24:00Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Leucoencefalopatía posterior reversible: un caso recurrente y atípico en hemodiálisis
Palacios Parada, María Anthoanet
Acosta Ochoa, María Isabel
Núñez García, Jesús Matías
Aller Aparicio, Carmen
Sanz Ballesteros, María Sandra
Mendiluce Herrero, Alicia
Riñones - Enfermedades
Diálisis
Hemodiálisis
Cerebro - Enfermedades
Producción Científica
La leucoencefalopatía posterior reversible (LEPR) es un síndrome clínico-radiográfico descrito en 1996. Su patogénesis todavía no está clara y existen 2 teorías: 1) por hiperperfusión cerebral y 2) por intenso vasoespasmo1–3. Se asocia con HTA maligna, eclampsia y condiciones que coexisten en pacientes
con enfermedad renal crónica (ERC) como HTA, enfermedades vasculares o autoinmunes, inmunosupresores, eritropoyetina y trasplante.
2022-01-03
2022-01-03
2016
info:eu-repo/semantics/article
Nefrología, 2016, vol. 36, n. 2, p. 192-193
0211-6995
https://uvadoc.uva.es/handle/10324/51153
10.1016/j.nefro.2015.09.002
192
2
193
Nefrología
36
spa
https://www.revistanefrologia.com/es-leucoencefalopatia-posterior-reversible-un-caso-articulo-S021169951500140X
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2016 Sociedad Española de Nefrología
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Sociedad Española de Nefrología
oai:uvadoc.uva.es:10324/511852022-02-07T10:34:53Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Role of the rs10401670 variant in the resistin gene on the metabolic response after weight loss secondary to a high‐fat hypocaloric diet with a Mediterranean pattern
Luis Román, Daniel Antonio de
Aller de la Fuente, Rocío
Izaola Jauregui, Olatz
Primo Martín, David
Producción Científica
Background:The single nucleotide polymorphism (SNP) (rs10401670) of theRETNgene has been associated with metabolic disorder in obese subjects andhas scarcely been evaluated after dietary interventions. The present studyaimed to analyse the effects of thers10401670 RETNgene polymorphismon metabolic changes secondary to weight loss and secondary to a high‐fathypocaloric diet with a Mediterranean dietary pattern.Methods:A Caucasian population comprising 284 obese patients withoutdiabetes mellitus was analysed. Before and after 3 months of a high‐fathypocaloric diet with a Mediterranean pattern, an anthropometric evaluation,an assessment of nutritional intake and a biochemical analysis were per-formed. A statistical analysis was conducted for the combinedCTandTTas agroup and for wild‐typeCCas a second group.Results:Decreases in weight, body mass index (BMI), fat mass, systolic bloodpressure and waist circumference were similar in both genotypes groups. InTallele carriers, insulin, homeostatic model assessment for insulin resistance(HOMA‐IR), triglycerides and C‐reactive protein levels were decreased.The decrease in these parameters was statistically significant for triglycerides(−22.3 ± 9.3 mg dl–1:p= 0.03), C‐reactive protein (−2.8 ± 0.5 mg dl–1:p= 0.03), insulin (−7.4 ± 2.9 mUI L–1:p= 0.03) and HOMA‐IR (−2.4 ± 1.0:p= 0.02). Leptin levels were decreased in both genotypes groups after thehypocaloric diet, as well as the anthropometric parameters BMI, weight, waistcircumference and fat mass. Resistin and adiponectin levels remained un-changed in both groups.Conclusions:In the present study, we have detected a significant associationbetween theTallele of this SNP and a better response of insulin resistance,triglycerides and C‐reactive protein compared to nonTallele carriers afterweight loss with a high‐fat hypocaloric diet and a Mediterranean diet.
2022-01-10
2022-01-10
2021
info:eu-repo/semantics/article
Journal of Human Nutrition and Dietetics, 2021, p. 1-9
0952-3871
https://uvadoc.uva.es/handle/10324/51185
10.1111/jhn.12975
Journal of Human Nutrition and Dietetics
1365-277X
eng
https://onlinelibrary.wiley.com/doi/full/10.1111/jhn.12975
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2021 The Authors
Atribución 4.0 Internacional
Wiley
oai:uvadoc.uva.es:10324/523682022-03-10T21:47:11Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Effect of Two Meal Replacement strategies on Cardiovascular Risk Parameters in Advanced Age Patients with Obesity and Osteoarthritis
López Gómez, Juan José
Izaola Jauregui, Olatz
Primo Martín, David
Torres Torres, Beatriz
Gómez Hoyos, Emilia
Ortolá Buigues, Ana
Martín Ferrero, Miguel Ángel
Luis Román, Daniel Antonio de
Producción Científica
Background and aims: Meal replacement diets consist of replacing one or more meals with an artificial nutritional supplement. The objective of this study was to compare the effect of one against two meal replacement strategies on body composition and cardiovascular risk parameters in patients with obesity. Methods: A randomized clinical trial was designed with a modified hypocaloric diet with an artificial nutritional preparation replacing one or two meals for three months in patients with obesity and osteoarthritis pending orthopedic surgery. An anthropometric evaluation and a measurement of the body composition were done with bioelectrical impedance measurement at the beginning and at three months. Results: A total of 112 patients were recruited. Fifty-two patients (46.4%) were randomized to one replacement and 60 patients (53.6%) to two meal replacements. Eighty-one patients (72.3%) were women, and the average age was 61 (11.03) years. The percentage of weight loss at three months was 8.27 (4.79)% (one meal replacement: 7.98 (5.97)%; two meal replacements: 8.50 (3.48)%; p = 0.56). A decrease in fat mass measured by the fat mass index (FMI) was detected (one meal replacement: −2.15 (1.45) kg/m2 vs. two meal replacements: −2.78 (2.55) kg/m2; p > 0.05), and a relative increase in fat-free mass was observed (one meal replacement: +3.57 (4.61)% vs. two meal replacements: +2.14 (4.45)%; p > 0.05). A decrease in HOMA-IR, systolic blood pressure (SBP), and total cholesterol was observed in both groups without differences between them. Conclusions: The substitution strategies of one or two meal replacements were effective in weight loss and fat mass decrease without differences between the two groups. An improvement in lipid parameters, glycemic control, and systolic blood pressure was observed without differences between strategies.
2022-03-10
2022-03-10
2020
info:eu-repo/semantics/article
Nutrients, 2020, vol. 12, n. 4, 976
2072-6643
https://uvadoc.uva.es/handle/10324/52368
10.3390/nu12040976
eng
https://www.mdpi.com/2072-6643/12/4/976
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2020 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/538592022-08-17T08:20:22Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry
Coco Martín, María Begoña
Leal Vega, Luis
Blázquez Cabrera, José Antonio
Navarro, Amalia
Moro, María Jesús
Arranz García, Francisca
Amérigo, María José
Sosa Henríquez, Manuel
Vázquez, María Ángeles
Montoya, María José
Díaz Curiel, Manuel
Olmos, José Manuel
Pérez Castrillon, José Luis
Filgueira Rubio, José
Sánchez Molini, Pilar
Aguado Caballero, José María
Armengol Sucarrats, Dolors
Calero Bernal, María Luz
Escalante Yanguas, Begoña de
Hernández de Sosa, Nerea
Hernández, José Luis
Jareño Chaumel, Julia
Miranda García, María José
Giner García, Mercedes
Miranda Díaz, Cristina
Cotos Canca, Rafael
Cobeta García, Juan Carlos
Rodero Hernández, Francisco Javier
Tirado Miranda, Raimundo
Producción Científica
Purpose: To examine the response to anti-osteoporotic treatment, considered as incident fragility fractures after a minimum follow-up of 1 year, according to sex, age, and number of comorbidities of the patients.
Methods: For this retrospective observational study, data from baseline and follow-up visits on the number of comorbidities, prescribed anti-osteoporotic treatment and vertebral, humerus or hip fractures in 993 patients from the OSTEOMED registry were analyzed using logistic regression and an artificial network model.
Results: Logistic regression showed that the probability of reducing fractures for each anti-osteoporotic treatment considered was independent of sex, age, and the number of comorbidities, increasing significantly only in males taking vitamin D (OR = 7.918), patients without comorbidities taking vitamin D (OR = 4.197) and patients with ≥ 3 comorbidities taking calcium (OR = 9.412). Logistic regression correctly classified 96% of patients (Hosmer–Lemeshow = 0.492) compared with the artificial neural network model, which correctly classified 95% of patients (AUC = 0.6).
Conclusion: In general, sex, age and the number of comorbidities did not influence the likelihood that a given anti-osteoporotic treatment improved the risk of incident fragility fractures after 1 year, but this appeared to increase when patients had been treated with risedronate, strontium or teriparatide. The two models used classified patients similarly, but predicted differently in terms of the probability of improvement, with logistic regression being the better fit.
2022-07-05
2022-07-05
2022
info:eu-repo/semantics/article
Aging Clinical and Experimental Research, 2022
1594-0667
https://uvadoc.uva.es/handle/10324/53859
10.1007/s40520-022-02129-5
Aging Clinical and Experimental Research
1720-8319
eng
https://link.springer.com/article/10.1007/s40520-022-02129-5
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
Springer
oai:uvadoc.uva.es:10324/544002022-10-04T08:20:37Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors
González Martínez, Alicia
Guerrero Peral, Angel Luis
Arias Rivas, Susana
Silva, Lorenzo
Sierra, Álvaro
Gago Veiga, Ana Beatriz
García Azorín, David
Producción Científica
Background Headache is one of the most frequently reported symptoms in post-COVID patients. The clinical phenotype of
COVID-19 headache combines phenotypic features of both tension-type headache (TTH) and migraine. We aimed to assess
the efectiveness, side efects and predictors of amitriptyline (AMT) response in a real-world study setting.
Methods We performed an observational multicentric study with a retrospective cohort. All consecutive patients with con frmed COVID-19 infection who received AMT for post-COVID headache from March 2020 to May 2021 were included.
Response was evaluated by the reduction in the number of headache days per month (HDM) between weeks 8 and 12,
compared with the baseline. We explored which variables were associated with a higher probability of response to AMT.
Results Forty-eight patients were eligible for the study, 40/48 (83.3%) females, aged 46.85 (SD: 13.59) years. Patients had
history of migraine 15/48 (31.3%) or TTH 5/48 (10.4%). The mean reduction of HDM was 9.6 (SD: 10.9; 95% CI 6.5, 12.7)
days. Only 2/48 (5%) of patients discontinued AMT due to poor tolerability. History of TTH (10.9, 95% CI 1.3, 20.6) and
nausea (−8.5, 95% CI −14.6, −2.5) were associated with AMT response.
Conclusions This study provides real-world evidence of the potential beneft of AMT in patients with post-COVID-19
headache, especially in patients with history of TTH and without concomitant nausea.
2022-08-17
2022-08-17
2022
info:eu-repo/semantics/article
Journal of Neurology, 2022.
0340-5354
https://uvadoc.uva.es/handle/10324/54400
10.1007/s00415-022-11225-5
Journal of Neurology
1432-1459
eng
https://link.springer.com/article/10.1007/s00415-022-11225-5
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
Springer
oai:uvadoc.uva.es:10324/577852023-04-13T06:24:33Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Effect of intravenous pulses of methylprednisolone 250 mg versus dexamethasone 6 mg in hospitalised adults with severe COVID ‐19 pneumonia: An open‐label randomised trial
Corral Gudino, Luis
Cusácovich Torres, Iván
Martín González, José Ignacio
Muela Molinero, Alberto
Abadía Otero, Jésica
González Fuentes, Roberto
Ruiz de Temiño de la Peña, Ángela
Tapia Moral, Elena
Cuadrado Medina, Francisca
Martín Asenjo, Miguel
Miramontes González, José Pablo
Delgado González, José Luis
Inés, Sandra
Abad Manteca, Laura
Usategui Martín, Iciar
Ruiz Albi, Tomás
Miranda Riaño, Sara
Rodríguez Fortúnez, Patricia
Rodríguez Jiménez, Consuelo
López Franco, Esperanza
Marcos, Miguel
Producción Científica
Background: The efficacy and safety of high versus medium doses of glucocorticoids for the treatment of patients with COVID-19 has shown mixed outcomes in controlled trials and observational studies. We aimed to evaluate the effectiveness of methylprednisolone 250 mg bolus versus dexamethasone 6 mg in patients with severe COVID-19.
Methods: A randomised, open-label, controlled trial was conducted between February and August 2021 at four hospitals in Spain. The trial was suspended after the first interim analysis since the investigators considered that continuing the trial would be futile. Patients were randomly assigned in a 1:1 ratio to receive dexamethasone 6 mg once daily for up to 10 days or methylprednisolone 250 mg once daily for 3 days.
Results: Of the 128 randomised patients, 125 were analysed (mean age 60 ± 17 years; 82 males [66%]). Mortality at 28 days was 4.8% in the 250 mg methylprednisolone group versus 4.8% in the 6 mg dexamethasone group (absolute risk difference, 0.1% [95% CI, −8.8 to 9.1%]; p = 0.98). None of the secondary outcomes (admission to the intensive care unit, non-invasive respiratory or high-flow oxygen support, additional immunosuppressive drugs, or length of stay), or prespecified sensitivity analyses were statistically significant. Hyperglycaemia was more frequent in the methylprednisolone group at 27.0 versus 8.1% (absolute risk difference, −18.9% [95% CI, −31.8 to - 5.6%]; p = 0.007).
Conclusions: Among severe but not critical patients with COVID-19, 250 mg/d for 3 days of methylprednisolone compared with 6 mg/d for 10 days of dexamethasone did not result in a decrease in mortality or intubation.
2022-12-15
2022-12-15
2022
info:eu-repo/semantics/article
European Journal of Clinical Investigation, 2022, vol. 53, n. 1, e13881.
0014-2972
https://uvadoc.uva.es/handle/10324/57785
10.1111/eci.13881
1
European Journal of Clinical Investigation
53
1365-2362
eng
https://onlinelibrary.wiley.com/doi/full/10.1111/eci.13881
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc/4.0/
© 2022 The Author(s)
Atribución-NoComercial 4.0 Internacional
Wiley
oai:uvadoc.uva.es:10324/588792024-02-02T08:58:41Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Stimuli characteristics and psychophysical requirements for visual training in amblyopia: a narrative review
Hernández Rodríguez, Carlos J.
Piñero, David P.
Molina Martín, Ainhoa
Morales Quezada, León
Fez, Dolores de
Leal Vega, Luis
Arenillas Lara, Juan Francisco
Coco Martín, María Begoña
Amblyopia
Ojo - Enfermedades y defectos - Tratamiento
Producción Científica
Active vision therapy using perceptual learning and/or dichoptic or binocular environments has shown its potential effectiveness in amblyopia, but some doubts remain about the type of stimuli and the mode and sequence of presentation that should be used. A search was performed in PubMed, obtaining 143 articles with information related to the stimuli used in amblyopia rehabilitation, as well as to the neural mechanisms implied in such therapeutic process. Visual deficits in amblyopia and their neural mechanisms associated are revised, including visual acuity loss, contrast sensitivity reduction and stereopsis impairment. Likewise, the most appropriate stimuli according to the literature that should be used for an efficient rehabilitation of the amblyopic eye are described in detail, including optotypes, Gabor’s patches, random-dot stimuli and Vernier’s stimuli. Finally, the properties of these stimuli that can be modified during the visual training are discussed, as well as the psychophysical method of their presentation and the type of environment used (perceptual learning, dichoptic stimulation or virtual reality). Vision therapy using all these revised concepts can be an effective option for treating amblyopia or accelerating the treatment period when combining with patching. It is essential to adapt the stimuli to the patient’s individual features in both monocular and binocular training.
2023-03-08
2023-03-08
2020
info:eu-repo/semantics/article
Journal of Clinical Medicine, 2020, Vol. 9, Nª. 12, 3985
2077-0383
https://uvadoc.uva.es/handle/10324/58879
10.3390/jcm9123985
3985
12
Journal of Clinical Medicine
9
2077-0383
eng
https://www.mdpi.com/2077-0383/9/12/3985
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2020 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/588862023-03-08T14:36:59Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Assessment of nocturnal autonomic cardiac imbalance in positional obstructive sleep apnea. A multiscale nonlinear approach
Álvarez González, Daniel
Arroyo Domingo, Carmen Ainhoa
Frutos Arribas, Julio Fernando de
Crespo Sedano, Andrea
Cerezo Hernández, Ana
Gutiérrez Tobal, Gonzalo César
Vaquerizo Villar, Fernando
Barroso García, Verónica
Moreno Torrero, Fernando
Ruiz Albi, Tomás
Hornero Sánchez, Roberto
Campo Matias, Félix del
Apnea del sueño
Cardiopatías
Cardiology
Análisis funcional no lineal
Entropía
Ritmo cardíaco - Trastornos
Entropía
Producción Científica
Positional obstructive sleep apnea (POSA) is a major phenotype of sleep apnea. Supine-predominant positional patients are frequently characterized by milder symptoms and less comorbidity due to a lower age, body mass index, and overall apnea-hypopnea index. However, the bradycardia-tachycardia pattern during apneic events is known to be more severe in the supine position, which could affect the cardiac regulation of positional patients. This study aims at characterizing nocturnal heart rate modulation in the presence of POSA in order to assess potential differences between positional and non-positional patients. Patients showing clinical symptoms of suffering from a sleep-related breathing disorder performed unsupervised portable polysomnography (PSG) and simultaneous nocturnal pulse oximetry (NPO) at home. Positional patients were identified according to the Amsterdam POSA classification (APOC) criteria. Pulse rate variability (PRV) recordings from the NPO readings were used to assess overnight cardiac modulation. Conventional cardiac indexes in the time and frequency domains were computed. Additionally, multiscale entropy (MSE) was used to investigate the nonlinear dynamics of the PRV recordings in POSA and non-POSA patients. A total of 129 patients (median age 56.0, interquartile range (IQR) 44.8–63.0 years, median body mass index (BMI) 27.7, IQR 26.0–31.3 kg/m2) were classified as POSA (37 APOC I, 77 APOC II, and 15 APOC III), while 104 subjects (median age 57.5, IQR 49.0–67.0 years, median BMI 29.8, IQR 26.6–34.7 kg/m2) comprised the non-POSA group. Overnight PRV recordings from positional patients showed significantly higher disorderliness than non-positional subjects in the smallest biological scales of the MSE profile (τ = 1: 0.25, IQR 0.20–0.31 vs. 0.22, IQR 0.18–0.27, p < 0.01) (τ = 2: 0.41, IQR 0.34–0.48 vs. 0.37, IQR 0.29–0.42, p < 0.01). According to our findings, nocturnal heart rate regulation is severely affected in POSA patients, suggesting increased cardiac imbalance due to predominant positional apneas.
2023-03-08
2023-03-08
2020
info:eu-repo/semantics/article
Entropy, 2020, Vol. 22, Nº. 12, 1404
1099-4300
https://uvadoc.uva.es/handle/10324/58886
10.3390/e22121404
1404
12
Entropy
22
1099-4300
eng
https://www.mdpi.com/1099-4300/22/12/1404
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2020 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/589022023-03-13T08:40:30Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Clinical profile, treatment and predictors during the first COVID-19 wave: a population-based registry analysis from Castile and Leon hospitals
Gutiérrez Abejón, Eduardo
Tamayo Gómez, Eduardo
Martín García, Débora
Álvarez González, Francisco Javier
Herrera Gómez, Francisco Magno
SARS (Disease)
COVID-19
Enfermedades por virus - Tratamiento
Mortalidad
Novel respiritory viral diseases
Nephrology
Riñones - Enfermedades
Producción Científica
The first wave of the COVID-19 pandemic collapsed the hospitals in Castile and Leon (Spain). An analysis of the clinical characteristics, drug therapies and principal outcome predictors in the COVID-19 hospitalized patients from 1 March to 31 May 2020 is presented through a population-based registry study. Hospital stay variables, ventilation mode data and clinical outcomes were observed. In Castile and Leon hospitals, 7307 COVID-19 patients were admitted, with 57.05% being male and a median of 76 years. The mortality rate was 24.43%, with a high incidence of severe acute respiratory syndrome (SARS) (14.03%) and acute kidney injury (AKI) (10.87%). The most used medicines were antibiotics (90.83%), antimalarials (42.63%), steroids (44.37%) and antivirals, such as lopinavir/ritonavir (42.63%). The use of tocilizumab (9.37%) and anti-SIRS (systemic inflammatory response syndrome) medicines (7.34%) were remarkable. Fundamentally, death occurred more likely over 65 years of age (OR: 9.05). In addition, the need for ventilation was associated with a higher probability of death (OR: 3.59), SARS (OR: 5.14) and AKI (OR: 2.31). The drug-use pattern had been modified throughout the COVID-19 first wave. Multiple factors, such as age, gender and the need for mechanical ventilation, were related to the worst evolution prognosis of the disease.
2023-03-09
2023-03-09
2020
info:eu-repo/semantics/article
International Journal of Environmental Research and Public Health. 2020, Vol.17, Nº. 24, 9360
1660-4601
https://uvadoc.uva.es/handle/10324/58902
10.3390/ijerph17249360
9360
24
International Journal of Environmental Research and Public Health
17
1660-4601
eng
https://www.mdpi.com/1660-4601/17/24/9360
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/589712023-03-17T20:02:50Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Relationship between insulin resistance (HOMA-IR), trabecular bone score (TBS), and three-dimensional dual-energy X-ray absorptiometry (3D-DXA) in non-diabetic postmenopausal women
Campillo Sánchez, Francisco
Usategui Martín, Ricardo
Ruiz de Temiño de la Peña, Ángela
Gil, Judith
Ruiz Mambrilla, Marta María
Fernández Gómez, José María Fidel
Dueñas Laita, Antonio
Pérez Castrillon, José Luis
Gynecology
Endocrinology
Osteoporosis
Producción Científica
Background: Insulin may play a key role in bone metabolism, where the anabolic effect predominates. This study aims to analyze the relationship between insulin resistance and bone quality using the trabecular bone score (TBS) and three-dimensional dual-energy X-ray absorptiometry (3D-DXA) in non-diabetic postmenopausal women by determining cortical and trabecular compartments. Methods: A cross-sectional study was conducted in non-diabetic postmenopausal women with suspected or diagnosed osteoporosis. The inclusion criteria were no menstruation for more than 12 months and low bone mass or osteoporosis as defined by DXA. Glucose was calculated using a Hitachi 917 auto-analyzer. Insulin was determined using an enzyme-linked immunosorbent assay (EIA). Insulin resistance was estimated using a homeostasis model assessment of insulin resistance (HOMA-IR). DXA, 3D-DXA, and TBS were thus collected. Moreover, we examined bone parameters according to quartile of insulin, hemoglobin A1C (HbA1c), and HOMA-IR. Results: In this study, we included 381 postmenopausal women. Women located in quartile 4 (Q4) of HOMA-IR had higher values of volumetric bone mineral density (vBMD) but not TBS. The increase was higher in the trabecular compartment (16.4%) than in the cortical compartment (6.4%). Similar results were obtained for insulin. Analysis of the quartiles by HbA1c showed no differences in densitometry values, however women in Q4 had lower levels of TBS. After adjusting for BMI, statistical significance was maintained for TBS, insulin, HOMA-IR, and HbA1c. Conclusions: In non-diabetic postmenopausal women there was a direct relationship between insulin resistance and vBMD, whose effect is directly related to greater weight. TBS had an inverse relationship with HbA1c, insulin, and insulin resistance unrelated to weight. This might be explained by the formation of advanced glycosylation products (AGEs) in the bone matrix, which reduces bone deformation capacity and resistance, as well as increases fragility.
2023-03-17
2023-03-17
2020
info:eu-repo/semantics/article
Journal Clinical Medicine, 2020, vol.9, n.6, 1732
https://uvadoc.uva.es/handle/10324/58971
10.3390/jcm9061732
1732
6
Journal of Clinical Medicine
9
2077-0383
eng
https://www.mdpi.com/2077-0383/9/6/1732
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2020 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/589862023-03-21T20:00:32Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Predictive value and dynamic risk stratification of high sensitive basal or stimulated thyroglobulin assay in a long-term thyroid carcinoma cohort
Fernández Velasco, Pablo
Díaz Soto, Gonzalo
Pérez López, Paloma
Torres Torres, Beatriz
Luis Román, Daniel Antonio de
Producción Científica
Purpose: To evaluate the predictive value of the rhTSH thyroglobulin stimulation test (rhTSH-Tg) compared to basal high- sensitive thyroglobulin (hs-Tg) under TSH suppressive therapy at 12 months after the completion of initial treatment to predict the long-term response and Dynamic Risk Stratification (DRS) at the last follow-up visit in a long-term DTC cohort. Methods: Prospective study in 114 DTC patients (77.2% women, mean age 46.4 ± 14.1 years old, median/IQR evolution 6.7[3.1–8.0] years) from 2013 to 2020 undergoing total thyroidectomy and radioiodine ablation in whom hs-Tg and rhTSH- Tg was performed 12 months after completing initial treatment. Pearson correlation, receiving operating characteristics (ROC) and DRS at initial and last follow-up visit were analyzed. Results: hs-Tg and rhTSH-Tg show a strong positive linear correlation (r = 0.864, p < 0.001). The diagnostic performance of initial hs-Tg and rhTSH-Tg levels were evaluated via ROC-AUC as a predictor of excellent response (ER) in the last follow-up visit. Hs-Tg showed a better AUC (0.969, 95%CI = 0.941–0.997) than rhTSH-Tg (0.944, 95%IC = 0.905–0.984; p < 0.001). The hs-Tg and rhTSH-Tg cutoff point of highest sensitivity (S) and specificity (E) was 0.110 and 0.815 ng/dl, respectively. Hs-Tg showed a higher diagnostic accuracy than rhTSH-Tg (S = 100% vs 96.8%, E = 84.3% vs 84.3%, NPV = 100% vs 98.6%, PPV = 70.5% vs 69.7%; p < 0.05). The DRS based on initial hs-Tg showed better ability to predict ER (93.3% vs 86.7%) and biochemical incomplete response (53.3%vs13.3%) in the last follow-up visit compared to rhTSH-Tg. Conclusions: Both initial hs-Th and rhTSH-Tg were good predictors of long-term ER. In patients with hs-Tg, the rhTSH-test did not provide relevant prognosis information. An ER after initial treatment was associated with a very high NPV at subsequent follow-up.
2023-03-21
2023-03-21
2023
info:eu-repo/semantics/article
Endocrine, 2023.
https://uvadoc.uva.es/handle/10324/58986
10.1007/s12020-023-03320-y
Endocrine
1559-0100
eng
https://link.springer.com/article/10.1007/s12020-023-03320-y
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2023 The Author(s)
Atribución 4.0 Internacional
Springer
oai:uvadoc.uva.es:10324/590872023-04-12T19:00:43Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Immune system disorders, cancer and viral infections: A new treatment opportunity for the immune checkpoint inhibitors
Olivares Hernández, Alejandro
Figuero Pérez, Luis
Miramontes González, José Pablo
López Gutiérrez, Álvaro
González Sarmiento, Rogelio
Cruz Hernández, Juan Jesús
Fonseca Sánchez, Emilio
Medicina
Medicina Interna
Cancer Research
Producción Científica
The relationship between viral infections and cancer is well known and has been established for decades. Multiple tumours are generated from alterations secondary to viral infections 2 resulting from a dysregulation of the immune system in many cases. Certain causal relationships, such as that between the Epstein–Barr virus (EBV) in nasopharyngeal cancer or hepatitis C and B viruses in hepatocarcinoma, have been clearly established, and their implications for the prognosis and treatment of solid tumours are currently unknown. Multiple studies have evaluated the role that these infections may have in the treatment of solid tumours using immunotherapy. A possible relationship between viral infections and an increased response to immune checkpoint inhibitors (ICIs) has been established at a theoretical level in solid neoplasms, such as EBV-positive cavum cancer and human papillomavirus (HPV)-positive and oropharyngeal cancer. These could yield a greater response associated with the activation of the immune system secondary to viral infection, the consequence of which is an increase in survival in these patients. That is why the objective of this review is to assess the different studies or clinical trials carried out in patients with solid tumours secondary to viral infections and their relationship to the response to ICIs.
2023-04-12
2023-04-12
2021
info:eu-repo/semantics/article
Life, 2021, vol. 11, n. 12, 1400
https://uvadoc.uva.es/handle/10324/59087
10.3390/life11121400
1400
12
Life
11
2075-1729
eng
https://www.mdpi.com/2075-1729/11/12/1400
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2021 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/590952023-04-13T19:02:03Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Predictive modeling of poor outcome in severe COVID-19: A single-center observational study based on clinical, cytokine and laboratory profiles
Gorgojo Galindo, Óscar
Martín Fernández, Marta
Peñarrubia Ponce, María Jesús
Álvarez González, Francisco Javier
Ortega Loubon, Christian Joseph
Gonzalo Benito, Hugo
Martínez de Paz, Pedro José
Miramontes González, José Pablo
Gómez Sánchez, Esther
Poves Álvarez, Rodrigo
Jorge Monjas, Pablo
Tamayo Gómez, Eduardo
Heredia Rodríguez, María
Tamayo Velasco, Álvaro
COVID-19
COVID-19 (Disease) - Diagnosis
Coronaviruses - Diagnosis
Cytokines - Therapeutic use
Producción Científica
Pneumonia is the main cause of hospital admission in COVID-19 patients. We aimed to perform an extensive characterization of clinical, laboratory, and cytokine profiles in order to identify poor outcomes in COVID-19 patients. Methods: A prospective and consecutive study involving 108 COVID-19 patients was conducted between March and April 2020 at Hospital Clínico Universitario de Valladolid (Spain). Plasma samples from each patient were collected after emergency room admission. Forty-five serum cytokines were measured in duplicate, and clinical data were analyzed using SPPS version 25.0. Results: A multivariate predictive model showed high hepatocyte growth factor (HGF) plasma levels as the only cytokine related to intubation or death risk at hospital admission (OR = 7.38, 95%CI—(1.28–42.4), p = 0.025). There were no comorbidities included in the model except for the ABO blood group, in which the O blood group was associated with a 14-fold lower risk of a poor outcome. Other clinical variables were also included in the predictive model. The predictive model was internally validated by the receiver operating characteristic (ROC) curve with an area under the curve (AUC) of 0.94, a sensitivity of 91.7% and a specificity of 95%. The use of a bootstrapping method confirmed these results. Conclusions: A simple, robust, and quick predictive model, based on the ABO blood group, four common laboratory values, and one specific cytokine (HGF), could be used in order to predict poor outcomes in COVID-19 patients.
2023-04-13
2023-04-13
2021
info:eu-repo/semantics/article
Journal of Clinical Medicine, 2021, Vol. 10, Nº. 22, 5431
2077-0383
https://uvadoc.uva.es/handle/10324/59095
10.3390/jcm10225431
5431
22
Journal of Clinical Medicine
10
2077-0383
eng
https://www.mdpi.com/2077-0383/10/22/5431
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2021 The authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/592242023-04-20T19:00:31Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
The influence of diet and probiotics on the response of solid tumours to immunotherapy: Present and future perspectives
Olivares Hernández, Alejandro
Figuero Pérez, Luis
González Sarmiento, Rogelio
León Jiménez, David
Cruz Hernández, Juan Jesús
Miramontes González, José Pablo
Cancer Research
Immunology
Medicina Interna
Oncología
Producción Científica
Currently, various immunotherapeutic treatments are revolutionizing therapies that treat solid neoplasms. For these treatments, within immunotherapy, immune checkpoint inhibitors (ICIs) are the most widely used drugs. Diverse studies have shown the influence of diet and probiotics on the response to ICIs and consequently on the survival rates associated with different neoplasms. The use of various antibiotics, probiotics, and prebiotics has been associated with changes in the gut microbiota, and this, in turn, with resistance to immunotherapy. Together with the above, a lower intake of red meat and greater consumption of a Mediterranean, vegetarian, or vegan diet have led to a new way of understanding the mechanisms of resistance to ICIs. Omega-3 and polyphenol supplements are also powerful regulators of the microbiome whose influence on the immune system. Therefore, this review covers the influence of diet and probiotics on the response to immunotherapy in patients who have solid tumours.
2023-04-20
2023-04-20
2021
info:eu-repo/semantics/article
Applied Sciences, 2021, vol. 11, n. 18, 8445
https://uvadoc.uva.es/handle/10324/59224
10.3390/app11188445
8445
18
Applied Sciences
11
2076-3417
eng
https://www.mdpi.com/2076-3417/11/18/8445
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2021 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/592372024-02-02T08:51:53Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Differences in contrast reproduction between electronic devices for visual assessment: Clinical implications
Molina Martín, Ainhoa
Piñero, David P.
Coco Martín, María Begoña
Leal Vega, Luis
Fez, Dolores de
Medicina
Diagnóstico
Tecnología médica
Producción Científica
The easy access to electronic devices for users has resulted in the development of a vast range of programs and applications for visual evaluation and diagnosis that can be downloaded to any device. Some of them are based on tasks and stimuli that depend on luminance. The aim of the present study was to evaluate differences in luminance reproduction between electronic devices and their implications for contrast reproduction. A total of 20 Galaxy Tab A devices with 8-bit graphics processing units were evaluated. Characterization of every screen was performed obtaining the response curve for the achromatic stimulus. Mean, maximum and minimum luminance, standard deviation and coefficient of variation were obtained to assess differences between devices. Variation of luminance with increasing digital level was observed in all devices following a gamma distribution. Comparison between devices for mean results showed that some of them differed by as much as 45 cd/m2. The coefficient of variation varied from ~5 to 9%. Mean percentage of differences in luminance between devices reached 30%. In conclusion, differences in luminance reproduction between devices were present, even considering devices from the same manufacturing batch. It cannot be assumed that the characterization of one device can be extrapolated to other devices. Every device used for research purposes should be individually characterized to ensure the correct reproduction. For clinical purposes, limitations should be considered by visual specialists.
2023-04-20
2023-04-20
2021
info:eu-repo/semantics/article
Technologies, 2021, vol. 9, n. 3, 68
https://uvadoc.uva.es/handle/10324/59237
10.3390/technologies9030068
68
3
Technologies
9
2227-7080
eng
https://www.mdpi.com/2227-7080/9/3/68
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2021 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/592522023-04-26T19:00:32Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Environmental factors are associated to hospital outcomes in COVID-19 patients during lockdown and post-lockdown in 2020: A nationwide study
Sánchez de Prada, Laura
Eiros Bachiller, José María
Tamayo Velasco, Álvaro
Martín Fernández, Marta
Álvarez González, Francisco Javier
Giner Baixauli, Carlos
Tamayo Gómez, Eduardo
Resino, Salvador
Álvaro Meca, Alejandro
Medicina
Infectious Diseases
COVID-19 (Disease)
Producción Científica
This study analyzed, at a postcode detailed level, the relation-ship between short-term exposure to environmental factors and hospital ad-missions, in-hospital mortality, ICU admission, and ICU mortality due to COVID-19 during the lockdown and post-lockdown 2020 period in Spain. Short-term exposure to air pollutants impacts COVID-19 out-comes during the lockdown, especially PM2.5, PM10, NO2, and SO2. These pollutants are associated with hospital admission, hospital mortality and ICU admission, while ICU mortality is mainly associated with PM2.5 and PM10. Our findings reveal the importance of monitoring air pollutants in respiratory infectious diseases.
2023-04-24
2023-04-24
2023
info:eu-repo/semantics/article
Environmental Research, 2023, vol. 229, 115904
0013-9351
https://uvadoc.uva.es/handle/10324/59252
10.1016/j.envres.2023.115904
115904
Environmental Research
eng
https://www.sciencedirect.com/science/article/pii/S0013935123006965?via%3Dihub
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2023 The Authors
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Elsevier
oai:uvadoc.uva.es:10324/594732023-05-03T19:07:15Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
RP11-362K2.2:RP11-767I20.1 Genetic variation is associated with post-reperfusion therapy parenchymal hematoma. A GWAS meta-analysis
Muiño, Elena
Cárcel Márquez, Jara
Carrera, Caty
Llucià Carol, Laia
Gallego Fabrega, Cristina
Cullell, Natalia
Lledós, Miquel
Castillo Sánchez, José
Sobrino Moreiras, Tomás
Campos Pérez, Francisco
Rodríguez Castro, Emilio
Millán, Mònica
Muñoz Narbona, Lucía
Bustamante, Alejandro
López Cancio, Elena
Ribó, Marc
Álvarez Sabín, José
Jiménez Conde, Jordi
Roquer, Jaume
Giralt Steinhauer, Eva
Soriano Tárraga, Carolina
Vives Bauza, Cristófol
Díaz Navarro, Rosa
Tur, Silvia
Obach, Victor
Arenillas Lara, Juan Francisco
Segura, Tomás
Serrano Heras, Gemma
Martí Fàbregas, Joan
Delgado Mederos, Raquel
Camps Renom, Pol
Prats Sánchez, Luis
Guisado, Daniel
Guasch, Marina
Marin, Rebeca
Martínez Domeño, Alejandro
Freijo Guerrero, María del Mar
Moniche, Francisco
Cabezas, Juan Antonio
Castellanos Rodríguez, María del Mar
Krupinsky, Jerzy
Strbian, Daniel
Tatlisumak, Turgut
Thijs, Vincent
Lemmens, Robin
Slowik, Agnieszka
Pera, Joanna
Heitsch, Laura
Ibañez, Laura
Cruchaga, Carlos
Dhar, Rajat
Lee, Jin-Moo
Montaner, Joan
Fernández Cadenas, Israel
Consortium, on
Consortium, the
Genoma humano
Genomics
Genómica
Producción Científica
Stroke is one of the most common causes of death and disability. Reperfusion therapies are the only treatment available during the acute phase of stroke. Due to recent clinical trials, these therapies may increase their frequency of use by extending the time-window administration, which may lead to an increase in complications such as hemorrhagic transformation, with parenchymal hematoma (PH) being the more severe subtype, associated with higher mortality and disability rates. Our aim was to find genetic risk factors associated with PH, as that could provide molecular targets/pathways for their prevention/treatment and study its genetic correlations to find traits sharing genetic background. We performed a GWAS and meta-analysis, following standard quality controls and association analysis (fastGWAS), adjusting age, NIHSS, and principal components. FUMA was used to annotate, prioritize, visualize, and interpret the meta-analysis results. The total number of patients in the meta-analysis was 2034 (216 cases and 1818 controls). We found rs79770152 having a genome-wide significant association (beta 0.09, p-value 3.90 × 10−8) located in the RP11-362K2.2:RP11-767I20.1 gene and a suggestive variant (rs13297983: beta 0.07, p-value 6.10 × 10−8) located in PCSK5 associated with PH occurrence. The genetic correlation showed a shared genetic background of PH with Alzheimer’s disease and white matter hyperintensities. In addition, genes containing the ten most significant associations have been related to aggregated amyloid-β, tau protein, white matter microstructure, inflammation, and matrix metalloproteinases.
2023-05-03
2023-05-03
2021
info:eu-repo/semantics/article
Journal of Clinical Medicine, 2021, Vol. 10, Nº. 14, 3137
2077-0383
https://uvadoc.uva.es/handle/10324/59473
10.3390/jcm10143137
3137
14
Journal of Clinical Medicine
10
2077-0383
eng
https://www.mdpi.com/2077-0383/10/14/3137
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2021 The authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/595482023-05-09T19:00:37Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Daily headache in chronic migraine Is a predictive factor of response in patients who had completed three sessions of OnabotulinumtoxinA
Martínez Pías, Enrique
Guerrero Peral, Angel Luis
Sierra, Álvaro
Trigo, Javier
García Azorín, David
Neurology
Internal Medicine
Producción Científica
OnabotulinumtoxinA is one of the main preventive treatments for chronic migraine. Despite that up to one third of patients with chronic migraine suffer from daily headache, these individuals have hardly been studied. We conducted a prospective cohort study, including patients with chronic migraine and treated with OnabotulinumtoxinA according to the PREEMPT paradigm. The primary endpoint was to assess whether patients with chronic migraine and daily headache had a different response after three sessions of OnabotulinutoxinA than patients without daily headache. The secondary endpoint was to analyse the presence of predictive factors that could be associated with a higher response to OnabotulinumtoxinA. Patients with daily headache had a reduction of 14.9 (SD: 9.7) headache days per month, patients with 22–29 headache days a reduction of 10.6 (SD: 9.9) days, and patients with 15–21 headache days a reduction of 8.6 (SD: 7.1) days (p < 0.001). In the univariate regression analysis, a higher number of headache days per month at baseline was associated with higher odds of reduction in the number of headache days per month after OnabotulinumtoxinaA treatment (OR: 0.474, 95% CI: 0.278–0.670, p < 0.001). This association was maintained in the multivariate regression analysis (OR: 0.540, 95% CI: 0.333–0.746, p < 0.001). In our sample, daily headache was not associated with a worse response to OnabotulinumtoxinA treatment. A higher frequency of headache at baseline was a predictor of better response to OnabotulinumtoxinA treatment.
2023-05-09
2023-05-09
2021
info:eu-repo/semantics/article
Toxins, 2021, vol. 13, n. 6, 432
https://uvadoc.uva.es/handle/10324/59548
10.3390/toxins13060432
432
6
Toxins
13
2072-6651
eng
https://www.mdpi.com/2072-6651/13/6/432
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2021 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/597002023-05-26T19:00:38Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: A new therapeutic targeting of haematological malignancies
Olivares Hernández, Alejandro
Figuero Pérez, Luis
Terán Brage, Eduardo
López Gutiérrez, Álvaro
Tamayo Velasco, Álvaro
González Sarmiento, Rogelio
Cruz Hernández, Juan Jesús
Miramontes González, José Pablo
Hematology
Oncology
Blood - Diseases
Sangre - Enfermedades
Immunology
Médula ósea - Tumores
Cancer research
Producción Científica
Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice.
2023-05-26
2023-05-26
2021
info:eu-repo/semantics/article
Journal of Clinical Medicine, 2021, Vol. 10, Nº. 9, 1919
2077-0383
https://uvadoc.uva.es/handle/10324/59700
10.3390/jcm10091919
1919
9
Journal of Clinical Medicine
10
2077-0383
eng
https://www.mdpi.com/2077-0383/10/9/1919
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2021 The authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/597152023-09-05T19:05:04Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Enfermedad ósea de Paget: 1877-2023. Etiología y abordaje de una enfermedad en transición epidemiológica
Corral Gudino, Luis
Huesos Enfermedades
Medicina
Diagnóstico
Producción Científica
La enfermedad ósea de Paget se caracteriza por la alteración, en una o varias localizaciones óseas, del equilibrio entre formación y resorción ósea. Este desequilibrio da lugar a un hueso ensanchado, desorganizado, en muchos casos con una densidad ósea aumentada, aunque más frágil. Existiría una predisposición genética para su desarrollo, que explicaría entre un 5 y un 40% de los casos, sobre la que actuarían distintos factores ambientales. La enfermedad ósea de Paget fue considerada clásicamente la segunda enfermedad metabólica ósea más frecuente. Sin embargo, durante las últimas décadas presenta un marcado descenso tanto de la incidencia como de la gravedad clínica, lo que ha llevado a especular sobre la disminución o desaparición de la influencia de algún factor ambiental. Este descenso en la incidencia no debe servir como excusa para el abandono de su estudio, sino ser la razón para tratar de entender mejor su patogenia.
2023-05-31
2023-05-31
2023
info:eu-repo/semantics/article
Medicina Clínica, 2023, vol. 161, issue 5, p. 207-216
0025-7753
https://uvadoc.uva.es/handle/10324/59715
10.1016/j.medcli.2023.05.005
Medicina Clínica
spa
https://www.sciencedirect.com/science/article/pii/S0025775323002592?via%3Dihub
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
© 2023 The Authors
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Elsevier
oai:uvadoc.uva.es:10324/597452023-06-06T19:00:44Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Adiponectin gene variant rs3774261, effects on lipid profile and adiponectin levels after a high polyunsaturated fat hypocaloric diet with Mediterranean pattern
Luis Román, Daniel Antonio de
Primo Martín, David
Izaola Jauregui, Olatz
Gómez Hoyos, Emilia
López Gómez, Juan José
Adiponectina
Obesity
Obesidad - Dietoterapia
Diet therapy
Insulin resistance
Nutrition
Nutrición
Dietetics
Dietética
Producción Científica
The role of ADIPOQ gene variants on metabolic improvements after weight change secondary to different hypocaloric diets remained unclear. We evaluate the effect of rs3774261 of ADIPOQ gene polymorphism on biochemical improvements and weight change after high polyunsaturated fat hypocaloric diet with a Mediterranean dietary pattern for 12 weeks. A population of 361 obese subjects was enrolled in an intervention trial with a calorie restriction of 500 calories over the usual intake and 45.7% of carbohydrates, 34.4% of fats, and 19.9% of proteins. The percentages of different fats was; 21.8% of monounsaturated fats, 55.5% of saturated fats, and 22.7% of polyunsaturated fats. Before and after intervention, an anthropometric study, an evaluation of nutritional intake and a biochemical evaluation were realized. All patients lost weight regardless of genotype and diet used. After 12 weeks with a similar improvement in weight loss (AA vs. AG vs. GG); total cholesterol (delta: −28.1 ± 2.1 mg/dL vs. −14.2 ± 4.1 mg/dL vs. −11.0 ± 3.9 mg/dL; p = 0.02), LDL cholesterol (delta: −17.1 ± 2.1 mg/dL vs. −6.1 ± 1.9 mg/dL vs. −6.0 ± 2.3 mg/dL; p = 0.01), triglyceride levels (delta: −35.0 ± 3.6 mg/dL vs. 10.1 ± 3.2 mg/dL vs. −9.7 ± 3.1 mg/dL; p = 0.02), C reactive protein (CRP) (delta: −2.3 ± 0.1 mg/dL vs. −0.2 ± 0.1 mg/dL vs. −0.2 ± 0.1 mg/dL; p = 0.02), serum adiponectin (delta: 11.6 ± 2.9 ng/dL vs. 2.1 ± 1.3 ng/dL vs. 3.3 ± 1.1 ng/dL; p = 0.02) and adiponectin/leptin ratio (delta: 1.5 ± 0.1 ng/dL vs. 0.3 ± 0.2 ng/dL vs. 0.4 ± 0.3 ng/dL; p = 0.03), improved only in AA group. AA genotype of ADIPOQ variant (rs3774261) is related with a significant increase in serum levels of adiponectin and ratio adiponectin/leptin and decrease on lipid profile and C-reactive protein (CRP).
2023-06-06
2023-06-06
2021
info:eu-repo/semantics/article
Nutrients, 2021, Vol. 13, Nº. 6, 1811
2072-6643
https://uvadoc.uva.es/handle/10324/59745
10.3390/nu13061811
1811
6
Nutrients
13
2072-6643
eng
https://www.mdpi.com/2072-6643/13/6/1811
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2021 The authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/598572023-06-15T19:00:35Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Comparison of plasma lipoprotein composition and function in cerebral amyloid angiopathy and Alzheimer’s disease
Bonaterra Pastra, Anna
Fernández de Retana, Sofia
Rivas Urbina, Andrea
Puig, Nuria
Benítez, Sonia
Pancorbo, Olalla
Rodríguez Luna, David
Pujadas, Francesc
Freijo Guerrero, María del Mar
Tur, Silvia
Martínez Zabaleta, Maite
Cardona Portela, Pere
Vera, Rocío
Lebrato Hernández, Lucía
Arenillas Lara, Juan Francisco
Pérez Sánchez, Soledad
Montaner, Joan
Sánchez Quesada, Jose Luis
Hernández Guillamon, Mar
Alzheimer's disease
Alzheimer, Enfermedad de
Lipids
Neurology
Cerebro - Enfermedades
Lípidos
Proteins
Proteinas
Producción Científica
Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer’s disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation.
2023-06-15
2023-06-15
2021
info:eu-repo/semantics/article
Biomedicines, 2021, Vol. 9, Nº. 1, 72
2227-9059
https://uvadoc.uva.es/handle/10324/59857
10.3390/biomedicines9010072
72
1
Biomedicines
9
2227-9059
eng
https://www.mdpi.com/2227-9059/9/1/72
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2021 The authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/599652023-06-27T19:00:34Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Circulating AQP4 levels in patients with cerebral amyloid angiopathy-associated intracerebral hemorrhage
Marazuela, Paula
Bonaterra Pastra, Anna
Faura, Júlia
Penalba, Anna
Pizarro, Jesús
Pancorbo, Olalla
Rodríguez Luna, David
Vert, Carla
Rovira, Alex
Pujadas, Francesc
Freijo Guerrero, María del Mar
Tur, Silvia
Martínez Zabaleta, Maite
Cardona Portela, Pere
Vera, Rocío
Lebrato Hernández, Lucía
Arenillas Lara, Juan Francisco
Pérez Sánchez, Soledad
Montaner, Joan
Delgado, Pilar
Hernández Guillamon, Mar
Brain - Hemorrhage
Neurology
Cerebrovascular diseases
Enfermedades cerebrovasculares
Magnetic resonance
Resonancia magnética
Angiopatia
Cerebro - Anomalias
Neurosurgery
Producción Científica
Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA–ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH.
2023-06-27
2023-06-27
2021
info:eu-repo/semantics/article
Journal of Clinical Medicine, 2021, Vol. 10, Nº. 5, 989
2077-0383
https://uvadoc.uva.es/handle/10324/59965
10.3390/jcm10050989
989
5
Journal of Clinical Medicine
10
2077-0383
eng
https://www.mdpi.com/2077-0383/10/5/989
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2021 The authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/599932023-06-29T19:00:31Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Prognostic role of TAPSE to PASP ratio in patients undergoing MitraClip procedure
Trejo Velasco, Blanca
Estevez Loureiro, Rodrigo
Carrasco Chinchilla, Fernando
Fernández Vázque, Felipe
Arzamendi, Dabit
Pan, Manuel
Pascual, Isaac
Nombela Franco, Luis
Amat Santos, Ignacio Jesús
Freixa, Xavier
Hernández Antolín, Rosa Ana
Trillo Nouche, Ramiro
Andraka Ikazuriaga, Leire
López Mínguez, José R.
Sanmiguel Cervera, Dario
Sanchis, Juan
Diez Gil, José Luis
Ruiz Quevedo, Valeriano
Urbano Carrillo, Cristóbal
Becerra Muñoz, Víctor Manuel
Benito González, Tomás
Li, Chi Hion
Mesa, Dolores
Avanzas, Pablo
Armijo, Germán
Serrador Frutos, Ana María
Sanchis, Laura
Fernández-Golfín Lobán, Covadonga
Cid Álvarez, Belén
Hernández García, José María
Garrote Coloma, Carmen
Fernández Peregrina, Estefanía
Romero, Miguel
León Arguero, Víctor
Cruz González, Ignacio
Cardiac surgery
Cardiology
Corazón - Cirugía
Pulmonary hypertension
Hipertensión pulmonar
Echocardiography
Mitral valve - Diseases - Imaging
Heart valves - Diseases - diagnostic imaging
Heart - Diseases
Corazón - Enfermedades
Producción Científica
Background: Transcatheter mitral valve repair (TMVR) is an effective therapy for high-risk patients with severe mitral regurgitation (MR) but heart failure (HF) readmissions and death remain substantial on mid-term follow-up. Recently, right ventricular (RV) to pulmonary arterial (PA) coupling has emerged as a relevant prognostic predictor in HF. In this study, we aimed to assess the prognostic value of tricuspid annular plane systolic excursion (TAPSE) to PA systolic pressure (PASP) ratio as a non-invasive measure of RV-to-PA coupling in patients undergoing TMVR with MitraClip (Abbott, CA, USA). Methods: Multicentre registry including 228 consecutive patients that underwent successful TMVR with MitraClip. The sample was divided in two groups according to TAPSE/PASP median value: 0.35. The primary combined endpoint encompassed HF readmissions and all-cause mortality. Results: Mean age was 72.5 ± 11.5 years and 154 (67.5%) patients were male. HF readmissions and all-cause mortality were more frequent in patients with TAPSE/PASP ≤ 0.35: Log-Rank 8.844, p = 0.003. On Cox regression, TAPSE/PASP emerged as a prognostic predictor of the primary combined endpoint, together with STS-Score. TAPSE/PASP was a better prognostic predictor than either TAPSE or PASP separately. Conclusions: TAPSE/PASP ratio appears as a novel prognostic predictor in patients undergoing MitraClip implantation that might improve risk stratification and candidate selection.
2023-06-29
2023-06-29
2021
info:eu-repo/semantics/article
Journal of Clinical Medicine, 2021, Vol. 10, Nº. 5, 1006
2077-0383
https://uvadoc.uva.es/handle/10324/59993
10.3390/jcm10051006
1006
5
Journal of Clinical Medicine
10
2077-0383
eng
https://www.mdpi.com/2077-0383/10/5/1006
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2021 The authors
Atribución 4.0 Internacional
oai:uvadoc.uva.es:10324/602532023-07-12T19:00:43Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Gender differences in anxiety, attitudes, and fear among nursing undergraduates coping with CPR training with PPE kit for COVID
Maestre Miquel, Clara
Martín Rodríguez, Francisco
Durántez Fernández, Carlos
Martín Conty, José Luis
Viñuela, Antonio
Polonio López, Begoña
Romo Barrientos, Carmen
Criado Álvarez, Juan José
Torres Falguera, Francisca
Conty Serrano, Rosa
Jorge Soto, Cristina
Mohedano Moriano, Alicia
Anxiety
Ansiedad
Attitude (Psychology)
Actitud (Psicología)
Miedo
Nursing
Nurses - Training of
Enfermería
Enfermeras
Personal protective equipment
COVID-19
Producción Científica
Background: The aim of this study was to examine the attitudes, fears, and anxiety level of nursing students faced with a critical clinical simulation (cardiopulmonary reanimation) with and without personal protective equipment (PPE). Methods: A pilot before–after study as conducted from 21 to 25 June 2021, with 24 students registered in the nursing degree of the Faculty of Health Sciences of the Castilla-La Mancha University (UCLM) in the city of Talavera de la Reina (Toledo, Spain). From 520 possible participants, only 24 were selected according to the exclusion and inclusion criteria. The STAI Manual for the State-Trait Anxiety Inventory, a self-evaluation questionnaire, was used to study trait STAI (basal anxiety), trait STAI before CPR, state STAI after CPR, total STAI before CPR, and total STAI after CPR as the main variables. A t-test was used to study the STAI variables according to sex and the physiological values related to the anxiety level of participants. An ANOVA statistical test was used to perform a data analysis of the STAI variables. Results: A total of 54.2% of participants (IC 95% 35.1–72.1) suffered from global anxiety before the cardiopulmonary reanimation maneuvers (CPR). The results of the STAI before CPR maneuvers showed significant differences according to gender in state anxiety (p = 0.04), with a higher level of anxiety in women (22.38 ± 7.69 vs. 15.82 ± 7.18). Conclusions: This study demonstrates different levels of anxiety in terms of gender suffered by nursing students in high-pressure environments, such as a CPR situation.
2023-07-12
2023-07-12
2022
info:eu-repo/semantics/article
International Journal of Environmental Research and Public Health, 2022, Vol. 19, Nº. 23, 15713
1660-4601
https://uvadoc.uva.es/handle/10324/60253
10.3390/ijerph192315713
15713
23
International Journal of Environmental Research and Public Health
19
1660-4601
eng
https://www.mdpi.com/1660-4601/19/23/15713
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/603982023-07-26T10:34:00Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Real-world evaluation of the tolerability to onabotulinum toxin A: The RETO study
García Azorín, David
Martínez, Blanca
Gutiérrez, María
Ruiz Piñero, Marina
Echavarría, Ana
Sierra, Álvaro
Guerrero Peral, Angel Luis
Botulinum toxin - Therapeutic use
Toxina botulínica
Neurology
Migraine
Migraña
Chronic pain
Dolor crónico
Pain medicine
Pain - Treatment
Dolor - Tratamiento
Médicaments - Effets secondaires
Medicamentos - Efectos secundarios
Toxicology
Producción Científica
Onabotulinumtoxin A (onabotA) has shown efficacy in chronic migraine (CM), with good tolerability and a low rate of adverse effects, most of them not severe. The aim of this study is to evaluate tolerability and adverse effects of onabotA in clinical practice and to analyze if there is a relationship between tolerability to treatment administration, adverse effects’ (AEs) occurrence and clinical response. We included patients with CM that received treatment with onabotA for the first time. Tolerability to treatment was evaluated by a 0–10 numeric rating scale (0: worst possible, 10: optimal tolerability). We assessed the presence of AEs by using a standardized questionnaire. Treatment response was based on the 50 and 75% responder rate between weeks 20 and 24, compared with the baseline, according to headache diaries. We analyzed whether the tolerability was associated with a higher frequency of AEs or a higher probability of clinical response. We included 105 patients, 87.7% female, with an age of 43.9 ± 10.7 years. Mean tolerability was 7.8/10 and 7.2/10 in the first and second onabotA administration, respectively. AEs were reported by (first-second) 71.4–68.6% patients. The percentage of patients with a 50% response was 56.3%. There was no association between tolerability and AEs’ occurrence or clinical response.
2023-07-18
2023-07-18
2022
info:eu-repo/semantics/article
Toxins, 2022, Vol. 14, Nº. 12, 850
2072-6651
https://uvadoc.uva.es/handle/10324/60398
10.3390/toxins14120850
850
12
Toxins
14
2072-6651
eng
https://www.mdpi.com/2072-6651/14/12/850
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/606062023-09-29T08:33:18Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Effects of a short-term meal replacement hypocaloric diet in subjects with obesity and high fatty liver index
Luis Román, Daniel Antonio de
Primo Martín, David
Izaola Jauregui, Olatz
López Gómez, Juan José
Fatty liver
Liver - Diseases
Hígado - Enfermedades
Obesity
Obesidad
Nutrition
Nutrition disorders
Enfermedades de la nutrición
Dietetics
Dietética
Regímenes alimentarios
Enzymes
Enzimas
Producción Científica
Introduction: Dietary changes play a role in metabolic response of patients with metabolic-associated fatty liver disease, and there is little evidence on the use of partial meal replacement (pMR) diets in this pathology. Aim: We decided to evaluate the modifications in transaminases levels after a pMR hypocaloric diet in subjects with obesity and elevated fatty liver index (FLI). Material and methods: A sample of 606 patients with obesity and FLI ≥ 60 were enrolled and treated during 3 months with a pMR diet. Patients were divided as group I (Alanine amino transferase (ALT) normal) or group II (ALT ≥ 43 UI/L). Results: Body mass index, body weight, total fat mass, waist circumference, blood pressure, fasting glucose, total cholesterol, Low-density lipoprotein (LDL) cholesterol, triglycerides, insulin, Homeostasis Model assessment (HOMA-IR), and FLI index improved significantly in the total group with pMR diet, without differences between group I and II. ALT, aspartate aminotransferase activity (AST), Gama glutamine transferase (GGT), and ratios of AST/ALT improved in both groups, too. This improvement was higher in group II (deltas group I vs. deltas group II); ALT (−4.2 ± 0.9 UI/L vs. −32.1 ± 5.7 UI/L: p = 0.01), AST (−4.8 ± 1.8 UI/L vs. −14.1 ± 1.9 UI/L: p = 0.02), GGT (−4.8 ± 1.4 UI/L vs. −37.1 ± 4.2 UI/L: p = 0.01), and AST/ALT ratio (−0.04 ± 0.002 units vs. −0.19 ± 0.04 units: p = 0.01). Conclusions: We reported that a pMR diet is an effective method to lose weight and to improve metabolic parameters in patients with obesity and high FLI. The decrease in liver parameters was greater in patients with ALT ≥ 43 UI/L.
2023-07-27
2023-07-27
2022
info:eu-repo/semantics/article
Nutrients, 2022, Vol. 14, Nº. 24, 5353
2072-6643
https://uvadoc.uva.es/handle/10324/60606
10.3390/nu14245353
5353
24
Nutrients
14
2072-6643
eng
https://www.mdpi.com/2072-6643/14/24/5353
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/606462023-08-28T09:29:55Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Role of Beta2 adrenergic receptor polymorphism (rs1042714) on body weight and glucose metabolism response to a meal-replacement hypocaloric diet
Luis Román, Daniel Antonio de
Izaola Jauregui, Olatz
Primo Martín, David
López Gómez, Juan José
Nutrición-Investigación
Metabolismo
Producción Científica
The Beta2-adrenergic receptor (ADRB2) is involved in energy balance regulation. The objective of our study was to evaluate the role of rs1042714 genetic variant of ADRB2 gene on weight loss, body composition and metabolic changes secondary to partial Meal replacement (pMR) hypocaloric diet in women with obesity. G allele of rs rs1042714 predicts the magnitude of weight loss resulting from a pMR diet. These adiposity improvements produce a better improvement of insulin resistance and percentage of impaired glucose metabolism in G allele carriers.
2023-07-28
2023-07-28
2023
info:eu-repo/semantics/article
Nutrition, 2023, vol. 116, 112170
0899-9007
https://uvadoc.uva.es/handle/10324/60646
10.1016/j.nut.2023.112170
112170
Nutrition
eng
https://www.sciencedirect.com/science/article/pii/S0899900723001983?via%3Dihub
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2023 The Authors
Atribución 4.0 Internacional
Elsevier
oai:uvadoc.uva.es:10324/612682023-08-31T19:01:35Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Sprouting and hydrolysis as biotechnological tools for development of nutraceutical ingredients from oat grain and hull
Jiménez Pulido, Iván Jesús
Rico, Daniel
Martínez Villaluenga, Cristina
Pérez Jiménez, Jara
Luis Román, Daniel Antonio de
Martín Diana, Ana Belén
Oats
Avena
Grain
Cereales
Hydrolysis
Hidrólisis
Antioxidants
Antioxidantes
Glycemic index
Glucosa
Anti-inflammatory
Food
Producción Científica
Oat consumption has increased during the last decade because of the health benefits associated with its soluble dietary fiber (β-glucan), functional proteins, lipids, and the presence of specific phytochemicals, such as avenanthramides. Oat is consumed mainly as whole grain, and the hull (seed coat), comprising 25–35% of the entire grain, is removed, generating a large amount of waste/by-product from the milling industry. The objective of this study was to evaluate the use of biotechnological strategies, such as sprouting for oat grain (OG) and hydrolysis for oat hull (OH), to enhance antioxidant and anti-inflammatory properties and lower the glycemic index (GI). Sprouting produced significant (p ≤ 0.05) increases in free (32.10 to 76.62 mg GAE (100 g)−1) and bound phenols (60.45 to 124.36 mg GAE (100 g)−1), increasing significantly (p ≤ 0.05) the avenanthramide (2c, 2p and 2f) soluble phenolic alkaloid content and anti-inflammatory properties of OG. On the other hand, the hydrolysis of OH using Viscoferm (EH2-OH) and Ultraflo XL (EH21-OH) increased by 4.5 and 5-fold the release of bound phenols, respectively; meanwhile, the use of Viscoferm increased the 4.55-fold soluble β-glucan content in OH, reaching values close to those of OG (4.04 vs. 4.46 g (100 g)−1). The study shows the potential of both strategies to enhance the nutritional and bioactive properties of OG and OH and describes these processes as feasible for the industry to obtain an ingredient with high antioxidant and anti-inflammatory activities. Single or combined biotechnological tools can be used on oat grains and hulls to provide nutraceutical ingredients.
2023-08-31
2023-08-31
2022
info:eu-repo/semantics/article
Foods, 2022, Vol. 11, Nº. 18, 2769
2304-8158
https://uvadoc.uva.es/handle/10324/61268
10.3390/foods11182769
2769
18
Foods
11
2304-8158
eng
https://www.mdpi.com/2304-8158/11/18/2769
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/616022023-09-18T19:00:39Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry
Coco Martín, María Begoña
Leal Vega, Luis
Blázquez Cabrera, José Antonio
Navarro, Amalia
Moro, María Jesús
Arranz García, Francisca
Amérigo, María José
Sosa Henríquez, Manuel
Vázquez, María Ángeles
Montoya, María José
Díaz Curiel, Manuel
Olmos, José Manuel
Ruiz Mambrilla, Marta María
Filgueira Rubio, José
Pérez Castrillon, José Luis
Hernández de Sosa, Nerea
Calero Bernal, María Luz
Armengol Sucarrats, Dolors
Escalante Yanguas, Begoña de
Miranda Díaz, Cristina
Miranda García, María José
Giner García, Mercedes
Jareño Chaumel, Julia
Cotos Canca, Rafael
Hernández, José Luis
Rodero Hernández, Francisco Javier
Sánchez Molini, Pilar
Aguado Caballero, José María
Cobeta García, Juan Carlos
Tirado Miranda, Raimundo
Producción Científica
Purpose To evaluate the effect of different non-osteoporotic drugs on the increase or decrease in the risk of incident fragility
fractures (vertebral, humerus or hip) in a cohort of patients diagnosed with osteoporosis on active anti-osteoporotic therapy.
Methods For this retrospective longitudinal study, baseline and follow-up data on prescribed non-osteoporotic treatments
and the occurrence of vertebral, humerus or hip fractures in 993 patients from the OSTEOMED registry were analyzed
using logistic regression models. The drugs evaluated with a possible beneficial effect were thiazides and statins, while the
drugs evaluated with a possible harmful effect were antiandrogens, aromatase inhibitors, proton pump inhibitors, selective
serotonin reuptake inhibitors, benzodiazepines, GnRH agonists, thyroid hormones, and oral and inhaled corticosteroids.
Results Logistic regression analyses indicated that no treatment significantly improved fracture risk, with the only treatments
that significantly worsened fracture risk being letrozole (OR = 0.18, p-value = 0.03) and oral corticosteroids at doses ≤ 5 mg/
day (OR = 0.16, p-value = 0.03) and > 5 mg/day (OR = 0.27, p-value = 0.04).
Conclusion The potential beneficial or detrimental effects of the different drugs evaluated on fracture risk are masked by
treatment with anabolic or antiresorptive drugs that have a more potent action on bone metabolism, with two exceptions:
letrozole and oral corticosteroids. These findings may have important clinical implications, as patients receiving these treat-
ments are not fully protected by bisphosphonates, which may imply the need for more potent anti-osteoporotic drugs such
as denosumab or teriparatide.
2023-09-18
2023-09-18
2023
info:eu-repo/semantics/article
European Journal of Clinical Pharmacology, 2023, vol. 79, n. 10, p. 1333-1339.
0031-6970
https://uvadoc.uva.es/handle/10324/61602
10.1007/s00228-023-03544-x
1333
10
1339
European Journal of Clinical Pharmacology
79
1432-1041
eng
https://link.springer.com/article/10.1007/s00228-023-03544-x
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2023 The Author(s)
Atribución 4.0 Internacional
Springer
oai:uvadoc.uva.es:10324/618522023-09-29T19:00:36Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Association of the APOA-5 genetic variant rs662799 with metabolic changes after an intervention for 9 months with a low-calorie diet with a Mediterranean profile
Luis Román, Daniel Antonio de
Primo Martín, David
Izaola Jauregui, Olatz
Aller de la Fuente, Rocío
Human genetics
Genética humana
Regímenes alimentarios
Nutrition
Nutrición
Dietetics
Dietética
Diet therapy
Diet
Dieta
Food Science
Triglycerides
Triglicéridos
Producción Científica
In cross-sectional studies, the genetic variant rs662799 of the APOA5 gene is associated with high serum triglyceride concentrations, and in some studies, the effect of short-term dietary interventions has been evaluated. The aim of the present investigation was to evaluate the role of this genetic variant in metabolic changes after the consumption of a low-calorie diet with a Mediterranean pattern for 9 months. A population of 269 Caucasian obese patients was recruited. Adiposity and biochemical parameters were measured at the beginning (basal level) and after 3 and 9 months of the dietary intervention. The rs662799 genotype was assessed with a dominant analysis (TT vs. CT + CC). The APOA5 variant distribution was: 88.1% (n = 237) (TT), 11.5% (n = 31) (TC) and 0.4% (n = 1) (CC). There were significant differences only in triglyceride levels at all times of the study between the genotype groups. After 3 and 9 months of dietary intervention, the following parameters improved in both genotype groups: adiposity parameters, systolic pressure, total cholesterol, LDL cholesterol, leptin, adiponectin and the leptin/adiponectin ratio. The intervention significantly decreased insulin levels, HOMA-IR and triglyceride levels in non-C allele carriers (Delta 9 months TT vs. TC + CC). i.e., insulin levels (delta: −3.8 + 0.3 UI/L vs. −1.2 + 0.2 UI/L; p = 0.02), HOMA-IR levels (delta: −1.2 + 0.2 units vs. −0.3 + 0.1 units; p = 0.02), triglyceride levels (delta: −19.3 + 4.2 mg/dL vs. −4.2 + 3.0 mg/dL; p = 0.02). In conclusion, non-C allele carriers of rs662799 of the APOA5 gene showed a decrease of triglyceride, insulin and HOMA-IR levels after consuming a low-calorie diet with a Mediterranean pattern; we did not observe this effect in C allele carriers, despite a significant weight loss.
2023-09-29
2023-09-29
2022
info:eu-repo/semantics/article
Nutrients, 2022, Vol. 14, Nº. 12, 2427
2072-6643
https://uvadoc.uva.es/handle/10324/61852
10.3390/nu14122427
2427
12
Nutrients
14
2072-6643
eng
https://www.mdpi.com/2072-6643/14/12/2427
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/619252023-10-09T19:02:59Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Impact of protein content on the antioxidants, anti-inflammatory properties and glycemic index of wheat and wheat bran
Jiménez Pulido, Iván Jesús
Rico Bargués, Daniel
Pérez Jiménez, Jara
Martínez Villaluenga, Cristina
Luis Román, Daniel Antonio de
Martín Diana, Ana Belén
Valorization
Dietary fiber
Fibra alimentaria
Wheat bran
Trigo
Antioxidants
Antioxidantes
Glycemic index
Glúcidos - Análisis
Anti-inflammatory
Antiinflamatorios
Alimentos - Análisis
Food science
Agriculture
Producción Científica
Conventional wheat milling generates important volumes of wheat bran (WB), which is a concentrated source of polyphenols and insoluble fiber. In terms of health benefits and based on epidemiological and experimental evidence, these compounds contribute to reducing the risk of certain chronic pathologies. Protein concentration is the main quality factor conditioning wheat use in the agroindustry. When turning waste into feasible resources, it is essential to evaluate the variability of the raw material. The aim of this study was the evaluation of the impact of protein content in the valorization of WB based on its antioxidants, anti-inflammatory properties and glycemic index (GI). A significantly (p ≤ 0.05) lower content of phenolic compounds was found in the whole grain (WG) fractions, both free (FP) and bound (BP), as compared to the WB phenolic fractions, differences that ranged from 4- to 6-fold (538 to 561 mg GAE 100 g−1 in WG vs. 1027 to 1236 in WB mg GAE 100 g−1 in FP and 2245 to 2378 vs. 6344 to 7232 mg GAE 100 g−1 in BP). A significant (p ≤ 0.05) effect of the protein content on the resulting phenolic content and antioxidant capacity was observed, especially in WG, but also in WB, although in the latter a significant (p ≤ 0.05) negative correlation was observed, and increasing the protein content resulted in decreasing total phenolic content, antioxidants, and ferric-reducing capacities, probably due to their different types of proteins. The highest protein content in WB produced a significant (p ≤ 0.05) reduction in GI value, probably due to the role of protein structure in protecting starch from gelatinization, along with phytic acid, which may bind to proteins closely associated to starch and chelate calcium ions, required for α-amylase activity. A significant (p ≤ 0.05) effect of the protein content on the GI was also found, which may be explained by the structural effect of the proteins associated with starch, reducing the GI (21.64). The results obtained show the importance of segregation of WB in valorization strategies in order to increase the efficiency of the processes.
2023-10-09
2023-10-09
2022
info:eu-repo/semantics/article
Foods, 2022, Vol. 11, Nº. 14, 2049
2304-8158
https://uvadoc.uva.es/handle/10324/61925
10.3390/foods11142049
2049
14
Foods
11
2304-8158
eng
https://www.mdpi.com/2304-8158/11/14/2049
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/620582023-10-18T19:01:17Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Influence of DNA mismatch repair (MMR) system in survival and response to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC): Retrospective analysis
Olivares Hernández, Alejandro
Barco Morillo, Edel del
Parra Pérez, Carmen
Miramontes González, José Pablo
Figuero Pérez, Luis
Martín Gómez, Teresa
Escala Cornejo, Roberto
Bellido Hernández, Lorena
González Sarmiento, Rogelio
Cruz Hernández, Juan Jesús
Ludeña de la Cruz, María Dolores
DNA repair
Immunotherapy
Inmunoterapia
Oncology
Cancer research
Immune checkpoint inhibitors (ICIs)
Non small cell lung cancer
Lungs - Cancer
Pulmones - Cáncer
Survival
Supervivencia
Retrospective analysis
Genetics
Genetica
Molecular biology
Producción Científica
Mutations in the mismatch repair (MMR) system predict the response to immune checkpoint inhibitors (ICIs) like colon or gastric cancer. However, the MMR system’s involvement in non-small cell lung cancer (NSCLC) remains unknown. Addressing this issue will improve clinical guidelines in the case of mutations in the main genes of the MMR system (MLH1, MSH2, MSH6, and PMS2). This work retrospectively assessed the role that these gene mutations play in the response to and survival of ICIs in NSCLC. Patients with NSCLC treated with nivolumab as the second-line treatment in the University Hospital of Salamanca were enrolled in this study. Survival and response analyses were performed according to groups of MMR system gene expression (MMR expression present or deficiency) and other subgroups, such as toxicity. There was a statistically significant relationship between the best response obtained and the expression of the MMR system (p = 0.045). The presence of toxicity grade ≥ 3 was associated with the deficiency expression of MMR (dMMR/MSI-H) group (p = 0.022; odds ratio = 10.167, 95% confidence interval (CI) 1.669–61.919). A trend towards greater survival and response to ICIs was observed in NSCLC and dMMR. Assessing the genes in the MMR system involved in NSCLC is key to obtaining personalized immunotherapy treatments.
2023-10-18
2023-10-18
2022
info:eu-repo/semantics/article
Biomedicines, 2022, Vol. 10, Nº. 2, 360
2227-9059
https://uvadoc.uva.es/handle/10324/62058
10.3390/biomedicines10020360
360
2
Biomedicines
10
2227-9059
eng
https://www.mdpi.com/2227-9059/10/2/360
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/624662023-10-30T20:00:53Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Impact of glucose variability on the assessment of the glycemia risk index (GRI) and classic glycemic metrics
Pérez López, Paloma
Fernández Velasco, Pablo
Bahillo Curieses, María del Pilar
Luis Román, Daniel Antonio de
Díaz Soto, Gonzalo
Producción Científica
Objective To evaluate the impact of glucose variability on the relationship between the GRI and other glycemic metrics in a
cohort of pediatric and adult patients with type 1 diabetes (T1D) using intermittent scanning continuous glucose monitoring
(isCGM).
Methods We performed a cross-sectional study of 202 patients with T1D under intensive insulin treatment (25.2% CSII)
using isCGM. Clinical, metabolic, and glycemic metrics were collected, and the GRI was calculated with its hypoglycemia
(CHypo) and hyperglycemia (CHyper) components. The correlation between the GRI and other classical glycometrics in
relation to the coefficient of variation (CV) was evaluated.
Results A total of 202 patients were included (53% male; 67.8% adults) with a mean age of 28.6 ± 15.7 years and
12.5 ± 10.9 years of T1D evolution (TIR 59.0 ± 17.0%; CV 39.8 ± 8.0%; GMI 7.3 ± 1.1%). The mean GRI was 54.0 ± 23.3
with a CHypo and CHyper component of 5.7 ± 4.8 and 23.4 ± 14.3, respectively. A strong negative correlation was observed
between the GRI and TIR (R = −0.917; R2 = 0.840; p < 0.001), showing differences when dividing patients with low
glycemic variability (CV < 36%) (R = −0.974; R2 = 0.948; p < 0.001) compared to those with greater CV instability (≥36%)
(R = −0.885; R2 = 0.784; p < 0.001). The relationship of GRI with its two components was strongly positive with CHyper
(R = 0.801; R2 = 0.641; p < 0.001) and moderately positive with CHypo (R = 0.398; R2 = 0.158; p < 0.001). When the GRI
was evaluated with the rest of the classic glycemic metrics, a strong positive correlation was observed with HbA1c
(R = 0.617; R2 = 0.380; p < 0.001), mean glucose (R = 0.677; R2 = 0.458; p < 0.001), glucose standard deviation
(R = 0.778; R2 = 0.605; p < 0.001), TAR > 250 (R = 0.801; R2 = 0.641; p < 0.001), and TBR < 54 (R = 0.481; R2 = 0.231;
p < 0.001).
Conclusions The GRI correlated significantly with all the glycemic metrics analyzed, especially with the TIR. Glycemic
variability (GV) significantly affected the correlation of the GRI with other parameters and should be taken into
consideration
2023-10-30
2023-10-30
2023
info:eu-repo/semantics/article
Endocrine, 2023.
https://uvadoc.uva.es/handle/10324/62466
10.1007/s12020-023-03511-7
Endocrine
1559-0100
eng
https://link.springer.com/article/10.1007/s12020-023-03511-7
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2023 The Author(s)
Atribución 4.0 Internacional
Springer
oai:uvadoc.uva.es:10324/625182023-10-31T20:00:38Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Influence of obesity on bone turnover markers and fracture risk in postmenopausal women
López Gómez, Juan José
Pérez Castrillon, José Luis
García de Santos, Isabel María
Pérez Alonso, María
Izaola Jauregui, Olatz
Primo Martín, David
Luis Román, Daniel Antonio de
Bones - Diseases
Huesos - Enfermedades
Bones - Metabolism - Disorders
Huesos - Metabolismo, trastornos del
Obesity
Obesidad
Osteoporosis
Fractures
Huesos - Fracturas
Bone turnover markers
Postmenopausal women
Menopause
Menopausia
Nutrition
Producción Científica
Background and aims: The relationship between obesity and bone metabolism is controversial. In recent decades, the protective role of obesity in the development of osteoporosis is questioned. The aims of this study are the following: to evaluate the differences in bone turnover markers between postmenopausal women with and without obesity and to compare the risk of fracture at five years between these groups. Methods: An observational longitudinal prospective cohort study of postmenopausal women with obesity (O) (body mass index (BMI) > 30 kg/m2) and non-obesity (NoO) (BMI < 30 kg/m2) is designed. 250 postmenopausal women are included in the study (NoO: 124 (49.6%) and O: 126 (50.4%)). It measures epidemiological variables, dietary variables (calcium intake, vitamin D intake, smoking, alcohol consumption, and physical activity), biochemicals (β-crosslap, type I procollagen amino-terminal peptide (P1NP), 25OH-vitamin D, and parathyroid hormone (PTH)), anthropometric variables, and fracture data five years after the start of the study. The mean age is 56.17 (3.91) years. Women with obesity showed lower levels of vitamin D (O: 17.27 (7.85) ng/mL, NoO: 24.51 (9.60) ng/mL; p < 0.01), and higher levels of PTH (O: 53.24 (38.44–65.96) pg/mL, NoO: 35.24 (25.36–42.40) pg/mL; p < 0.01). Regarding the bone formation marker (P1NP), it was found to be high in women without obesity, O: 45.46 (34.39–55.16) ng/mL, NoO: 56.74 (45.34–70.74) ng/mL; p < 0.01; the bone resorption marker (β-crosslap) was found to be high in women with obesity, being significant in those older than 59 years (O: 0.39 (0.14) ng/mL, NoO 0.24 (0.09) ng/mL; p < 0.05). No differences are observed in the risk of fracture at 5 years based on BMI (OR = 0.90 (95%CI 0.30–2.72); p = 0.85). Conclusions: Postmenopausal women with obesity showed lower levels of bone formation markers; older women with obesity showed higher markers of bone resorption.
2023-10-31
2023-10-31
2022
info:eu-repo/semantics/article
Nutrients, 2022, Vol. 14, Nº. 8, 1617
2072-6643
https://uvadoc.uva.es/handle/10324/62518
10.3390/nu14081617
1617
8
Nutrients
14
2072-6643
eng
https://www.mdpi.com/2072-6643/14/8/1617
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/626732023-11-06T20:01:31Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Treatment of vitamin D deficiency with calcifediol: Efficacy and safety profile and predictability of efficacy
Pérez Castrillon, José Luis
Usategui Martín, Ricardo
Pludowski, Pawel
Clinical nutrition
Cholecalciferol
Vitamin D deficiency
Vitamin D
Vitamina D
Safety profile
Food - Biotechnology
Food science
Pharmacology
Toxicity
Toxicology
Dietary supplements
Suplementos nutritivos
Producción Científica
Calcifediol (25-OH-vitamin D3) is the prohormone of the vitamin D endocrine system. It is used to prevent and treat vitamin D deficiency. Calcifediol, as well as cholecalciferol (vitamin D3), is efficient and safe in the general population, although calcifediol has certain advantages over cholecalciferol, such as its rapid onset of action and greater potency. This review analyzed studies comparing the efficacy and safety of both calcifediol and cholecalciferol drugs in the short and long term (>6 months). Calcifediol was found to be more efficacious, with no increase in toxicity. We also assessed the predictability of both molecules. A 25OHD increase depends on the dose and frequency of calcifediol administration. In contrast, after cholecalciferol administration, 25OHD increase depends on more factors than dose and frequency of administration, also phenotypic aspects (such as obesity and malabsorption), and genotypic factors impacts in this increase.
2023-11-06
2023-11-06
2022
info:eu-repo/semantics/article
Nutrients, 2022, Vol. 14, Nº. 9, 1943
2072-6643
https://uvadoc.uva.es/handle/10324/62673
10.3390/nu14091943
1943
9
Nutrients
14
2072-6643
eng
https://www.mdpi.com/2072-6643/14/9/1943
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2022 The Authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/634872023-12-05T20:00:42Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Predict the effects of dolutegravir (DTG) plus lamivudine (3TC) on immunological responses in people living with HIV (PLWHIV)
Troya, Jesús
Pedrero Tomé, Roberto
Buzón, Luis
Dueñas Gutiérrez, Carlos Jesús
HIV
HIV infections
VIH
Infecciones por VIH
AIDS (Disease)
Sida
Infectious diseases
Immunology
Medicine
Public health
Producción Científica
Background: Immune recovery in people living with HIV (PLWHIV) is a residual aspect of antiretroviral treatment (ART) in most patients, but in a non-negligible proportion of them, the CD4+ lymphocytes count, or CD4/CD8 ratio remains suboptimal. Methods: We performed a model of the immune response after 24 weeks of switching to a 2DR with DTG plus 3TC in a retrospective multicenter cohort of undetectable and experienced patients using significant predictor variables associated with the parameters or situations defined as success and failure. Clinical variables studied were CD4+ and CD8+ lymphocyte count, percentage of CD4, and CD4/CD8 ratio. These parameters were assessed at baseline and 24 weeks after the switch. Based on the evolution of each variable, four categories of immune response and four categories of non-immune response were defined. Immune response was defined as CD4+ count > 500 cells/mm3, %CD4 > 30%, CD8+ count < 1000 cells/mm3 and CD4/CD8 ratio ≥ 0.9. Non-response is just the opposite. Results: In our different models of immunological response, the presence of stage of AIDS (p = 0.035, p = 0.065) and current age over 50 years (p = 0.045) are postulated as statistically significative limiting factors in achieving an improvement in CD4, %CD4, CD8, and CD4/CD8 ratio. Late HIV diagnosis (p = 0.156), without statistical significance, enhanced late the previous variables. In contrast, conditions where patients start with CD4 > 500 cells/mm3 (p = 0.054); CD4 > 30% (p = 0.054, p = 0.084); CD8 < 1000 cells/mm3 (p = 0.018), and CD4/CD8 ≥ 0.9 (p = 0.013, p = 0.09) are detected as stimulating or conducive to DTG plus 3TC treatment success. Conclusion: These models represent a proof of concept that could become a valuable tool for clinicians to predict the effects of DTG plus 3TC on immunological responses prior to the switch in undetectable pre-treated PLWHIV with immune dysfunction. The main predictors for immunological failure were late HIV diagnosis, stage of AIDS, and current age over 50 years. In contrast, starting with a normalized immune status was detected as stimulating or conducive to DTG plus 3TC treatment success.
2023-12-05
2023-12-05
2023
info:eu-repo/semantics/article
Journal of Clinical Medicine, 2023, Vol. 12, Nº. 3, 1176
2077-0383
https://uvadoc.uva.es/handle/10324/63487
10.3390/jcm12031176
1176
3
Journal of Clinical Medicine
12
2077-0383
eng
https://www.mdpi.com/2077-0383/12/3/1176
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
© 2023 The authors
Atribución 4.0 Internacional
MDPI
oai:uvadoc.uva.es:10324/636172023-12-13T20:00:48Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Gene expression analysis identify a metabolic and cell function alterations as a hallmark of obesity without metabolic syndrome in peripheral blood, a pilot study
De Luis, Daniel
El propósito de nuestro estudio piloto fue evaluar los perfiles de expresión génica en sangre de pacientes obesos sin otras complicaciones metabólicas.Una muestra de 17 pacientes obesos sin síndrome metabólico y 15 sujetos control no obesos se evaluó de forma prospectiva. La edad promedio del grupo de estudio fue de 43,6 ± 19,7 años con una distribución por sexo del 64,7% del sexo femenino
y 35,3% hombres. No se detectaron diferencias estadísticas con controles sanos 41,9 ± 12,3 años con un sexo distribución de 70% mujeresy 30% varones. Los pacientes obesos mostraron 1436 genes que fueron diferencialmente expresados en comparación con el grupo de control. El Ingenuity Pathway Analysis mostró que estos genes participaban en 13 categorías diferentes relacionadas con el metabolismo y las funciones celulares. En el conjunto de genes de la función celular, los genes más importantes fueron la región C-terminal de la proteína 1 de la molécula similar a Nel (NELL1) y Pigment factor derivado del epitelio (SPEDF), ambos genes estaban sobreexpresados. En el conjunto de genes del metabolismo, la insulina factor de crecimiento tipo 1 (IGF1), ApoA5 (apolipoproteína subtipo 5), Foxo4 (factor de transcripción Forkhead 4),ADIPOR1 (receptor de adiponectina tipo 1) y AQP7 (proteínas del canal de acuaporina7) estaban sobreexpresados.
Además, PIKFYVE (PtdIns(3) P 5-quinasa) y ROCK-2 (rho-quinasa II) estaban infraexpresados. En conclusión: Mostramos que las células sanguíneas perfericas de sujetos obesos presentaron cambios significativos en la expresión génica, exhibiendo 1436 genes expresados diferencialmente en comparación con sujetos no obesos. Además, nuestros datos mostraron una serie de genes involucrados en procesos relevantes implicados en el metabolismo, con genes que presentan altos valores de cambio (regulación al alza y regulación a la baja) asociados
con el metabolismo de lípidos, carbohidratos y proteínas.
2023-12-13
2023-12-13
2018
info:eu-repo/semantics/article
Clinical Nutrition 2018;37: 1348-1353.
0261-5614
https://uvadoc.uva.es/handle/10324/63617
10.1016/j.clnu.2017.06.006
1348
4
1353
Clinical Nutrition
37
spa
info:eu-repo/semantics/openAccess
oai:uvadoc.uva.es:10324/636182023-12-13T20:00:49Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
rs6923761 gene variant in glucagon-like peptide 1 receptor: Allelic frequencies and influence on cardiovascular risk factors in a multicenter study of Castilla-Leon
De Luis, Daniel
Nuestro objetivo fue investigar la distribución alélica del polimorfismo del receptor GLP-1 rs6923761 en un área geográfica de España (Comunidad de Castilla y León) y evaluar la influencia de este polimorfismo sobre parámetros antropométricos de obesidad y factores de riesgo cardiovascular en ayunas en pacientes obesos. Una muestra de 341 sujetos obesos fue analizada. Se determinaron en ayunas; glucosa, proteína C reactiva (PCR), insulina plasmática, resistencia a la insulina (HOMA-IR) y perfil lipídico. Se registraron parámetros antropométricos, ingesta dietética y presión arterial. Ciento cuarenta y tres pacientes (42,0%) tenían el genotipo GG (genotipo salvaje) y ciento noventa y ocho (58,0%) pacientes eran portadores de A: GA (164 pacientes, 48,1%) o AA (34 pacientes, 9,9%) (grupo genotipo mutante). Las áreas sanitarias de Valladolid y Segovia presentan el menor porcentaje de genotipo salvaje y alelo G (que otras Áreas de Salud). El Área de Salud de Burgos presenta un mayor porcentaje de salvajes genotipo. En el grupo con genotipo salvaje (genotipo GG), IMC (0,9 ± 1,3 kg/m2 ; p < 0,05), peso (3,3 ± 1,1 kg; p < 0,05), masa grasa (2,5 ± 1,1 kg; p < 0,05), relación cintura cadera (0,02 ± 0,005 cm; p < 0,05), perímetro de cintura (2,8 ± 1,1 cm; p < 0,05), triglicéridos ( 14,4 ± 3,3 mg/dl; p < 0,05) insulina (3,1 ± 1,0 mg/dl; p < 0,05) y HOMA-IR (1,2 ± 0,9 mg/dl; p < 0,05) fueron superiores a los portadores del alelo A. En los no portadores del alelo A, se encontraron niveles de colesterol HDL superiores a los portadores del alelo A (6,4 ± 2,3 mg/dl; p < 0,05).
Los datos de nuestro estudio revelaron una distribución alélica diferente en esta área geográfica, con mejores parámetros (Índice de masa corporal, peso, masa grasa, circunferencia de la cintura, triglicéridos, insulina, HOMA-IR y
colesterol HDL) en los portadores del alelo A que en los no portadores.
2023-12-13
2023-12-13
2018
info:eu-repo/semantics/article
Clin Nutr. 2018;37:2144-2148
0261-5614
https://uvadoc.uva.es/handle/10324/63618
10.1016/j.clnu.2017.10.013
2144
6
2148
Clinical Nutrition
37
spa
info:eu-repo/semantics/openAccess
Elsevier
oai:uvadoc.uva.es:10324/636202023-12-14T20:00:47Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Factors Related to Weight Gain in Subjects with Sleeve Gastrectomy During Lockdown by the COVID-19 Pandemic
De Luis, Daniel
El objetivo de este estudio fue evaluar los factores relacionados con la ganancia de peso durante el confinamiento en pacientes con gastrectomía en manga. Se reclutaron un grupo de 48 sujetos obesos con cirugía bariátrica previa. Después de un confinamiento de 7 semanas, se realizó una entrevista telefónica. En esta llamada telefónica, se registró el aumento de peso corporal autoinformado y diferentes factores. Para obtener los datos basales y prequirúrgicos, se registraron parámetros bioquímicos y antropométricos de la historia electronica. La edad media fue de 45,3±8,0 años (rango: 23-61) y el índice de masa corporal (IMC) medio fue de 32,5±7,5 kg/m2 (rango:28.6–34.2). La distribución por género fue de 38 mujeres (79,2%) y 10 hombres (20,8%). El aumento en el peso corporal autoinformado fue 3,8±2,1 kg durante las 7 semanas de confinamiento. Y el aumento de peso corporal autoinformado fue menor en sujetos con realización regular de ejercicio (4,6±0,9 vs 1,1±0,3 kg; p=0,02). El número de visitas presenciales a la consulta de nutrición que no asistieron fue de 0,61 ±0,81 (rango: 0-4) por paciente. En el análisis de regresión múltiple con ganancia de peso corporal autoinformada como variable dependiente, la actividad física (minutos/semana) se mantuvo como factor protector con un coeficiente beta de −0,09 (IC 95%: −0,001 a 0,016; p=0,03) y el número de citas presenciales en la consulta de nutrición perdidas como factor de riesgo con un coeficiente beta de
9,65 (IC 95%: 1,17-18,12; p=0,03). En conclusión, el aumento del peso corporal autorreferido se asocia con una disminución de la actividad física y la pérdida de visitas presenciales a la Unidad de Nutrición.
2023-12-13
2023-12-13
2021
info:eu-repo/semantics/article
Obesity Surgery 2021;1:1-6
0960-8923
https://uvadoc.uva.es/handle/10324/63620
10.1007/s11695-021-05253-9
2197
5
2202
Obesity Surgery
31
1708-0428
spa
info:eu-repo/semantics/openAccess
Springer
oai:uvadoc.uva.es:10324/636212023-12-14T20:00:48Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Adiponectin Gene Variant rs3774261, Effects on Lipid Profile and Adiponectin Levels after a High Polyunsaturated Fat Hypocaloric Diet with Mediterranean Pattern
De Luis, Daniel
Evaluamos el efecto del polimorfismo rs3774261 del gen ADIPOQ en las mejoras bioquímicas y el cambio de peso después de una dieta hipocalórica alta en grasas poliinsaturadas con un patrón de dieta mediterránea durante 12 semanas. Una población de 361 sujetos obesos se reclutaron en un ensayo de intervención con una restricción calórica de 500 calorías sobre la ingesta habitual y el 45,7% de hidratos de carbono, el 34,4% de grasas y el 19,9% de proteínas. los porcentajes de diferentes grasas era; 21,8% de grasas monoinsaturadas, 55,5% de grasas saturadas y 22,7% de grasas poliinsaturadas. Antes y después de la intervención, un estudio antropométrico, una evaluación del estado nutricional. Se realizó valoración de la ingesta y evaluación bioquímica. Todos los pacientes perdieron peso independientemente del genotipo y la dieta utilizada. Después de 12 semanas con una mejora similar en la pérdida de peso (AA vs AG vs GG); total colesterol (delta: −28,1 ± 2,1 mg/dL frente a −14,2 ± 4,1 mg/dL frente a −11,0 ± 3,9 mg/dL; p = 0,02), colesterol LDL (delta: −17,1 ± 2,1 mg/dL frente a −6,1 ± 1,9 mg/dL frente a −6,0 ± 2,3 mg/dL; p = 0,01), niveles de triglicéridos (delta: −35,0 ± 3,6 mg/dL frente a 10,1 ± 3,2 mg/dL frente a −9,7 ± 3,1 mg/dL; p = 0,02), Proteína C reactiva (PCR) (delta: −2,3 ± 0,1 mg/dL frente a −0,2 ± 0,1 mg/dL frente a −0,2 ± 0,1 mg/d; p = 0,02), adiponectina sérica (delta: 11,6 ± 2,9 ng/dL frente a 2,1 ± 1,3 ng/dL frente a 3,3 ± 1,1 ng/dL;
p = 0,02) y relación adiponectina/leptina (delta: 1,5 ± 0,1 ng/dL vs. 0,3 ± 0,2 ng/dL vs. 0,4 ± 0,3 ng/dL; p = 0,03), mejoró solo en el grupo AA. El genotipo AA de la variante ADIPOQ (rs3774261) está relacionado con un aumento significativo de los niveles séricos de adiponectina y de la relación adiponectina/leptina y disminución de los lípidos y proteína C reactiva (PCR).
2023-12-13
2023-12-13
2021
info:eu-repo/semantics/article
Nutrients. 2021 May 26;13(6):1811.
https://uvadoc.uva.es/handle/10324/63621
10.3390/nu13061811
1811
6
Nutrients
13
2072-6643
spa
info:eu-repo/semantics/openAccess
MDPI
oai:uvadoc.uva.es:10324/636222023-12-14T20:00:44Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Impact of an oral nutritional supplement enriched in leucine, EPA, DHA, and β-glucans on the increase of muscle mass in patients with cancer and malnutrition: The alisenoc trial
De Luis, Daniel
Se realizó un ensayo clínico multicéntrico, controlado, aleatorizado, doble ciego, de grupos paralelos en pacientes con cáncer y desnutrición durante el tratamiento ambulatorio. Los pacientes fueron asignados al azar para recibir un suplemento oral nutricional (SON) específico rico en calorías y proteínas enriquecido con leucina, EPA, DHA y β-glucanos o un isocalórico, isonitrogenado SON estándar durante ocho semanas. La desnutrición se diagnosticó mediante el SGA y se evaluó la composición corporal.evaluado mediante bioimpedancia.
Resultados: Se reclutaron 57 pacientes y 37 completaron el período de intervención. Después de la intervención nutricional, Los pacientes que recibieron SON enriquecido mostraron un aumento significativo en la masa muscular, que no se detectó con el SON estándar [1,92 (4,31) kg frente a ± 0,68 (1,45) kg); p = 0,009)], y no hubo una reducción significativa en el porcentaje de pacientes con desnutrición severa y moderada.
Conclusión: Un SON enriquecido en EPA, DHA, leucina y β-glucanos aumenta la masa muscular y podría promover la recuperación del estado nutricional y funcional en pacientes con cáncer y desnutrición.
2023-12-13
2023-12-13
2023
info:eu-repo/semantics/article
Journal of Functional foods 2023;110:105833
https://uvadoc.uva.es/handle/10324/63622
doi.org/10.1016/j.jff.2023.105833
spa
info:eu-repo/semantics/openAccess
Elsevier
oai:uvadoc.uva.es:10324/636232023-12-14T20:00:45Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Impact of Percutaneous Endoscopic Gastrostomy (PEG) on the Evolution of Disease in Patients with Amyotrophic Lateral Sclerosis (ALS)
De Luis, Daniel
La disfagia es un síntoma muy prevalente en la Esclerosis Lateral Amiotrófica (ELA), y la implantación de una gastrostomía endoscópica percutánea (PEG) es un evento muy frecuente. El El objetivo de este estudio fue evaluar la influencia de la implantación de PEG en la supervivencia y las complicaciones. en ELA. Un registro interhospitalario de pacientes con ELA de seis hospitales de la región de Castilla-León (España) se creó entre enero de 2015 y diciembre de 2017. Se compararon los datos de aquellos a quienes se les implantó un PEG y a quienes no. Se analizaron un total de 93 pacientes.
La edad media de los pacientes fue de 64,63 ± 17,67 años. Un total de 38 pacientes (38,8%) tuvieron una PEG. implantación. Se observó una mejora en los parámetros antropométricos entre los pacientes que tuvieron una PEG desde el inicio del seguimiento nutricional respecto a los que no la hicieron, tanto en IMC (kg/m2) (PEG: 0 meses, 22,06; 6 meses, 23,04; p < 0,01; NoPEG: 0 meses, 24,59-23,87; p > 0,05). Entre los pacientes fallecidos, 38 (40,4%) tenían implantado un PEG (20 pacientes (52,6%) tenían un mayor tiempo de supervivencia (PEG: 23 (15-35,5) meses; NoPEG 11 (4,75-18,5) meses; p = 0,01). una clavija mostró un beneficio de supervivencia entre los pacientes con ELA. La implantación temprana de un PEG produjo una reducción en
ingresos asociados a complicaciones derivadas del mismo.
2023-12-13
2023-12-13
2021
info:eu-repo/semantics/article
Nutrients 2021, 13, 2765
https://uvadoc.uva.es/handle/10324/63623
10.3390/nu13082765
2765
8
Nutrients
13
2072-6643
spa
info:eu-repo/semantics/openAccess
MDPI
oai:uvadoc.uva.es:10324/636392023-12-14T20:00:49Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
A single FTO gene variant rs9939609 is associated with weight change and insulin resistance improvement in response to a robotic sleeve gastrectomy in individuals with severe obesity
De Luis, Daniel
Antecedentes: Se han involucrado mecanismos genéticos en la respuesta de perdida de peso secundaria a la cirugía bariátrica. Objetivo: El objetivo de nuestro estudio fue evaluar los efectos de la variante genética rs9939609 en
La pérdida de peso y parámetros metabólicos después de la gastrectomía en manga. Métodos: Se inscribieron un total de 95 pacientes, se evaluaron comorbilidades, bioquímica y parámetros antropométricos, estos datos se registraron antes y después del seguimiento a los 3, 6 y 12 meses. o
Se evaluó el SNP rs9939609 del gen FTO (masa grasa y asociado a la obesidad).
Resultados: Agrupamos a los participantes en 2 grupos: portadores del alelo A (TA-AA, 69,5%) y no portadores del alelo A (TT, 30,5%). Detectamos una reducción estadísticamente significativa de la presión arterial, parámetros bioquímicos y antropométricos en los 3 cortes durante el seguimiento. Después de 6 meses, los cambios de algunos parámetros fueron mayores en portadores del alelo no A: peso (–39,6 ± 4,0 kg frente a –24,6 ±2,8 kilogramos; P=0,02), circunferencia de la cintura (–21,1 ± 2,1 cm versus –16,2 ± 1,8 cm; P= 0,04), insulina (–12,3 ± 1,9 mUI/L frente a –8,9 ± 11,2 mUI/L; P=0,02) y la resistencia a la insulina mediante HOMA (–3,1 ± 1 ,1 unidades frente a –2,3 ± 1 ,1 unidades; P=0,02 ). Después de 12 meses, cambios de lo antes mencionado.
Los parámetros permanecieron mayores en los portadores del alelo no A. El porcentaje de participantes con la diabetes disminuyó antes en los no portadores del alelo A que en los portadores del alelo A en el seguimiento de 6 meses. El porcentaje de participantes con diabetes al final del estudio fue menor en los no portadores del alelo A (3,4% versus 12,1%; P=0,02).
Conclusiones: Nuestros datos sugieren que los no portadores del alelo no A de la variante genética (rs9939609) del FTO presentan una mayor mejora de los parametros antropométricos y niveles de insulina que los portadores del alelo A después de un Gastrectomía en manga robótica. Ambas mejoras están asociadas a un menor porcentaje de participantes con diabetes a los 12 meses
2023-12-14
2023-12-14
2023
info:eu-repo/semantics/article
Surg Obes Relat Dis. 2023;19:459-465
1550-7289
https://uvadoc.uva.es/handle/10324/63639
10.1016/j.soard.2022.10.035
459
5
465
Surgery for Obesity and Related Diseases
19
spa
info:eu-repo/semantics/openAccess
oai:uvadoc.uva.es:10324/644372024-02-02T08:56:41Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Stimuli Characteristics and Psychophysical Requirements for Visual Training in Amblyopia: A Narrative Review
Hernández Rodríguez, Carlos J.
Piñero, David P.
Molina Martín, Ainhoa
Morales Quezada, León
Fez, Dolores de
Leal Vega, Luis
Arenillas, Juan F.
Coco-Martín, María Begoña
Producción Científica
Active vision therapy using perceptual learning and/or dichoptic or binocular environments has shown its potential effectiveness in amblyopia, but some doubts remain about the type of stimuli and the mode and sequence of presentation that should be used. A search was performed in PubMed, obtaining 143 articles with information related to the stimuli used in amblyopia rehabilitation, as well as to the neural mechanisms implied in such therapeutic process. Visual deficits in amblyopia and their neural mechanisms associated are revised, including visual acuity loss, contrast sensitivity reduction and stereopsis impairment. Likewise, the most appropriate stimuli according to the literature that should be used for an efficient rehabilitation of the amblyopic eye are described in detail, including optotypes, Gabor's patches, random-dot stimuli and Vernier's stimuli. Finally, the properties of these stimuli that can be modified during the visual training are discussed, as well as the psychophysical method of their presentation and the type of environment used (perceptual learning, dichoptic stimulation or virtual reality). Vision therapy using all these revised concepts can be an effective option for treating amblyopia or accelerating the treatment period when combining with patching. It is essential to adapt the stimuli to the patient's individual features in both monocular and binocular training.
2024-01-11
2024-01-11
2020
info:eu-repo/semantics/article
J Clin Med. 2020 Dec 9;9(12):3985
2077-0383
https://uvadoc.uva.es/handle/10324/64437
10.3390/jcm9123985
3985
12
Journal of Clinical Medicine
9
2077-0383
spa
info:eu-repo/semantics/openAccess
http://creativecommons.org/publicdomain/zero/1.0/
CC0 1.0 Universal
MDPI
oai:uvadoc.uva.es:10324/644382024-01-11T20:01:03Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Brain Atrophy and the Risk of Futile Endovascular Reperfusion in Acute Ischemic Stroke
Pedraza, María I.
de Lera, Mercedes
Bos, Daniel
Calleja, Ana I.
Cortijo, Elisa
Gómez-Vicente, Beatriz
Reyes, Javier
Coco-Martín, María Begoña
Calonge, Teodoro
Agulla, Jesús
Martínez-Pías, Enrique
Talavera, Blanca
Pérez-Fernández, Santiago
Schüller, Miguel
Galván, Jorge
Castaño, Miguel
Martínez-Galdámez, Mario
Arenillas, Juan F.
Background
Brain atrophy is suggested to impair the potential for functional recovery after acute ischemic stroke. We assessed whether the effect of endovascular treatment is modified by brain atrophy in patients with acute ischemic stroke due to large vessel occlusion.
Methods
We used data from MR CLEAN, a multicenter trial including patients with acute ischemic stroke due to anterior circulation large vessel occlusion randomized to endovascular treatment plus medical care (intervention) versus medical care alone (control). We segmented total brain volume (TBV) and intracranial volume (ICV) on baseline non-contrast computed tomography (n = 410). Next, we determined the degree of atrophy as the proportion of brain volume in relation to head size (1 - TBV/ICV) × 100%, analyzed as continuous variable and in tertiles. The primary outcome was a shift towards better functional outcome on the modified Rankin Scale expressed as adjusted common odds ratio. Treatment effect modification was tested using an interaction term between brain atrophy (as continuous variable) and treatment allocation.
Results
We found that brain atrophy significantly modified the effect of endovascular treatment on functional outcome (P for interaction = 0.04). Endovascular treatment led to larger shifts towards better functional outcome in the higher compared to the lower range of atrophy (adjusted common odds ratio, 1.86 [95% CI: 0.97-3.56] in the lowest tertile vs. 1.97 [95% CI: 1.03-3.74] in the middle tertile vs. 3.15 [95% CI: 1.59-6.24] in the highest tertile).
Conclusion
Benefit of endovascular treatment is larger in the higher compared to the lower range of atrophy, demonstrating that advanced atrophy should not be used as an argument to withhold endovascular treatment.
2024-01-11
2024-01-11
2020
info:eu-repo/semantics/article
Stroke. 2020 May;51(5):1514-1521
0039-2499
https://uvadoc.uva.es/handle/10324/64438
10.1161/STROKEAHA.119.028511
1514
5
1521
Stroke
51
1524-4628
spa
info:eu-repo/semantics/openAccess
http://creativecommons.org/publicdomain/zero/1.0/
CC0 1.0 Universal
AHA Journals
oai:uvadoc.uva.es:10324/644392024-02-07T07:27:25Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Visual processing speed in hemianopia patients secondary to acquired brain injury: a new assessment methodology
Mena-Garcia, Laura
Maldonado-Lopez, Miguel J.
Fernandez, Itziar
Coco-Martin, Maria B.
Finat-Saez, Jaime
Martinez-Jimenez, Jose L.
Pastor Jimeno, José Carlos
Arenillas, Juan F.
Producción Científica
Background: There is a clinical need to identify diagnostic parameters that objectively quantify and monitor the
effective visual ability of patients with homonymous visual field defects (HVFDs). Visual processing speed (VPS) is an
objective measure of visual ability. It is the reaction time (RT) needed to correctly search and/or reach for a visual
stimulus. VPS depends on six main brain processing systems: auditory-cognitive, attentional, working memory,
visuocognitive, visuomotor, and executive. We designed a new assessment methodology capable of activating
these six systems and measuring RTs to determine the VPS of patients with HVFDs.
Methods: New software was designed for assessing subject visual stimulus search and reach times (S-RT and R-RT
respectively), measured in seconds. Thirty-two different everyday visual stimuli were divided in four complexity
groups that were presented along 8 radial visual field positions at three different eccentricities (10o, 20o, and 30o).
Thus, for each HVFD and control subject, 96 S- and R-RT measures related to VPS were registered. Three additional
variables were measured to gather objective data on the validity of the test: eye-hand coordination mistakes
(ehcM), eye-hand coordination accuracy (ehcA), and degrees of head movement (dHM, measured by a head-tracker
system). HVFD patients and healthy controls (30 each) matched by age and gender were included. Each subject
was assessed in a single visit. VPS measurements for HFVD patients and control subjects were compared for the
complete test, for each stimulus complexity group, and for each eccentricity.
Results: VPS was significantly slower (p < 0.0001) in the HVFD group for the complete test, each stimulus
complexity group, and each eccentricity. For the complete test, the VPS of the HVFD patients was 73.0% slower
than controls. They also had 335.6% more ehcMs, 41.3% worse ehcA, and 189.0% more dHMs than the controls.
Conclusions: Measurement of VPS by this new assessment methodology could be an effective tool for objectively
quantifying the visual ability of HVFD patients. Future research should evaluate the effectiveness of this novel
method for measuring the impact that any specific neurovisual rehabilitation program has for these patients.
2024-01-11
2024-01-11
2020
info:eu-repo/semantics/article
J Neuroeng Rehabil. 2020 Jan 31;17(1):12
1743-0003
https://uvadoc.uva.es/handle/10324/64439
10.1186/s12984-020-0650-5
1
Journal of NeuroEngineering and Rehabilitation
17
1743-0003
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/publicdomain/zero/1.0/
CC0 1.0 Universal
BMC
oai:uvadoc.uva.es:10324/644402024-02-02T08:48:39Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Imaging Biomarkers and Prevalence of Complex Aortic Plaque in Cryptogenic Stroke: A Systematic Review
Sakai, Yu
Cao, Quy
Rubin, Jeremy
Witsch, Jens
Cohen‐Addad, Dan
de Macedo Rodrigues, Katyucia
Coco Martín, María Begoña
Pasyar, Pouyan
Juega, Jesús
Fan, Zhaoyang
Kasner, Scott E.
Cucchiara, Brett L.
Song, Jae W.
Producción Científica
BACKGROUND: Complex aortic plaque (CAP) is a potential embolic source in patients with cryptogenic stroke (CS). We review
CAP imaging criteria for transesophageal echocardiogram (TEE), computed tomography angiography (CTA), and magnetic
resonance imaging and calculate CAP prevalence in patients with acute CS.
METHODS AND RESULTS: PubMed and EMBASE databases were searched up to December 2022 in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Two independent reviewers extracted data on
study design, imaging techniques, CAP criteria, and prevalence. The Cochrane Collaboration tool and Guideline for Reporting
Reliability and Agreement Studies were used to assess risk of bias and reporting completeness, respectively. From 2293
studies, 45 were reviewed for CAP imaging biomarker criteria in patients with acute CS (N=37 TEE; N=9 CTA; N=6 magnetic
resonance imaging). Most studies (74%) used ≥4 mm plaque thickness as the imaging criterion for CAP although ≥1 mm (N=1,
CTA), ≥5 mm (N=5, TEE), and ≥6 mm (N=2, CTA) were also reported. Additional features included mobility, ulceration, thrombus,
protrusions, and assessment of plaque composition. From 23 prospective studies, CAP was detected in 960 of 2778
patients with CS (0.32 [95% CI, 0.24–0.41], I2=94%). By modality, prevalence estimates were 0.29 (95% CI, 0.20–0.40; I2=95%)
for TEE; 0.23 (95% CI, 0.15–0.34; I2=87%) for CTA and 0.22 (95% CI, 0.06–0.54; I2=92%) for magnetic resonance imaging.
CONCLUSIONS: TEE was commonly used to assess CAP in patients with CS. The most common CAP imaging biomarker was
≥4 mm plaque thickness. CAP was observed in one-third of patients with acute CS. However, high study heterogeneity suggests
a need for reproducible imaging methods.
2024-01-11
2024-01-11
2023
info:eu-repo/semantics/article
J Am Heart Assoc. 2023 Dec 5;12(23)
2047-9980
https://uvadoc.uva.es/handle/10324/64440
10.1161/JAHA.123.031797
1
23
13
Journal of the American Heart Association
12
2047-9980
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/publicdomain/zero/1.0/
CC0 1.0 Universal
AHA Journals
oai:uvadoc.uva.es:10324/644422024-02-02T08:55:16Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Digital Transformation in Healthcare: Technology Acceptance and Its Applications
Molina Martín, Ainhoa
Piñero, David P.
Coco Martín, María Begoña
Leal Vega, Luis
Fez, Dolores de
Producción Científica
The easy access to electronic devices for users has resulted in the development of a vast
range of programs and applications for visual evaluation and diagnosis that can be downloaded to
any device. Some of them are based on tasks and stimuli that depend on luminance. The aim of the
present study was to evaluate differences in luminance reproduction between electronic devices and
their implications for contrast reproduction. A total of 20 Galaxy Tab A devices with 8-bit graphics
processing units were evaluated. Characterization of every screen was performed obtaining the
response curve for the achromatic stimulus. Mean, maximum and minimum luminance, standard
deviation and coefficient of variation were obtained to assess differences between devices. Variation
of luminance with increasing digital level was observed in all devices following a gamma distribution.
Comparison between devices for mean results showed that some of them differed by as much as
45 cd/m2. The coefficient of variation varied from ~5 to 9%. Mean percentage of differences in
luminance between devices reached 30%. In conclusion, differences in luminance reproduction
between devices were present, even considering devices from the same manufacturing batch. It
cannot be assumed that the characterization of one device can be extrapolated to other devices.
Every device used for research purposes should be individually characterized to ensure the correct
reproduction. For clinical purposes, limitations should be considered by visual specialists.
2024-01-11
2024-01-11
2021
info:eu-repo/semantics/article
Technologies. 2021; 9(3):68
2227-7080
https://uvadoc.uva.es/handle/10324/64442
10.3390/technologies9030068
68
9
Differences in Contrast Reproduction between Electronic Devices for Visual Assessment: Clinical Implications
1660-4601
2227-7080
eng
info:eu-repo/semantics/openAccess
MDPI
oai:uvadoc.uva.es:10324/644452024-02-07T07:26:29Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Multitasking Compensatory Saccadic Training Program for Hemianopia Patients: A New Approach With 3-Dimensional Real-World Objects
Mena-Garcia, Laura
Pastor Jimeno, José Carlos
Maldonado, Miguel J.
Coco-Martin, Maria B.
Fernandez, Itziar
Arenillas, Juan F.
Producción Científica
Purpose: To examinewhether a noncomputerized multitasking compensatory saccadic
training program (MCSTP) for patients with hemianopia, based on a reading
regimen and eight exercises that recreate everyday visuomotor activities using threedimensional
(3D) real-world objects, improves the visual ability/function, quality of life
(QL), and functional independence (FI).
Methods: The 3D-MCSTP included four in-office visits and two customized homebased
daily training sessions over 12weeks. A quasiexperimental, pretest/posttest study
designwas carried out with an intervention group (IG) (n = 20) and a no-training group
(NTG) (n = 20) matched for age, hemianopia type, and brain injury duration.
Results: The groups were comparable for the main baseline variables and all participants
(n = 40) completed the study. The IGmainly showed significant improvements in
visual-processing speed (57.34% ± 19.28%; P < 0.0001) and visual attention/retention
ability (26.67% ± 19.21%; P < 0.0001), which also were significantly greater (P < 0.05)
than in the NTG. Moreover, the IG showed large effect sizes (Cohen’s d) in 75% of the
totalQL and FI dimensions analyzed; in contrast to the NTGthat showed negligiblemean
effect sizes in 96% of these dimensions.
Conclusions: The customized 3D-MCSTP was associated with a satisfactory response in
the IG for improving complex visual processing, QL, and FI.
Translational Relevance: Neurovisual rehabilitation of patientswith hemianopia seems
more efficient when programs combine in-office visits and customized home-based
training sessions based on real objects and simulating real-life conditions, than no treatment
or previously reported computer-screen approaches, probably because of better
stimulation of patients´ motivation and visual-processing speed brain mechanisms.
2024-01-11
2024-01-11
2021
info:eu-repo/semantics/article
Transl Vis Sci Technol. 2021 Feb 5;10(2):3
2164-2591
https://uvadoc.uva.es/handle/10324/64445
10.1167/tvst.10.2.3
3
2
Translational Vision Science & Technology
10
eng
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
TVST
oai:uvadoc.uva.es:10324/644462024-01-11T20:01:12Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Perfil de los pacientes que acuden al médico internista para valoración de osteoporosis: registro OSTEOMED
Blázquez Cabrera, J.A.
Sosa Henriquez, M.
Diaz-Curiel, M.
Sánchez Molini, P.
Arranz Garcia, F.
Montoya, M.J.
Filgueira, J.
Olmos, J.M.
Coco-Martín, M.B.
Castrillón, J.L. Pérez
José Amerigo, María
Navarro, Amalia
Jesús Moro, María
María Aguado Caballero, José
Armengol Sucarrats, Dolors
Luz Calero Bernal, María
Carlos Cobeta, Juan
Cotos Canca, Rafael
de Escalante Yanguas, Begoña
Hernández de Sosa, Nerea
Luis Hernández, José
Jareño Chaumel, Julia
Ángeles Vázquez Gómez, M.
José Miranda García, M.
Giner García, Mercedes
Miranda Díaz, Cristina
Pascual Vergara, Antonio
Javier Rodero Hernández, Francisco
Tirado Miranda, Raimundo
Producción Científica
Antecedentes y objetivo: La osteoporosis se considera un trastorno generalizado del esqueleto
en el que existe una alteración de la resistencia ósea que predispone a la persona a un mayor
riesgo de fractura. Este estudio transversal pretende recoger y presentar las principales características
clínicas de los pacientes que acuden a la consulta de los médicos internistas en Espa˜na.
Conocer estas características podría facilitar la puesta en marcha de planes de actuación para
mejorar la atención de estos pacientes de manera más eficaz y eficiente.
Material y métodos: A través del análisis del registro OSTEOMED (Osteoporosis en Medicina
Interna), este trabajo presenta las principales características clínicas de los pacientes con
osteoporosis que acudieron a las consultas de Medicina Interna en 23 centros hospitalarios
espa˜noles entre 2012 y 2017. Se han analizado los motivos de consulta, los valores densitométricos,
la presencia de comorbilidades, el tratamiento prescrito y otros factores relacionados
con el estilo de vida.
Resultados: En total se evaluó a 2.024 pacientes con osteoporosis (89,87% mujeres, 10,13%
hombres). La edad media de los pacientes fue de 64,1
±
12,1 a˜nos (mujeres, 64,7
±
11,5 a˜nos;
hombres, 61,2
±
14,2 a˜nos). No hubo diferencia entre sexos en la historia de caídas recientes
(9,1-6,7%), mientras que sí se apreció en la ingesta diaria de calcio de lácteos (553,8
±
332,6 mg en mujeres vs. 450,2 ± 303,3 mg en hombres; p < 0,001) y en causas secundarias de osteoporosis(13% de hombres vs. 6,5% de mujeres; p < 0,001). En la muestra se observaron un total de 404fracturas (20%), destacando el número de fracturas vertebrales confirmadas (17,2%, 35,6% enhombres vs. 15,2% de las mujeres; p < 0,001). Una gran parte de los pacientes no recibía eltratamiento indicado y presentaba bajos niveles de actividad física y exposición solar. Un por-centaje importante de pacientes presentó comorbilidades asociadas, siendo las más frecuentesla hipertensión (32%) y la dislipidemia (28%).Conclusiones: Estos resultados definen el perfil del paciente con osteoporosis que acude a laconsulta de Medicina Interna en Espa˜na. Además, ponen de manifiesto el carácter multisistémicode esta entidad que junto con su elevada prevalencia determinan que las consultas específicasde Medicina Interna dedicadas a su manejo son el lugar adecuado para la atención de estos pacientes.
2024-01-11
2024-01-11
2020
info:eu-repo/semantics/article
Rev Clin Esp. 2020 Jul 15:S0014-2565(20)30174-0
0014-2565
https://uvadoc.uva.es/handle/10324/64446
10.1016/j.rce.2020.06.004
9
1
17
Revista Clínica Española
221
spa
info:eu-repo/semantics/restrictedAccess
Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI).
Elsevier
oai:uvadoc.uva.es:10324/644502024-03-18T13:28:46Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Trapeziometacarpal total joint arthroplasty for osteoarthritis: 199 patients with a minimum of 10 years follow-up
Martin-Ferrero, Miguel
Simón-Pérez, Clarisa
Coco Martín, María Begoña
Vega-Castrillo, Aureliio
Aguado-Hernández, Héctor
Mayo-Iscar, Agustín
Martin-Ferrero, Miguel Angel
Trigueros Larrea, José María
Martin-de la Cal, Elsa
Coco-Martin, Begoña
Simon-Perez, Clarisa
Producción científica
Trapeziometacarpal osteoarthritis (TMCOA) is a highly prevalent disease in the older
population. Many different types of surgical treatments are possible, depending on the degree of
joint involvement, the personal and professional circumstances of the patient and the preferences
of the orthopedic surgeon. This paper evaluated the clinical and radiological results of consecutive
cohorts of patients over 65 years old treated with total joint arthroplasties (TJA) of the ball and socket
type (B&S) for TMCOA, with a minimum of 10 years follow-up. The survival rate (Kaplan–Meier) of
the functional prostheses at 10 years was 92.2% (95% CI (89.1%, 96.1%). These functional arthroplasty
patients, after 10 years of follow-up, showed little or no pain, good function and good key pinch,
without radiological alterations. TJAs of the B&S type are a long lasting, effective and reliable
alternative to surgical treatment of TMCOA in patients over 65 years of age, when they are performed
with the patient selection criteria and surgical technique described throughout this study.
2024-01-11
2024-01-11
2021
9999-01-01
info:eu-repo/semantics/article
J Hand Surg Eur Vol. 2020 Jun;45(5):443-451. doi: 10.1177/1753193419871660
1753-1934
https://uvadoc.uva.es/handle/10324/64450
10.1177/1753193419871660
65
6
2043-6289
2043-6289
eng
info:eu-repo/semantics/embargoedAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
SAGE
oai:uvadoc.uva.es:10324/645252024-01-15T20:01:14Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Role of Oxidative Stress and Lipid Peroxidation in the Pathophysiology of NAFLD
Martín-Fernández, Marta
Arroyo, Víctor
Carnicero, Carmen
Sigüenza, Rebeca
Busta, Reyes
Mora, Natalia
Antolín, Beatriz
Tamayo, Eduardo
Aspichueta, Patricia
Carnicero-Frutos, Irene
Gonzalo-Benito, Hugo
Aller de la Fuente, Rocío
Non-alcoholic fatty liver disease (NAFLD) is characterised by an excess of hepatic fat that can progress to steatohepatitis, fibrosis, cirrhosis and hepatocarcinoma. The imbalance between lipid uptake/lipogenesis and lipid oxidation/secretion in the liver is a major feature of NAFLD. Given the lack of a non-invasive and reliable methods for the diagnosis of non-alcoholic steatohepatitis (NASH), it is important to find serum markers that are capable of discriminating or defining patients with this stage of NASH. Blood samples were obtained from 152 Caucasian subjects with biopsy-proven NAFLD due to persistently elevated liver enzyme levels. Metabolites representative of oxidative stress were assessed. The findings derived from this work revealed that NAFLD patients with a NASH score of ≥ 4 showed significantly higher levels of lipid peroxidation (LPO). Indeed, LPO levels above the optimal operating point (OOP) of 315.39 μM are an independent risk factor for presenting a NASH score of ≥ 4 (OR: 4.71; 95% CI: 1.68−13.19; p = 0.003). The area under the curve (AUC = 0.81, 95% CI = 0.73−0.89, p < 0.001) shows a good discrimination ability of the model. Therefore, understanding the molecular mechanisms underlying the basal inflammation present in these patients is postulated as a possible source of biomarkers and therapeutic targets in NASH.
2024-01-15
2024-01-15
2022
info:eu-repo/semantics/article
Antioxidants (Basel). 2022 Nov 10;11(11):2217
https://uvadoc.uva.es/handle/10324/64525
10.3390/antiox11112217
2217
11
Antioxidants
11
2076-3921
spa
info:eu-repo/semantics/openAccess
MDPI
oai:uvadoc.uva.es:10324/645262024-01-19T09:45:30Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Lipid peroxidation as a hallmark of severity in COVID-19 patients
Martín-Fernández, Marta
Aller de la Fuente, Rocío
Heredia-Rodríguez, María
Gómez-Sánchez, Esther
Martínez-Paz, Pedro
Gonzalo-Benito, Hugo
Sánchez-de Prada, Laura
Gorgojo, Óscar
Carnicero-Frutos, Irene
Tamayo, Eduardo
Tamayo-Velasco, Álvaro
Background: Oxidative stress may be a key player in COVID-19 pathogenesis due to its significant role in response
to infections. A defective redox balance has been related to viral pathogenesis developing a massive induction of
cell death provoked by oxidative stress. The aim of this study is to perform a complete oxidative stress profile
evaluation regarding antioxidant enzymes, total antioxidant capacity and oxidative cell damage in order to
characterize its role in diagnosis and severity of this disease.
Methods: Blood samples were obtained from 108 COVID-19 patients and 28 controls and metabolites representative of oxidative stress were assessed. The association between lipid peroxidation and 28-day intubation/death
risk was evaluated by multivariable regression analysis. Probability of intubation/death to day-28 was analyzed
by using Kaplan-Meier curves and tested with the log-rank test.
Results: Antioxidant enzymes (Superoxide dismutase (SOD) and Catalase) and oxidative cell damage (Carbonyl
and Lipid peroxidation (LPO)) levels were significantly higher in COVID-19 patients while total antioxidant
capacity (ABTS and FRAP) levels were lower in these patients. The comparison of oxidative stress molecules’
levels across COVID-19 severity revealed that only LPO was statistically different between mild and intubated/
death COVID-19 patients. COX multivariate regression analysis identified LPO levels over the OOP
(LPO>1948.17 μM) as an independent risk factor for 28-day intubation/death in COVID-19 patients [OR: 2.57;
95% CI: 1.10–5.99; p = 0.029]. Furthermore, Kaplan-Meier curve analysis revealed that COVID-19 patients
showing LPO levels above 1948.17 μM were intubated or died 8.4 days earlier on average (mean survival time
15.4 vs 23.8 days) when assessing 28-day intubation/death risk (p < 0.001).
Conclusion: These findings deepen our knowledge of oxidative stress status in SARS-CoV-2 infection, supporting
its important role in COVID-19. In fact, higher lipid peroxidation levels are independently associated to a higher
risk of intubation or death at 28 days in COVID-19 patients.
2024-01-15
2024-01-15
2021
info:eu-repo/semantics/article
Redox Biol. 2021 Nov 6;48:102181
2213-2317
https://uvadoc.uva.es/handle/10324/64526
10.1016/j.redox.2021.102181
102181
Redox Biology
48
spa
info:eu-repo/semantics/openAccess
elsevier
oai:uvadoc.uva.es:10324/645272024-01-19T09:44:46Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Implication of the rs670 variant of APOA1 gene with lipid profile, serum adipokine levels and components of metabolic syndrome in adult obese subjects
de Luis, Daniel Antonio
Izaola, Olatz
Primo, David
Aller de la Fuente, Rocío
El objetivo de la presente investigación fue describir la asociación de la variante genética rs670 con el síndrome metabólico (SME) y parámetros metabólicos. El estudio involucró una población de 1000 sujetos obesos. Se registraron parámetros antropométricos , presión arterial, glucemia en ayunas, proteína C reactiva (PCR), concentración de insulina, resistencia a la insulina (HOMA-IR), perfil lipídico, niveles de adipoquinas y prevalencia de SME. Se recluto una muestra de 1000 sujetos obesos con un IMC medio de 36,5 ± 5,0 kg/m2. en varones, peso (delta: 3,3 ± 1,2 kg; p ¼ 0,01), masa grasa (delta: 2,7 ± 1,1 kg; p ¼ 0,01), circunferencia de la cintura (delta: 2,8 ± 1,1 cm; p ¼ 0,02), glucosa en ayunas (delta: 8,9 ± 2,2 mg/dl; p ¼ 0,01), niveles de insulina (delta: 3,7 ± 1,2 UI/L; p = 0,04) y HOMA-IR (delta: 1,2 ± 1,1 unidades; p = 0,02) fueron mayores en los no portadores del alelo A que en los portadores del alelo A. En los hombres sin el alelo A se detecto un mayor riesgo de hiperglucemia (OR ¼ 1,40, IC del 95 % ¼ 1,09 e2.09, p ¼ 0.04), porcentaje de obesidad central (OR ¼ 4.55, 95% IC ¼ 1.36e15.39, p ¼ 0.01), porcentaje de C-HDL bajo (OR ¼ 2,02, IC 95% ¼ 1,02-4,03, p ¼ 0,03) y prevalencia de diabetes mellitus (OR ¼ 2,14, 95%IC = 1,03-5,04, p = 0,03). Conclusiones: El rs670 del gen APOA1 tiene una influencia específica de género sobre la glucosa sérica, insulina, HOMA-IR, grasa masa, peso y perímetro de cintura. Los varones sin el alelo A mostraron altas tasas de obesidad central, bajas niveles de HDL, hiperglucemia y diabetes mellitus.
ISSN0261-5614
Revisión por paresSI
2024-01-15
2024-01-15
2019
info:eu-repo/semantics/article
Clin Nutr. 2019;38:407-411
0261-5614
https://uvadoc.uva.es/handle/10324/64527
10.1016/j.clnu.2017.12.007
407
1
411
Clinical Nutrition
38
spa
info:eu-repo/semantics/openAccess
oai:uvadoc.uva.es:10324/645282024-01-15T20:01:19Zcom_10324_1179com_10324_931com_10324_894col_10324_1306
Common polymorphism in the cannabinoid receptor gene type 2 (CB2R) rs3123554 are associated with metabolic changes after two different hypocaloric diets with different dietary fatty profiles
Aller de la Fuente, Rocío
Primo, D.
Izaola, O.
de Luis, D.A.
Background: The role of CB2R gene variants on weight loss after a dietary intervention has been investigated in few studies.
Objective: We evaluate the effect of this genetic variant (rs3123554) of CB2R gene on cardiovascular risk
factors and weight loss secondary to high monounsaturated fat vs a high polyunsaturated fat hypocaloric
diets.
Design: A Caucasian population of 362 obese patients was enrolled. Patients were randomly allocated
during 3 months to one of two diets (Diet P high polyunsaturated (PUFAs) fat hypocaloric diet vs, Diet M
high monounsaturated (MUFAs) fat hypocaloric diet).
Results: In both genotype groups (GG vs GAþAA), body weight, body mass index (BMI), fat mass, waist
circumference and systolic blood pressure decreased after diet P and M. Body weight, BMI, fat mass and
waist circumference were higher in A allele carriers than non A allele carriers. The improvement of these
parameters was higher in non A allele carriers than A allele carriers. In non A allele carriers with both
diets, the decrease of total cholesterol, LDL-cholesterol, insulin and HOMA-IR was higher than A allele
carriers after both diets. After diet P, triglyceride levels decrease in non A allele carriers.
Conclusion: Our data suggest that carriers of the minor allele of rs3123554 variant of CB2R gene lose less
body weight during to different hypocaloric diets with different fatty acid. Moreover, non A-allele carriers showed a better response of LDL-cholesterol, HOMA-IR and insulin levels than A-carriers with both
hypocaloric diets
2024-01-15
2024-01-15
2019
info:eu-repo/semantics/article
Clin Nutr. 2019 Dec;38(6):2632-2638
0261-5614
https://uvadoc.uva.es/handle/10324/64528
10.1016/j.clnu.2018.11.013
2632
6
2638
Clinical Nutrition
38
spa
info:eu-repo/semantics/openAccess
etdms///col_10324_1306/100